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Abstract
Drug hypersensitivity reactions are believed to involve activation of the immune system, and in particular T-cells, although the mechanisms involved are not well understood. The studies reported in this thesis were intended to explore the possibility that drug metabolism and reactive metabolites are involved in the pathogenesis of these reactions.There are two signals required for the activation of drug-specific T-cells, a primary event in the initiation of hypersensitivity, signal 1, or the antigenic signal, and signal 2, or danger signalling. Three paradigm drugs were used to explore the possibility that formation of reactive metabolites could supply one or both of these signals.Firstly, the ability of sulfamethoxazole (SMX) or the protein-reactive metabo­lite nitroso-sulfamethoxazole (SMX-NO) to provide danger signals was explored. In this study, increased CD40 expression, but not CD80, CD83, or CD86, was demon­strated with dendritic cell surfaces exposed to SMX (250-500 /¿M) or SMX-NO (1- 10 /iM). Increased CD40 expression was not associated with apoptosis or necrosis, or glutathione depletion, but covalently modified intracellular proteins were detected when SMX was incubated with dendritic cells. Importantly, the enzyme inhibitor 1- aminobenzotriazole (ABT) prevented the CD40 upregulation with SMX, but not with SMX-NO or lipopolysaccharide (LPS). The enzymes CYP2C9, CYP2C8, and myeloper­oxidase (MPO) were found to catalyse the conversion of SMX to sulfamethoxazole hydroxylamine, and MPO was found to be expressed in dendritic cells. SMX-NO im- munogenicity was inhibited in mice with a blocking anti-CD40L antibody. In addition, when a primary SMX-NO-specific T cell response using drug-naive human cells was generated, the magnitude of the response was enhanced when cultures were exposed to a stimulatory anti-CD40 antibody. These data indicate that local bioactivation by dendritic cells leads to dendritic cell maturation, an important event in SMX immuno- genicity.Secondly, T-cells isolated from individuals following carbamazepine (CBZ) hyper­sensitivity reactions were studied in order to explore their cross-reactivity with regards to several stable analogues of CBZ, and to determine the nature of the CBZ antigen to which they respond. PBMCs were found to proliferate in response to certain sta­ble analogues, namely, CBZ-10,11-epoxide, 10-OH-CBZ, oxcarbazepine and N-acetyl- iminostilbene. Other derivatives, including CBZ-10,11-diol, iminostilbene, 2-OH-CBZ and 3-OH-CBZ were unable to induce a response. Several approaches were taken to determine the mechanism of CBZ presentation to CBZ-specific T-cell clones, including pulsing or fixing antigen-presenting cells, inhibiting oxidative metabolism by preincu­bation with ABT, determining the kinetics of presentation by TCR downregulation and combined pulse methods, and addition of glutathione to quench reactive metabolites. These all produced data suggestive of a metabolism-independent mechanism of presen­
x
tation, in that enzyme inhibition or co-incubation with glutathione did not alter the proliferative response, whereas pulsed antigen-presenting cells were incapable of pre­senting the drug to T-cells. In addition, the T-cells did not demonstrate a requirement for antigen processing, as fixation of antigen-presenting cells did not affect their ability to present the drug, and kinetic studies found that T-cells were activated with 2 h of drug addition, which is faster than antigen processing allows.T-cell clones isolated from a patient following severe trimethoprim (TMP)-induced liver failure were similarly found to recognise the drug in the absence of metabolism and processing, as determined by a similar battery of tests.In conclusion, it was found that SMX has the potential to provide the ‘danger’ sig­nals required for the induction of hypersensitivity, as a result of localised bioactivation and covalent binding within the dendritic cell. Additionally, both CBZ and TMP were found to activate T-cells directly, with no prior requirement for covalent binding and hapten formation.
xi
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1.1 Adverse Drug Reactions
The World Health Organisation definition of an adverse drug reaction (ADR) has ex­
isted for over 30 years, and is as follows,
“A response to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease, 
or for modification of physiological function” (WHO, 1972)
More recently, Edwards & Aronson (2000) suggested an alternative definition in 
order to remove ambiguities and to highlight the possibility of ADRs as a consequence 
of prescribing or administration errors,
“An appreciably harmful or unpleasant reaction, resulting from an inter­
vention related to the use of a medicinal product, which predicts hazard 
from future administration and warrants prevention or specific treatment, 
or alteration of the dosage regimen, or withdrawal of the product” (Edwards 
& Aronson, 2000)
However they are defined, ADRs are a common clinical problem that can often 
compromise good patient care. While most ADRs are relatively mild and self-limiting, 
and merely require discontinuation of the drug, some can be extremely severe and even 
life-threatening.
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1.1.1 C lassification o f adverse drug reactions
The most commonly used system for the classification of ADRs is based on that devised
by Rawlins & Thompson (1991) and later refined (Park et al, 1992).
T ype A, or ‘Augmented’ reactions, are those in which the adverse effect is simply 
an extension of the primary or secondary pharmacology of the drug, and so is 
typically predictable and dose-dependent. These reactions are generally reversible 
upon withdrawal of the offending drug. Examples of Type A reactions include 
postural hypotension induced by beta-blockers or NSAID-related damage to the 
gastric mucosa.
T ype B reactions, known as either ‘Bizarre’ or ‘Idiosyncratic’ reactions, are those 
which cannot be predicted from the known pharmacology of the drug. These show 
no simple dose-response relationship, and typically only occur in a small propor­
tion of those exposed to the drug. Host factors, particularly metabolic/immunological 
idiosyncrasies, are believed to play an important role in determining individual 
susceptibility to idiosyncratic reactions, although these factors have not been fully 
elucidated in most cases. Examples of these reactions are the agranulocytosis as­
sociated with clozapine administration or immune-mediated adverse effects such 
as hypersensitivity or anaphylaxis.
T ype C reactions, or ‘Chemical’ reactions can be explained by the chemical behaviour 
of the drug or drug metabolites. These include paracetamol hepatotoxicity due 
to generation of a reactive n-acetylbenzoquinoneimine species.
T ype D reactions, or ‘Delayed’ reactions include such adverse effects as carcinogenic­
ity or teratogenicity and often present some time after treatment is completed.
T ype E reactions, or ‘End of treatment’ reactions, are reactions that occur following 
removal of a drug, especially following sudden withdrawal. These include the 
withdrawal symptoms seen after stopping many anxiolytics.
It is suggested that idiosyncratic reactions can be further divided into immune-
mediated or non-immune-mediated, although it is not always clear which category
3
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a particular reaction falls under. Subclassification of immune-mediated idiosyncratic 
reactions will be dealt with below (see 1.1.4.1)
1.1.2 Prevalence o f adverse drug reactions
A large-scale meta-analysis by Lazarou et al. (1998) estimated that ADRs occur in as 
many as 15% of all hospital patients, although this estimate has been widely disputed 
(Kvasz et al., 2000). In a more recent prospective study in the United Kingdom (Pirmo- 
hamed et al., 2004), the proportion of hospital admissions directly caused by ADRs was 
5.2%. Most of these reactions (76.2%-95%) were defined as Type A (dose-dependent) 
reactions, while a large proportion of the remainder were type B (idiosyncratic).
Estimates for the mortality rates of ADRs vary, although a figure of 0.13% incidence 
of fatal ADRs in patients admitted to hospital and 0.19% occurring in patients during 
their stay has been suggested (Lazarou et al., 1998). Other studies have found similar 
figures (0.15% and 0.11% of admissions respectively; Pirmohamed et al., 2004; van der 
Hooft et al., 2006), and a large-scale prospective study to investigate ADRs in the UK is 
underway (Davies et al., 2006). If these figures are accepted, then the overall mortality 
from ADRs is a major public health issue. It is estimated that the total mortality from 
ADRs in the US for the year 1994 was 106,000 (95% confidence interval: 76000-137000; 
Lazarou et al., 1998), which would put ADRs as between the fourth and sixth greatest 
causes of death in the country. The largest study of its kind in the UK has estimated 
that total deaths from ADRs in new admissions to hospital was 5,700 annually (3800- 
7600; Pirmohamed et al., 2004), although this is likely to be an underestimate of the 
total death rate from ADRs, as it does not include those occurring in hospitalised 
patients.
The cost, both financial and as bed occupancy, to the NHS has been evaluated 
in several of these studies. A systematic analysis of previous studies (Wiffen et al., 
2002) estimated the excess total bed-occupancy due to ADRs as admissions to be 
2-6 400-bed hospital equivalents, and that due to ADRs in inpatients to be 14 400- 
bed hospital equivalents, although there is a wide range (3-27). Financially, this was 
estimated to cost the NHS around T380m/year. Pirmohamed et al. (2004) estimated
4
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the burden on the NHS of ADRs in new admissions to be approximately 7 800-bed 
hospital equivalents, although they admitted that this extrapolation was uncertain. 
They derived a cost to the NHS from this of up to T466m/year, which is significantly 
higher than that estimated by Wiffen et al. (2002), as it does not include inpatient 
episodes. This suggests that the true picture is uncertain, and more studies may be 
required. In any case, it is clear from this that ADRs are a significant health problem, 
and anything that can be done to minimise their impact will be beneficial throughout 
the health service.
1.1.3 Im pact o f adverse drug reactions on drug developm ent
In addition to the clinical consequences of ADRs, it is worth considering their im­
pact on drug development. The attrition rates of novel chemical entities in preclinical 
testing, and that of lead compounds in clinical testing, remain exceedingly high, and 
have even increased over recent decades. To give some perspective on this, at present 
approximately 8% of lead compounds which enter clinical testing will eventually be 
successfully licensed, compared to the historical rate of 15% (FDA, 2004), despite the 
much greater intensity and concentration on preclinical screening and high-throughput 
analyses, which would be expected to reduce clinical attrition rates (Caldwell et al., 
2001; Kassel, 2004). This is one of the major causes of the exceptionally high cost of 
development of each drug which reaches marketing, estimated recently (DiMasi et al., 
2003) at $802m, an annual increase of 7.4% above inflation compared to a previous 
study (DiMasi et al., 1991).
The primary causes of attrition in drug discovery are either lack of efficacy (46% of 
compounds in clinical testing) or toxicological risks (27-40%; DiMasi, 1995; Kennedy, 
1997). While many types of ADR can be predicted quite readily either from their 
primary pharmacology, or from relatively simple preclinical testing, idiosyncratic reac­
tions pose two particular problems. Firstly, since idiosyncratic reactions are rare, they 
are unlikely to be identified until either phase III trials or post-marketing, which will 
obviously increase the overall cost. Secondly, our understanding of the mechanisms 
of idiosyncratic reactions is poor, which means that our ability to make predictions
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based solely on mechanistic considerations is correspondingly limited. For this reason, 
preclinical screening has concentrated largely on eliminating candidate lead compounds 
which show potential for formation of protein-reactive metabolites (Caldwell & Yan, 
2006; Williams & Park, 2003). However, this is a crude approach, and is probably 
responsible for unnecessary attrition of compounds which would not have produced 
problems, and so must be approached with an open mind (Evans et al., 2004; Williams 
8z Park, 2003). An improved understanding of the mechanisms of idiosyncratic reac­
tions would aid immeasurably in the development of more robust and reliable screening 
tools.
1.1.4 Im m une-m ediated adverse drug reactions
The work in this thesis will be primarily concerned with the pathogenesis and mecha­
nisms behind immune-mediated idiosyncratic reactions, in particular cutaneous delayed- 
type T-cell mediated reactions, often described as hypersensitivity reactions, although 
this does not accurately cover the heterogeneity of the reactions and their underlying 
pathologies.
1.1.4.1 Classification of immune-mediated ADRs
The clinical diagnosis of immune-mediated ADRs can be extremely problematic. In 
many cases, immune-mediated drug reactions may present in a similar fashion to many 
immunological pathologies, such as drug-induced lupus or rash, in which cases often the 
only indicator that the reactions are drug-induced is the temporal association between 
their incidence or termination and the period of drug exposure. Furthermore, even if 
the drug-associated nature of the reaction is unquestionable, it can be difficult to un­
equivocally identify the role of the immune system in the pathology. For instance, there 
is considerable evidence that the innate immune system is activated in paracetamol- 
induced liver injury (Liu & Kaplowitz, 2006), but whether this is primary or secondary, 
pathological or protective, or, indeed, merely epiphenomenological, is uncertain, and 
may vary from case to case.
These caveats notwithstanding, the most commonly used classification of immune-
6
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Table 1.1: Relationship of clinical symptoms to type of immune response (adapted from Pichler, 2003)
Extended Gell and Coombs classification
Type of Immune response Pathologie Characteris­tics Clinical Symptoms
Type I IgE Mast-cell degranulation Urticaria,anaphylaxiaType II IgG and FcR FcR-dependent cell de­struction Blood cell dyscrasiaType III IgG and complé­ment or FcR Immunocomplexdeposition VasculitisTypeIVa Thl (IFN-y) Monocyte activation EczemaType IVb Th2 (IL-5 and IL-4) Eosinophilie infiltration Maculopapular exan­thema, bullous exan­themaTypeIVc CTL (perforin and granzyme B) CD4- or CD8-mediated killing of cells Maculopapular exan­thema, eczema, bul­lous exanthema, pus­tular exanthemaTypeIVd T-cells (IL-8) Neutrophil recruitment and activation Pustular exanthema
mediated ADRs is the Gell and Coombs scheme (see table 1.1), first published as Gell 
& Coombs (1963). This divides reactions on the basis of clinical presentation, and 
allocates them tentatively to a proposed pathophysiology. This scheme was further 
enlarged by the subdivision of type IV reactions (delayed-type reactions mediated by 
T-cells) into four subcategories based on variations in T-cell polarisation (Pichler, 2003).
While this scheme is useful for gaining an understanding of some of the underlying 
pathology, it doesn’t necessarily accurately reflect the real-life situation. In particular, 
many delayed-type hypersensitivity reactions actually represent multiple overlapping 
pathologies. Furthermore, while the assignments of pathology are superficially plau­
sible, there is insufficient evidence in many cases to unequivocally identify the funda­
mental pathophysiology.
1.1.4.2 Clinical features of type IV immune-mediated ADRs
Type IV immune-mediated ADRs most commonly affect the skin, and cover a wide 
range of symptoms, the majority involving mild, self-limiting urticaria or morbilliform
7
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rashes. However, a small proportion of patients go on to develop a more severe reac­
tion, known as drug hypersensitivity syndrome. This normally occurs 1-3 weeks after 
commencement of treatment, although it may occur some months later, and is char­
acterised by the triad of rash, fever and internal involvement, often accompanied by 
lymphadenopathy (Knowles et al., 1999). For this reason, it is also known as drug rash 
with eosinophilia and systemic symptoms, or DRESS. This is particularly common 
with aromatic anticonvulsants, but it has been seen with antimicrobials (particularly 
sulfonamides) and NSAIDs. Although this condition can be life-threatening, prompt 
withdrawal of the drug, accompanied by corticosteroid or intravenous immunoglobulin 
treatment (Mostella et al., 2004; Scheuerman et al., 2001), is normally sufficient for a 
complete recovery.
Erythema multiforme is a similar condition, associated with the administration of 
several drugs, but particularly anticonvulsants and antimicrobials. Erythema multi­
forme minor consists of target lesions with mild cutaneous involvement, although the 
patients remain healthy. More severe cases, however, form a spectrum from erythema 
multiforme major and Stevens-Johnson syndrome to toxic epidermal necrolysis. In 
Stevens-Johnson syndrome there is widespread skin toxicity, including sloughing of < 
10% of total skin area, serious mucosal membrane involvement, and some degree of in­
ternal involvement, including lymphadenopathy. More severe cases, known as toxic epi­
dermal necrolysis, involve massive skin sloughing (> 30% of body surface), with severe 
risk of secondary infection and sepsis. These conditions axe often fatal, with mortal­
ity rates for toxic epidermal necrolysis in excess of 30% (Prendiville, 2002). High-dose 
corticosteroids are commonly used alongside supportive management, although there is 
some evidence that this can lead to increased mortality (Halebian et al., 1986) through 
weakened immune responses to infection (Jones et al., 1989).
1.2 Drug M etabolism
Most commonly used drugs are relatively lipophilic. This enhances their activity both 
by increased potency at their designated target, and by decreased excretion, hence 
allowing greater overall exposure to the drug. Therefore, in order to become readily
8
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excretable, most drugs require structural alteration. This process, known as drug 
metabolism, is a major area of pharmacological investigation, as it plays an important 
role in determining both the effectiveness and toxicity of the drug in vivo.
The reactions which make up drug metabolism are typically divided into Phase I 
and Phase II reactions (Williams, 1959), although this does not necessarily imply they 
are temporally sequential. Phase I reactions are those which either introduce or unmask 
a reactive group upon the molecule, whereas Phase II reactions typically conjugate a 
polar endogenous compound onto the molecule in order to increase the rate of excretion 
of the compound. Phase I metabolism therefore can be said to prime the molecule for 
Phase II reactions, which actually have the desired effect of increasing excretion.
1.2.1 P h ase I m etabolism
Phase I metabolism can be divided into three major classes of reaction, namely oxida­
tion, reduction and hydrolysis reactions. Oxidative Phase I reactions are summarised 
in table 1.2.
1.2.1.1 Cytochrome P450s
The quantitatively most important Phase I enzymes are the cytochrome P450 (CYP) 
enzymes. These are a family of structurally related haemoxygenases located in the 
endoplasmic reticulum. Although they are predominantly expressed in the liver, there 
is growing evidence that extrahepatic CYPs may be responsible for localised toxicity, 
which will be further discussed later (see 1.2.5).
CYP enzymes are classified according to amino acid sequence, with families being 
defined as CYPs which share greater than 40% sequence homology, and subfamilies 
sharing at least 59% similarity (Nebert et al., 1987). Nearly all of the CYPs responsible 
for xenobiotic metabolism fall within families CYP 1-4. Table 1.3 details the main 
isoforms responsible for drug metabolism.
CYPs enzymes are formed from a single polypeptide chain attached non-covalently 
via a conserved cysteine residue to the central iron atom of a haem group. Substrates 
bind to the iron centre, as Fe3+, which initiates electron transport and oxygen binding.
9
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Table 1.2: Phase I metabolism: Oxidative reactions
Type of Reaction Mechanism
OH
1. Aromatic Hydroxylation
2. Aliphatic Hydroxylation
3. Epoxidation
R -C H 3 r - c h 2o h
o
4. 0,N,S-dealkylation
5. Oxidative deamination
6. N-hydroxylation
7. S-oxidation
8. Dehalogenation
9. Desulphuration
10. Alcohol oxidation
11. Quinone formation
R -0 -C H 3 -
H
R - O - C - HI
OH
ROH +  HCHO
CH,I 3
R - C - N H ,  
H 2
CH,
-NH,
OH
c h 3
. + n h 3O
R—n h 2 ------- -- r - nT 0H
' h
R - S - R ' --------►  R - l - R '
H
-C -ICl Br R - C - O HH2
R = S  ------- -- R=0
OHI
H ,C -C -O H  — *‘H,C—C —OH- *- H X -C H O
3 H2 3 H
OH O
OH O
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Table 1.3: Characteristics of human cytochrome P450 metabolising enzymes
Isoform Location Substrate Inhibitor InducerCYP1A1 Primarily extra- hepatic Benzo( a) pyrene Napthoflavone 3-methylchol-anthreneCYP1A2 Liver Caffeine,Phenacetin Furafylline Benzo(a)pyreneCYP1B1 Leukocytes Benzo(a)pyrene,caffeine ResveratrolCYP2A6 Liver Coumarin Tranylcypromine BarbituratesCYP2B6 Liver Cyclophosphamide Orphenadrine PhenobarbitoneCYP2C8 Liver, intestine Tolbutamide,diclofenac QuercetinCYP2C9 Liver, intestine Tolbutamide, war­farin Sulfaphenazole RifampicinCYP2C19 Liver Omeprazole,proguanil Tranylcypromine RifampicinCYP2D6 Liver, intestine, kidney Bufuralol, debriso- quine QuinidineCYP2E1 Liver, intestine Paracetamol,ethanol Isoniazid EthanolCYP3A4 Liver, intestine Cyclosporin, car- bamazepine Kétoconazole,troleandomycin Rifampicin,phenytoinCYP3A5 Liver, placenta Nifedipine TroleandomycinCYP4A11 Lung Testosterone Clofibrate
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Electrons are transferred to the iron from reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) by cytochrome p450 reductase, the reduced iron (Fe2+) binds and 
reduces molecular oxygen, in concert with a further electron from either cytochrome 
p450 reductase or cytochrome bs. Loss of an atom of oxygen leaves the final oxida­
tive complex, a high valent iron-oxo species. This chemically inserts oxygen into the 
substrate and decomposes to regenerate the resting form of the enzyme (Fe3+). The 
overall reaction can be summarised as follows:
NADPH + 0 2 +  RH +  H+ —> NADP+ + ROH +  H20
1.2.1.2 Other phase I enzymes
In addition to CYP enzymes, there are several other important enzymes which catalyse 
Phase I reactions. These can be roughly divided into oxidative, reductive and hydrolytic 
enzymes, of which only the oxidative enzymes are of importance for this discussion. 
We will briefly discuss two major classes of oxidative enzymes, the peroxidases and the 
flavin-containing monooxygenases (FMOs).
The general mechanism of action of peroxidases involves the reduction of a hydroper­
oxide (often, but not exclusively, hydrogen peroxide) to the corresponding alcohol, and 
oxidation of the enzyme to an intermediate known as Compound I. This is capable of 
oxidising xenobiotics directly, although in the presence of halide ions (Cl-  in the case 
of myeloperoxidase (MPO), Br-  for thyroid peroxidase), it produces significant quan­
tities of hypochlorous acid (HOC1), a powerful oxidising agent. The native enzyme is 
regenerated via one or two further intermediates, Compounds II and III. Several peroxi­
dase enzymes have been associated with xenobiotic metabolism, including MPO (Cribb 
et al., 1990; Liu & Uetrecht, 1995), cyclooxygenase (COX; Vogel, 2000), lactoperoxidase 
(Goodwin et al., 1996) and thyroid peroxidase (Doerge et al., 1997). Of these, MPO 
is the best studied, and will be discussed further here. MPO is largely stored in the 
lysosomes of neutrophils and leukocytes, and is released along with H2 O2 as part of the 
respiratory burst. For this reason, reactive metabolites generated by myeloperoxidase 
are likely to be formed extracellularly, in contrast to those generated by the majority
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of drug metabolising enzymes, with potential implications for the likely protein targets 
and the overall canon of modified proteins. While MPO-mediated oxidation is unlikely 
to make up a large part of the overall metabolism of a xenobiotic, it is thought to 
contribute to several ADRs. This will be discussed further later in the chapter (see 
1.2.5.3).
FMOs are a family of microsomal oxidative metabolic enzymes, of which 5 are known 
to exist in humans, named FM01-5. These enzymes are largely expressed in the liver, 
although there is also evidence for expression of most isoforms in kidney, intestine, 
lung (Cashman & Zhang, 2006) and skin (Janmohamed et al., 2001). One of the key 
distinctions between reactions catalysed by these enzymes and reactions catalysed by 
CYPs is that FMO-catalysed reactions tend to be oxidations of nucleophilic centres, 
particularly N- and S-oxidations (Eswaramoorthy et al., 2006), rather than oxidation 
of carbon atoms. While certain compounds are known to be metabolised by one or 
more of these enzymes (Cashman, 2000), little is known about any possible role they 
may play in the formation of reactive metabolites.
1.2.2 P hase II m etabolism
Phase II metabolism involves the coupling of a large polar group to a reactive site on the 
target xenobiotic. With a few exceptions, this makes the molecule more hydrophilic, 
reduces its biological activity, and enhances its renal and biliary excretion.
The most important route of Phase II metabolism is glucuronidation, whereby a glu­
curonic acid moiety is transferred from uridine-5’-diphosphoglucuronic acid by uridine 
5’-diphospho-glucuronosyltransferase to an exposed functional group on a xenobiotic, 
typically alcohol or amine groups, although conjugation to thiols and carboxylic acids 
has also been described. Unusually for a Phase II reaction, this has been associated 
with the formation of reactive metabolites, the acyl glucuronides. It has been suggested 
that this may be one of the mechanisms of the idiosyncratic hepatotoxicity seen with 
diclofenac administration (Kenny et al., 2004). Other important pathways of Phase II 
metabolism are sulfation and acetylation. The latter is particularly important for aro­
matic amines, and is catalysed by the polymorphically expressed N-acetyl-transferase
13
1. G eneral Introduction
family.
Glutathione conjugation differs from the above Phase II metabolic pathways in that 
its main role is to detoxify electrophilic reactive metabolites rather than simply enhance 
their clearance. This will be discussed in greater detail later in the chapter (see 1.2.4)
1.2 .3  R eactive m etab olites
Whilst the majority of metabolic reactions reduce the biological impact of xenobiotics, 
this is not universally the case. Both Phase I and Phase II metabolism can transform, 
or bioactivate, chemically inert compounds to compounds capable of directly reacting 
with cellular macromolecules. Examples of these reactions are listed in table 1.4.
Table 1.4: R,eactive metabolitesXenobiotic Reaction Reactive species ToxicityBenzo( a) pyrene Epoxidation Epoxide HepatocarcinogenicityParacetamol Oxidation p-Quinoneimine HepatotoxicityHalothane Dehalogenation Trifluoroacetylradical HepatotoxicityCarbamazepine Epoxidation,Oxidation Quinoneimine, Arene oxide HypersensitivityClozapine Oxidation Nitrenium ion AgranulocytosisAmodiaquine Oxidation Quinoneimine Agranulocytosis, hepa­totoxicitySulfamethoxazole N-hydroxylation Arylnitroso Hypersensitivity,thrombocytopeniaDiclofenac Glucuronidation Acyl glucuronide HepatotoxicityIsoniazid Acetylation, oxi­dation Acetyl radical HepatotoxicityTamoxifen Sulfation, oxida­tion Carbocation Hepatocarcinogenicity
The toxicity generated by reactive metabolites occurs by several different mecha­
nisms, including direct toxicity and genotoxicity through protein and DNA adduction, 
and oxidative stress through either depletion of cellular antioxidant stores or direct 
production of reactive oxygen species.
It is not clear yet whether the toxicity that ensues from protein adduction is pro­
duced simply as a function of overwhelming nonspecific dysrégulation of proteins, or 
requires damage to critical target proteins (Park et al, 2005). As certain nontoxic 
compounds are known to produce adducts at similar levels to structurally-related hep-
14
1. General Introduction
atotoxins (for instance, 3-hydroxyacetanilide vs. paracetamol; Roberts et al., 1990), 
it would seem that simple quantity of adduct formation is unlikely to be the key de­
terminant of toxicity. In addition, the reactive sulfamethoxazole (SMX) metabolite 
nitroso-sulfamethoxazole (SMX-NO) only induces cell death in vitro above a threshold 
of adduct formation; below that it is apparently well tolerated (Naisbitt et al., 2002). It 
seems likely that certain sacrificial proteins, such as metallothionein (Liu et al., 1999), 
are more readily adducted as part of the evolved cellular defense against chemical 
stress. A recent project to categorise and codify adducted proteins following reactive 
species treatment (Hanzlik et al., 2007) will hopefully allow a better understanding of 
the relationship between patterns of adduction and toxicity.
1.2.4 Cellular defense
The body has evolved several approaches to minimising either the exposure to or the 
damage from reactive chemical species. Chemical species are detoxified either enzy­
matically or non-enzymatically, typically by reduction or conjugation reactions, and 
the damage induced by reactive species is carefully managed both by selective prote­
olysis and DNA repair, and ultimately programmed cell death or apoptosis. These 
processes axe not just passive, and the cell actively responds to enhanced chemical 
stress (Goldring et al., 2006).
Several low-molecular-weight compounds have an important role to play in reactive 
species detoxification. In particular, reduced glutathione (GSH), a tripeptide formed 
from cysteine, glycine and glutamate, acts as a powerful nucleophile to conjugate elec­
trophilic species, either directly or when catalysed by a member of the glutathione-s- 
transferase family. This conjugate is either excreted following derivatisation of mer- 
capturic acids, or they can react with unreacted GSH to produce the dithiol oxidised 
glutathione (GSSG), and release the reduced, and therefore less reactive, metabolite. 
GSSG is then reduced back to GSH by GSH reductase. Although this is initially pro­
tective, if the reduced metabolite is then oxidised, whether enzymatically or not, this 
can form a futile cycle, depleting intracellular stores of GSH and leading to cell dam­
age. Other important small-molecules with protective roles in the cell are ascorbate
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(vitamin C), tocopherol (vitamin E), and N-acetyl-cysteine.
1.2.5 M etabolism  in drug h ypersensitiv ity
The following section provides a brief overview of the importance of organ/tissue- 
specific metabolic drug activation in the development of drug hypersensitivity in some 
individuals but not others. We will focus specifically on metabolism in the liver, the 
skin, and the immune system. Although the liver is known to be the most important 
location for drug metabolism in the body, extrahepatic metabolism is also suspected 
to have an important role in the induction of hypersensitivity reactions.
1.2.5.1 Liver
Quantitatively, the liver is the most important organ for drug metabolism. Hepatic 
metabolism, primarily via CYPs, is the main route of bioactivation for drugs that have 
been linked to hypersensitivity, such as SMX (Cribb & Spielberg, 1992), carbamazepine 
(CBZ; Ju & Uetrecht, 1999; Pirmohamed et al., 1992), phenytoin (Cuttle et al., 2000), 
abacavir (Walsh et al., 2002), and halothane (Njoku et al., 1997). In most (although not 
all) cases, the reactive species formed are so reactive that they are unlikely to survive 
long in circulation, which implies that the liver will receive much greater exposure 
from reactive metabolites than other tissues. However, despite the increased exposure, 
the liver is rarely the main target for hypersensitivity reactions. There are 2 likely 
reasons for this discrepancy. First, the liver is very well protected from toxic insult 
(Park et al., 2005) by cellular cytoprotective measures, such as high GSH and N-acetyl 
cysteine (NAC) levels, and readily activates further defenses via Nrf2 and NF-kB driven 
transcription. Second, the liver is an immunologically privileged organ (Ju k. Pohl, 
2005), and hepatic activation of T-cells by Kupffer cells, the resident hepatic antigen- 
presenting cells (APCs), is likely to lead to tolerance rather than a pathogenic immune 
response. This is believed to be at least partly due to increased expression of FasL 
in nonlymphoid hepatic tissue (French & Tschopp, 1996), which will drive T-cells to 
apoptosis rather than activation.
Halothane hepatitis is well studied as a model of drug-induced immune-mediated
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hepatotoxicity. A transient increase in transaminases is seen in up to 20% of patients, 
whereas a severe reaction, characterised by massive cell necrosis, occurs in 1 patient 
per 35,000 on primary exposure, and 1 in 3700 on secondary exposure (Neuberger, 
1990). Halothane is metabolised in the liver, predominantly by CYP2E1 (Eliasson 
et al, 1998), to trifluoroacetic acid, chloride, and bromide (Cohen et al., 1975). How­
ever, the reactive metabolite trifluoroacetyl chloride is also formed, which readily forms 
trifluoroacetyl adducts to free amino groups on hepatic proteins (Kenna et ai, 1988a). 
The role of metabolism in the hepatitis associated with halothane administration is best 
illustrated by a global consideration of the relationship between the in vivo metabolism 
of general anesthetics and the observed incidence of ADRs in humans. Up to 50% of 
methoxyflurane and halothane is excreted as metabolites in human urine, and their ad­
ministration is associated with severe toxicities. In contrast, less than 3% of enflurane 
and isoflurane is excreted as urinary metabolites, and human exposure is only rarely 
associated with hepatotoxicity (Park et al, 1998).
Antibodies to adducted neoantigens, particularly certain microsomal proteins (Gut 
et al, 1993), have been identified in the sera of halothane hepatitis patients (Kenna 
et al, 1988b), which has led some to conclude that these adducts are immunologically 
relevant. However, similar adducts are found in non-hypersensitive halothane-exposed 
patients, where they do not appear to be pathogenic (Gut et al, 1993), indicating that 
the major determinant of response may be idiosyncrasies in the immune system rather 
than generation of reactive metabolites and adducts. Additionally, although cellular 
reactivity to halothane has been identified both in humans (Mieli-Vergani et al, 1980) 
and in a guinea pig model (Furst & Gandolfi, 1997; Furst et al, 1997), most studies 
have concentrated on the role of autoantibodies and antibodies to neoantigens. It is 
therefore possible that an important pathogenic mechanism is being overlooked, and 
further work is required in order to address this.
1.2.5.2 Skin
Recently, there has been a lot of interest in the metabolic potential of the skin (Swan­
son, 2004), as skin is the most common site of hypersensitivity reactions (although it
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must be noted that we do not know how many minor hypersensitivity reactions are 
associated with subclinical internal organ damage). Keratinocytes are metabolically 
active, expressing high levels of several CYP isoforms (Baron et al., 2001; Yengi et al., 
2003). CYP mRNA has also been identified in other skin cell types, such as fibroblasts 
and melanocytes (Saeki et al., 2002). When the activity of primary keratinocytes is 
compared with primary liver tissue (Swanson, 2004), conflicting data have been ob­
tained, which is likely to be due to the wide inter- and intraindividual variation in 
both skin and hepatic CYP expression. Interestingly, although most important hepatic 
CYPs are expressed in the skin (including CYPs 1A1, 1B1, 2B6, and 3A4), there are 
several CYPs which are much more abundant in the skin, including several members 
of the CYP2 family that have never been identified in the liver (Du et al., 2004). The 
relevance of this for hypersensitivity is not known, but it is possible that the relative 
proportion of metabolites produced in the skin may differ from those in the liver, with 
potential immunotoxicological implications.
One of the most important recent findings in this area was the demonstration that 
primary keratinocytes are capable of oxidative metabolism of both SMX and dapsone 
to their corresponding hydroxylamine metabolites (Reilly et al., 2000). Intracellular 
SMX- and dapsone-protein adducts have also been identified in primary human ker­
atinocytes when incubated with SMX, and these adducts co-localise on the cell surface 
with HLA-ABC (Roychowdhury et al., 2005). Although the enzyme(s) responsible do 
not appear to be CYPs (Vyas et al., 2006a), both peroxidases (but not MPO, lactoper- 
oxidase or thyroid peroxidase) and FMOs, particularly FM03, appear to play a role 
(Vyas et al., 2006b), although uncertain inhibitor specificity make it hard to draw pre­
cise conclusions. It is not known as yet whether these adducts are actively presented in 
the context of HLA or are simply co-localised, for instance as part of lipid rafts. Fur­
thermore, the ability of hapten-modified cutaneous protein to stimulate T-cells from 
hypersensitive patients has not been evaluated.
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1.2.5.3 Immune System
There is less known about the metabolic activity of cells of the immune system than 
is known about the metabolic activity of cells of the liver or the skin. CYP expression 
in peripheral blood lymphocytes has been assessed (Dey et al., 2001; Krovat et al.. 
2000; McConnachie et al., 2003; Starkel et al., 1999), although a wide variability in 
findings (Finnstrom et al., 2002) makes interpretation difficult. Other immune cells are 
not as well studied, but there is some evidence that monocyte-derived dendritic cells 
(Sieben et al., 1999) and Langerhans cells (Saeki et al., 2002) are metabolically active. 
A common feature of CYP expression in the immune system is the high levels of expres­
sion of CYP1B1 (Baron et al., 1998), which is not expressed hepatically. Furthermore, 
studies have shown that this isoform has specificity for several xenobiotics, (Shimada 
et al., 1997) suggesting that there is the potential for specific immunological activation 
of drugs. Although CYP enzymes are the most widely studied in xenobiotic bioacti­
vation, other enzyme systems, particularly peroxidases, are also capable of oxidative 
metabolism of small molecules. Two of these, MPO and cyclooxygenase (COX)-2, are 
highly expressed in cells of the immune system, particularly neutrophils and mono­
cytes. Several drugs associated with a relatively high incidence of hypersensitivity 
reactions—including SMX (Cribb et al., 1990; Uetrecht et al., 1993), CBZ (Furst & 
Uetrecht, 1993), dapsone (Cribb et al., 1990), and trimethoprim (TMP) (Lai et al., 
1999)—are metabolised to reactive intermediates by these systems. Neutrophils ex­
press both peroxidase systems (but low levels of CYPs) and can generate a powerful 
extracellular oxidising system when activated. For these reasons, and because of their 
sheer numbers in circulation, neutrophils have been described as “the greatest drug- 
metabolising engine outside of the liver” (Rubin k  Kretz-Rommel, 2001). The role of 
neutrophils in drug-induced lupus has been widely discussed and has been linked to 
the ability of lupus-inducing drugs to be bioactivated by MPO (Jiang et al., 1994). 
Langerhans cells and dendritic cells express COX (Norgauer et al., 2003), although 
there is contradictory evidence regarding the expression of MPO (Pickl et al., 1996; 
Scholz et al., 2004). Although the specialised antigen-presenting nature and metabolic 
activity of Langerhans and dendritic cells would presumably enhance their potential for
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initiating an immune response to haptenated proteins, this has not been unequivocally 
identified either in vivo or in vitro.
1.3 Immune A ctivation by Drugs
As discussed above, immune-mediated drug reactions are a major clinical problem. 
Despite extensive research, much is still unknown about the fundamental immunolog­
ical mechanisms behind such reactions. From an immunotoxicological perspective it 
is essential that these fundamental mechanisms are elucidated in order to reduce this 
burden, in order to inform the physician with regard to the safer use of existing treat­
ments and also to inform the medicinal chemist to facilitate the design of safer and 
better tolerated drugs.
Before considering the possibilities for a drug to activate the immune system, it is 
instructive to define some of the terms which will be used in this discussion, namely, 
hapten, antigen, and immunogen (Abbas 8z Lichtman, 2003; Park et al., 1998).
Hapten: A small molecule which can only induce an immunological response when 
bound to a carrier protein, either exogenous or endogenous.
Antigen: Any substance which can be specifically bound by an antibody or T-cell 
receptor.
Immunogen: A molecule which can stimulate a specific cellular or humoral immune 
response.
It is important to note that individual compounds may have any of a number of 
combinations of these properties - while all immunogens are antigens, not all antigens 
are immunogens, for instance self-proteins are antigenic, but do not normally stimulate 
an immune response.
The following discussion will focus on the various mechanisms by which the immune 
system is activated, and how drugs can interact with these pathways to induce immune 
activation.
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1.3.1 T he induction  and propagation of an im m une response
In this section, the process of T-cell activation in both the induction and propagation of 
an immune response will be reviewed. In order not to preempt later discussion, several 
areas will be necessarily left brief, and the reader will be directed to relevant reading 
later in the chapter.
The immune system continually surveys the body, especially exposed parts such as 
the skin, lungs and digestive system, for the presence of pathogens. This process is 
performed by the innate immune system, and in particular immature dendritic cells, 
which, as Langerhan’s cells, are continually present in skin. Detection of pathogens is 
performed either by detection of specific molecular patterns associated with pathogens 
(for instance, lipopolysaccharide; see 1.3.2.1) or by detection of the cellular damage 
which pathogens produce (see 1.3.2.2), and induces full maturation of the dendritic cells, 
including upregulation of several co-stimulatory markers, cytokine release, enhanced 
major histocompatibility complex (MHC) expression, and migration towards the lymph 
nodes. The overall effect of these maturational changes is to switch the dendritic cell’s 
function from surveillance and antigen capture and processing, to antigen presentation. 
It is not clear what induces these maturational changes in drug hypersensitivity, or 
even if there is any commonality between different reactions. Convincing arguments 
can be made for the importance of the presence of bacterial components, concurrent 
viral infection, or cellular damage induced by the action of the drug or its metabolites 
(for a fuller treatment, see 1.3.4). However, these are all little more than speculation at 
present, and this remains one of the most important questions which must be answered 
in order to fully understand these reactions. In particular, it must be noted that, 
although the possibility that reactive drug metabolites can activate dendritic cells is 
prima facie plausible, there is no evidence as yet that it occurs.
Dendritic cell activation is an essential step, but it is incapable of inducing a response 
without the presence of a foreign antigen—that is to say, an antigen to which responding 
T-cells have not previously been selected out in the thymus. The antigen is recognised 
in the context of an MHC molecule by the highly variable T-cell receptor (TCR), which 
induces a series of biochemical events within the cell, leading to either tolerance (in
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the absence of concurrent co-stimulation from the APC) or full activation of the cell 
(with co-stimulation). The requirements for T-cell activation by peptides, and the 
consequences of this are discussed later (see 1.3.5). How drugs can act as antigens is 
one of the key questions in the study of drug hypersensitivity reactions, and, despite 
considerable work, remains unclear. Two major hypotheses have been proposed (see
1.3.6 and 1.3.7 for a discussion of these), but conclusive evidence by which to choose one 
or the other, or to justify synthesising the two, is still elusive. A further complication is 
that the T-cell reactivity profile in vivo is known to develop over the course of a reaction. 
For instance, in several studies of the evolution of an immune response to peptide 
antigens it has been noted that over time the proportion of T-cells from high-affinity 
clones come to dominate over those from low-affinity clones (Amrani et al, 2000). This 
process, known as avidity maturation, is due in part to competition and preferential 
expansion (Busch & Pamer, 1999), although other effects, such as early suppression of 
high-affinity responses by central and peripheral tolerogenic mechanisms (Han et al., 
2005) and secondary receptor revision (the modification of TCR-specificity by mature 
lymphocytes; McMahan &; Fink, 2000; Serra et al., 2002) appear to be important too. 
Therefore, it is perfectly plausible that the antigen to which the immune response is 
initiated is different from that to which T-cells taken later respond.
T-cell activation and the induction of an immune response to a drug lead to cellular 
damage through several known mechanisms. Migration of T-cells from the vasculature 
into tissue occurs by means of the expression of chemokines within the tissue, and 
presented on the endothelial surface, and chemokine receptors, which are up-regulated 
on activated T-cells. These induce transendothelial migration and movement along a 
chemotaxic gradient towards a site of inflammation. Several studies have looked for 
the chemokine receptors associated with specific tissue involvement. For instance, skin 
infiltration appears to be largely mediated by CCR4, CCR10 and CLA (Soler et al., 
2003), and indeed, both CCR10 and CCR4 have been found to be expressed on the 
T-cells involved in drug-induced skin reactions (Tapia et al., 2004; Wu et al., 2007). In 
contrast however, while the chemokine receptors involved in liver infiltration in response 
to viral infection have been investigated (for a good review, see Heydtmann et al., 2001),
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and certain chemokine receptors, in particular CXCR3 and CCR5 (Shields et al., 1999), 
have been identified as important in this context, no studies have specifically looked 
for chemokine receptor involvement in liver-injury as part of a drug hypersensitivity 
reaction. A better understanding of why specific chemokine receptors are up-regulated 
on T-cells activated by drugs will hopefully allow greater insight into the causes of the 
specific pattern of organ involvement in drug hypersensitivity.
In addition to T-cell involvement, several other cell types are recruited, both as 
part of the innate and acquired immune systems. B-cell involvement leads to the 
production of drug-specific antibodies, although the pathogenic role of these is unsure. 
For instance, SMX antibodies have been detected both in SMX-hypersensitive and in 
SMX-tolerant individuals (Carr et al., 1993a), and in many cases are not detectable at 
all (Cribb et al., 1997; Gruchalla et al., 1998). It is true that, in general, anti-SMX 
antibodies are more often detected in hypersensitive individuals, but it is hard to see 
how they can play a major role in the pathology when their presence is so variable. 
The main other immunological cell type which are recruited in drug hypersensitivity 
are eosinophils. These are recruited by the release of IL-5 and eotaxin (Yawalkar et al., 
2000), and play an important role in the development of cutaneous exanthems through 
the release of proinflammatory molecules such as histamine, prostaglandins and major 
basic protein.
Following migration to the extravascular site of activity, T-cells are believed to 
produce the majority of the observed pathological effects. There is some evidence 
that differences in the nature of the T-cell response are the key determinants of dif­
ferences in the clinical picture (see the extended Gell & Coombs scheme; table 1.1). 
For instance, the cutaneous manifestations of bullous reactions, such as toxic epider­
mal necrolysis (TEN) or Stevens-Johnson syndrome, appear to be caused by CD8+ 
cytotoxic T-cells inducing widespread apoptosis of keratinocytes (Paul et al., 1996) 
through both release of soluble Fas ligand (Abe et al., 2003) and direct cell-mediated 
killing via the perforin/granzyme pathway (Nassif et al., 2004). Other reactions, such 
as maculopapular eruptions, appear to be more dependent on CD4+ T-cells, although 
keratinocyte apoptosis is still a major feature. In addition to the expansion of a large
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population of effector T-cells, a significant proportion of the activated T-cells become 
quiescent ’memory’ T-cells, and it is these cells which react to a later rechallenge with 
the same, or structurally similar, drug.
In addition to these populations of effector T-cells, there is a further population of 
CD4+ T-cells which constitutively express CD25 (rather than solely when activated, as 
other T-cells do). These cells, known as regulatory T-cells or Tregs, play an important 
role in the control and limitation of immunological reactions, either through release of 
inhibitory cytokines, such as IL-10, or through cell-cell interactions such as CTLA-4 
ligation of CD80/86 on effector T-cells. For a good review, see von Boehmer (2005). 
Regulatory T-cells have been found to play an important role in the suppression of T- 
cell responsiveness to typical allergens in atopy, and indeed, they appear to be a major 
determinant of allergy. An important study by Ling et al. (2004) found that PBMCs 
from atopic donors, but not non-atopic donors, responded vigorously to allergen (in 
this case, grass pollen) challenge. When CD4+CD25+ cells were depleted from the 
PBMC populations, however, cells from both atopic and non-atopic donors responded 
strongly. This appears to indicate that there is no lack of allergen-specific T-cells in 
non-atopic individuals, merely that there are kept under control by Tregs, and that it 
is actually differences in Tregs (or, possibly, differences in the response to Tregs) which 
determines whether or not allergy develops. A similar study (Cavani et al., 2003) has 
found that nickel responsiveness is similarly repressed in normal individuals by the 
action of Tregs, and so it is tempting to suggest that this may also be a factor in the 
induction of immune responses in drug hypersensitivity. However, at present no study 
has found evidence to either confirm or disconfirm this proposition.
1.3.2 D anger signalling
The danger hypothesis, postulated by Matzinger (1994) as an extension of Janeway’s 
work on the links between the innate and the adaptive immune systems (Janeway, 
1992), holds that the nonself nature of a foreign antigen is not what induces an immune 
response; instead, it is ‘danger signals,’ such as cell damage or infection, that activate 
the immune system. Therefore, it can be said that effective activation of the adaptive
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immune system requires 2 signals: signal 1, which is the TCR-mediated recognition 
of an MHC-restricted antigen; and signal 2, which represents the interactions between 
various co-stimulatory ligands and receptors between the T-cell and the APC, such 
as CD28:CD86 and CD40:CD154 (Naisbitt et al., 2000a). In the absence of signal 2, 
signal 1 simply leads to tolerance, either by anergy or by apoptosis of responding T-cells 
(Appleman &; Boussiotis, 2003). Danger signals act to enhance this signal 2 pathway, 
by upregulating co-stimulatory markers on professional APCs, such as dendritic cells.
1.3.2.1 Exogenous danger signals
Most studies of the activation of dendritic cells have concentrated on the effects of 
pathogen-associated molecular patterns (PAMPs). These typically produce dendritic 
cell maturation signals by interacting with Toll-like receptors (TLRs), a series of membrane- 
bound receptors. Thirteen individual mammalian TLRs have been identified to date, 
although only ten are known in man, numbered from TLR-1 to TLR-10 inclusive.
TLRs have been identified in many other vertebrates, and highly homologous proteins 
are present both in bacteria and in plants, where they play a similar role in resistance 
to infection (Nürnberger et al., 2004). TLRs therefore represent one of the most ancient 
components of the immune system.
The most commonly studied PAMP is the bacterial cell wall component lipopolysaccharide 
(LPS), which is known to interact with TLR-4 (Poltorak et al., 1998), the first TLR 
to be identified (Medzhitov et al., 1997), and induce dendritic cell maturation. Other 
well-known PAMP interactions are the interaction of unmethylated DNA CpG motifs 
with TLR-9 (Hemmi et al., 2000) and the interaction of double-stranded viral RNA 
with TLR-3 (Alexopoulou et al., 2001). See table 1.5 for an overview of known TLR 
functions.
1.3.2.2 Endogenous danger signals
In addition to these external sources of danger signals, several studies have focused on 
the ability of stressed, dead, or dying cells to provide maturation signals to dendritic 
cells. Initial studies revealed that cells killed necrotically, but not viable or apoptotic
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Table 1.5: Overview of TLR specificity
Toll-like receptor Known ligandTLR-1 TLR-2 TLR-3 TLR-4 TLR-5 TLR-6 TLR-7 TLR-8 TLR-9 TLR-10
Triacyl lipopeptides (with TLR-2) Lipoproteins; peptidoglycan; lipoteichoic acid Double-stranded RNA Lipopolysaccharide FlagellinDiacyl lipopeptides (with TLR-2) Single-stranded RNA (in mice) Single-stranded RNA Unmethylated CpG DNA Unknown
Refs: Alexopoulou et al. (2001); Diebold et al. (2004); Hayashi et al. (2001); Hasan et al. (2005); Heil et al. (2004); Hemmi et al. (2000); Poltorak et al. (1998); Schwandner et al. (1999); Takeda et al. (2002)
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cells, activate dendritic cells (Gallucci et a/., 1999), although later studies have also 
found an effect from cells undergoing apoptosis (Janssen et al., 2006). Heat shock 
proteins released from dying cells are obvious candidates as danger-signalling molecules, 
or ‘endogenous adjuvants’, and their ability to provide maturation signals to dendritic 
cells has been discussed in detail (Todryk et al., 2000). More recently, ground-breaking 
studies by Shi et al. (2003, 2006) have used chemical analyses to define uric acid crystals 
as potent messengers that are released by injured and dying cells and that can stimulate 
dendritic cell maturation and enhance CD8+ T-cell responses in vivo, although the 
relevance of these findings in humans has been questioned (Gu et al., 2004).
There is some evidence that signals from endogenous adjuvants are also transduced 
by TLR ligation, although this is less clear-cut than the evidence for PAMP-induced 
dendritic cell activation. It has been claimed that heat-shock proteins signal via TLR- 
4 (Asea et al., 2000; Ohashi et al., 2000), but other studies have suggested this may 
be due to LPS contamination (Bausinger et al., 2002; Gao &; Tsan, 2003). Certain 
other endogenous adjuvants have also been claimed to signal through TLRs, such as 
fibronectin via TLR-4 (Okamura et al., 2001), hyaluronan via TLR-2 (Scheibner et al., 
2006) and TLR-4 (Termeer et al., 2002), and fibrinogen via TLR-4 (Smiley et al., 2001). 
However, as can be seen from the controversy regarding heat-shock protein signalling, 
there remains a risk that these signals are due to bacterial contamination.
1.3.3 C o-stim ulatory signalling
Danger signals are primarily transmitted from the APC to the effector cell by means 
of co-stimulatory signalling. This refers to a range of ligand-receptor interactions be­
tween activated APCs and T-cells, including, but not limited to, CD40-CD154 and 
CD80/86-CD28 interactions. In addition to co-stimulation, there is increasing evidence 
of co-inhibition acting as a brake on the activation of the immune system. For a good 
review, see Subudhi et al. (2005). However, this discussion will concentrate largely on 
co-stimulation, and how it acts to provide modulation of immune-mediated drug reac­
tions. In particular it will cover the two best-understood pathways, the CD28/CTLA- 
4:CD80/86 and the CD40:CD154 pathways.
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1.3.3.1 CD28/CTLA-4:CD80/86 signalling
CD28 and CTLA-4 are structurally related T-cell surface receptors which interact with 
CD80 and CD86 on the surface of APCs. CD28, which is expressed on all T-cells, 
both active and naive, transduces activational signals which lead, in concert with the 
ligation of the TCR by a specific antigen, to full activation. CD28 ligation is essential 
for cytokine release (Thompson et al., 1989), enhances T-cell survival, prevents anergy 
(Harding et al., 1992; Jenkins et al., 1991), and stabilises expression of CD40L in order 
to provide signalling to dendritic cells and help to B-cells (Johnson-Lger et al., 1998).
CTLA-4 ligation, however, leads to inhibition of T-cell activation. It is believed 
that this occurs both by actively inhibiting the biochemical steps required for T-cell 
activation, including blockade of cell cycle progression and inhibition of IL-2 produc­
tion (Walunas et al., 1996), and by competing for CD80/86 molecules (CTLA-4 binds 
to CD80/86 with much higher affinity than CD28) and hence inhibiting CD28 sig­
nalling (Saito & Yamasaki, 2003). CTLA-4 is not expressed on naive T-cells, but is 
up-regulated on activated cells, and so acts as a ‘brake’ on excessive T-cell activation.
CD80/86 axe both expressed on APCs, and although there is some degree of ex­
pression of CD86, but not CD80, on immature dendritic cells, significant upregulation 
of both occurs alongside maturation. They both transduce signals from APC to T-cell 
via CD28 and CTLA-4, but less is known about any signals which they receive from 
the T-cell. Recent studies have suggested that CTLA-4 ligation of CD80/86 leads to 
inhibitory signalling within the APC (Grohmann et al., 2002; Munn et al., 2004). How­
ever, the primary role of CD80/86 is still believed to be due to their effects on T-cells 
induced by ligation of CD28 and CTLA-4.
1.3.3.2 CD40:CD154 signalling
CD40 is a cell surface receptor of the TNF-a receptor family. It is expressed on APCs 
where it transduces activational signals from activated T-cells. Ligation of CD40 by 
its natural ligand CD40L (otherwise known as CD 154) induces several changes within 
the APC through activation of Nf-ftB (O’Sullivan & Thomas, 2002), such as release 
of inflammatory mediators, enhanced cell survival, up-regulation of MHC-II, CD80,
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CD86, and release of pro-inflammatory cytokines (Caux et al., 1994; Celia et al., 1996).
CD40L is not expressed on the surface of resting T-cells, but becomes transiently 
expressed on the surface when T-cells become activated through the TCR. Both CD28 
signalling (Johnson-Lger et al., 1998) and cytokines, in particular IL-2 (Skov et al.,
2000), can stabilise this expression, and allow effective signalling to the APC.
The overall effect of CD40 signalling is to enhance the ability of APCs to present 
antigen to T-cells, and to drive an antigenic response from tolerance to immunity. As 
CD40 is itself up-regulated by APC activation (Verhasselt et al., 1997), this produces a 
positive feedback loop which amplifies the original inflammatory signal. Indeed, CD40 
interactions have been shown to be essential for persistence of immune responses in 
vivo (Miga et al., 2001).
1.3.4 D endritic cell activation  by drugs
The source of co-stimulatory signalling for the induction of primary immune responses 
to drugs is still controversial. It is possible that these signals are supplied by concurrent 
infection or other source of endotoxin (Roth et al., 2003), and indeed there is good 
evidence that viral infection is a major risk factor for hypersensitivity (Pirmohamed & 
Park, 2001). However, there is little evidence for a similar effect with bacterial infection, 
and there have been many documented cases of hypersensitivity in the absence of any 
overt infection. Therefore, it may be instructive to consider the possibility that drugs 
can directly induce innate immune activation.
It is possible for a drug to act pharmacologically to induce dendritic cell activation, 
as has been described for certain imidazoquinolene small anti-viral compounds such 
as imiquimod (Hemmi et al., 2002), which are agonistic at the TLR-6/7 receptors, 
and lenalidomide, a thalidomide analog which supplies co-stimulation to T-cells via 
activation of the B7-CD28 pathway (LeBlanc et al., 2004). Interestingly, both of these 
compounds have been associated with cutaneous reactions (Hadley et al., 2006; Sharma 
et al., 2006), although more work is required in order to determine whether these 
reactions are analogous to those seen in hypersensitivity. However, this seems to be 
an unlikely mechanism for most drugs associated with hypersensitivity, given the wide
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range of chemical classes involved. A more plausible source of danger signals is the cell 
damage produced by reactive drug metabolites.
When considering the potential for drug metabolites to interact with dendritic cells 
and provide maturation signals, lessons can be learned from studies with contact sensi- 
tisers, which because of their intrinsic protein reactivity are often toxic to immune cells 
at relatively low concentrations. This toxicity can be the result of covalent binding, 
either to specific target proteins or non-specifically, potentially exposing hydrophobic 
residues and activating toll-like receptors (Seong k  Matzinger, 2004). Alternatively, 
this toxicity could be due to the generation or impaired detoxification of reactive oxy­
gen species, a major factor in activation of the pro-inflammatory NF-kB pathway (Kabe 
et al., 2005), which is essential for complete dendritic cell maturation (Ardeshna et al., 
2000; Rescigno et al., 1998). It has been suggested that dendritic cell maturation in 
response to dinitrohalobenzenes may be due to inactivation of thioredoxin reductase 
and consequent impaired detoxification of reactive oxygen species (Nordberg k  Arner,
2001). However, this direct activation is inhibited by thiol antioxidants (Bruchhausen 
et al., 2003) but not other antioxidants, suggesting that the effect of thiol antioxidants 
is not solely due to radical scavenging. This idea is supported by the finding that 
glutathione depletion enhances this activation (Mizuashi et al., 2005).
A wide variety of structurally unrelated contact sensitisers have been found to pro­
voke signal 2 via direct activation of dendritic cells and monocytes, as determined by 
either up-regulation of cell surface markers, particularly CD80, CD86, CD40, HLA-DR, 
(Aiba et al., 1997; Coutant et al., 1999; Staquet et al., 2004; Tuschl et al., 2000) or 
chemokine receptors (Jugde et al., 2005); by activation of signal transduction pathways 
(Aiba et al., 2003; Arrighi et al., 2001; Becker et al., 2003; Bruchhausen et al., 2003; 
Iijima et al., 2003) or by functional effects, for instance, enhanced activation of allo­
geneic T-cells (Aiba et al., 2000; Coutant et al., 1999; Manome et al., 1999) or in vivo 
sensitisation (Aiba k  Katz, 1990). Recently, Hulette et al. (2005) showed that con­
tact sensitisers stimulate dendritic cell maturation only at concentrations associated 
with low levels of cell death, presumably via a classical ‘danger’ response (Matzinger, 
1994) and the recognition of released endogenous signals (Gallucci et al., 1999; Shi
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et al., 2003). However, a recent study using the hair dye allergen p-phenylenediamine 
as a paradigm (Coulter et al., 2006), has shown that dendritic cell maturation can 
be induced at concentrations below those associated with cell death, as measured by 
increased expression of CD40 and stimulation of allogeneic lymphocyte proliferation.
Based on the observation that many protein-reactive drug metabolites bind cova­
lently to thiol-rich protein, it is not unlikely that a similar effect may be driven by drug 
metabolites, although there is no published evidence at yet that this occurs.
1.3.5 T -cell activation  by proteins and drugs
In addition to the signal 2 transduced by co-stimulation from activated dendritic cells, 
T-cells also require signal 1, antigen-specific ligation of the TCR, for activation. This 
typically involves recognition of a peptide antigen presented in the context of an MHC 
molecule, although there are some exceptions, such as superantigens.
The MHC molecules are divided into two main families, MHC-I (in humans, HLA- 
A,B,C) and MHC-II (HLA-DR,DP,DQ). The MHC region in the genome is exception­
ally polymorphic, which is likely to be related to the evolutionary benefits of hetero­
geneity in pathogen immunity (Meyer &: Thomson, 2001). MHC-I is expressed on all 
cell types, and presents antigens derived from intracellular proteins to CD8+ T-cells, 
along with some derived from extracellular proteins, through a process called cross­
presentation. MHC-II, by contrast, is only expressed on professional APCs, and is 
up-regulated in response to APC maturation. This MHC presents antigens derived 
from extracellular proteins, taken up by the APC as part of its routine sampling of the 
surrounding milieu, to CD4+ T-cells.
Peptide antigens are specifically recognised by T cells via the TCRs interacting 
with the peptide bound non-covalently to the MHC molecule. Antigen-presenting cells 
process proteins into peptides, load them onto nascent MHC molecules and traffic 
them to the cell surface. The composite MHC-peptide surface then acts as a ligand 
for peptide-MHC-specific TCRs. Recent work has, elucidated many of the structural 
requirements for the TCR-peptide-MHC interaction (for review, see van der Merwe & 
Davis, 2003).
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Peptides fit into a specific groove on the surface of MHC molecules where they are 
held in place by non-covalent interactions, particularly at certain conserved residues 
known as anchor residues. MHC-I molecules typically accept nonameric peptides, al­
though some longer peptides have been seen. The N- and C-terminals are fixed in place, 
and longer peptides are accommodated by bulging of the peptide (Speir et al., 2001). 
In addition to the essential carboxy-terminal anchor position, MHC-I-bound peptides 
have up to three further anchor residues. MHC-II-bound peptides are generally held 
less tightly, and are less constrained in terms of peptide length (between 12 and 25 is 
common; Rammensee, 1995). The interactions between the peptide and MHC molecule 
are also less constrained, and involve more uniformly dispersed residues.
While anchor residues are particularly important for binding to MHC molecules, 
other residues make up a disproportionate amount of the binding to the TCR, especially 
for MHC-I-bound peptides. Indeed, in most studied MHC-I-bound 9-amino acid pep­
tides, the residue at position 5 is responsible for over half of all TCR-peptide contacts 
(Rudolph & Wilson, 2002). As was the case for MHC interactions, peptides bound to 
MHC-II are less dependent on certain residues for TCR interactions, but they still only 
contact the TCR through a subset of available residues.
A striking finding of recent studies of TCR-MHC-bound structures is the hetero­
geneity of the TCR-peptide-MHC interaction, as there appear to be very few common 
features to all interfaces visualised so far (Rudolph & Wilson, 2002). However, it has 
been discovered that the overall portion of the total binding area represented by TCR- 
peptide interactions is significantly lower than that supplied by TCR-MHC interactions.
An important conclusion from these studies on TCR recognition of peptides is that 
although the peptides are relatively large, only a small portion of them is actually 
involved in binding to the TCR, and that the TCR-MHC interactions overshadow 
TCR-peptide interactions.
There is evidence that the T-cell is exquisitely sensitive to tiny quantities of antigen, 
with as little as a single peptide antigen being sufficient to activate its cytolytic activities 
(Sykulev et al., 1996), and a further study finding transient Ca2+ mobilisation following 
a single TCR ligation, and immunological synapse formation with as few as 10 (Irvine
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et al., 2002). However, T-cell activation is believed to be triggered by the process of 
serial triggering (Valitutti et al., 1995). Under this paradigm, simple ligation of TCRs 
is insufficient to activate the cell; what is required is multiple ligation of distinct TCRs. 
This involves accumulation of signalling molecules, most likely members of the ERK 
family (Borovsky et al., 2002), until a threshold is reached, which allows full T-cell 
activation. This is due in part to the downregulation of TCRs following triggering, 
presumably a mechanism to prevent excessive activation. One of the consequences of 
this mechanism is that there is a relatively narrow window of affinity for TCR-antigen 
interactions, leading to a ’Goldilocks’ effect: too low, and it cannot trigger the TCR; 
too high, and it cannot dissociate rapidly enough to allow serial triggering (Kalergis 
et al., 2001).
1.3.6 H apten  h ypothesis
In 1935, Landsteiner and Jacobs undertook a series of seminal studies on the sensi­
tisation potential of low-molecular weight organic compounds (Landsteiner Sz Jacobs, 
1935). They found a strong correlation between the sensitisation potential in vivo and 
the protein reactivity in vitro. Additionally, on the basis of studies with modified poly- 
1-lysine peptides (for instance, see Stupp et al., 1971), it was not believed that small 
molecules (< 1000 Da) were able to act as an antigen. These findings have thereafter 
formed the basis of the hapten hypothesis, which posits that drugs-or more commonly, 
reactive metabolites formed by the normal processes of metabolising enzymes-are recog­
nised by drug-specific T-cells only following haptenation to self-proteins (Park et al., 
2001). This leads to formation of a neoantigen that can be recognised by T-cells to over­
ride self-tolerance, and induction of a potentially pathogenic immune response. This 
mechanism has been well documented for contact sensitisers such as dinitrohaloben- 
zenes (Cavani et al., 1995; Park et al., 1987; Weltzien et al., 1996) and respiratory aller­
gens such as trimellitic anhydride (Dearman et al., 1991, 2000). More speculatively, it 
is thought to be a mechanism for the breaking of self-tolerance in autoimmunity (Doyle 
&; Mamula, 2001; Kimber Sz Dearman, 2002; Palmer et al., 2004).
There is little direct evidence for the importance of hapten formation in drug hyper-
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sensitivity. That is not to say that there is no circumstantial evidence, which certainly 
appears to point to the importance of reactive metabolite generation and covalent 
binding in hypersensitivity reactions. In particular, there is convincing evidence that 
reactive metabolites are significantly more immunogenic in vivo than their parent com­
pounds. This will be discussed as regards SMX hypersensitivity later (see 1.3.8.3; also 
2.1). Furthermore, there is good evidence that human immunodeficiency virus (HIV) 
infection, which is associated with a greatly increased risk of hypersensitivity reactions 
(Lin et al, 2006; Pirmohamed 8z Park, 2001), is also associated with thiol and ascor­
bate depletion (Naisbitt et al., 2000b; Trepanier et al., 2004; Walmsley et al., 1997), 
which may thereby lead to a decreased ability to detoxify reactive metabolites (Naisbitt 
et al., 2000b) and to increased metabolite-mediated cellular toxicity (Wijsman et al., 
2005). However, viral infection will also have significant immunological effects unre­
lated to metabolite detoxification, such as deranged regulatory mechanisms (Eggena 
et al., 2005). Additionally, some studies have failed to find a link (Eliaszewicz et al.,
2002), so this remains controversial.
It is also worth pointing out that almost all drugs associated with a comparatively 
high incidence of hypersensitivity reactions are known to form reactive metabolites. It 
is not known whether this is simply observational bias, due to the increased research 
focus on these drugs, or is of genuine importance.
One of the difficulties with the hapten hypothesis is the generally poor association 
between exposure to reactive metabolite and incidence of reactions. Several studies 
have looked for associations of susceptibility to hypersensitivity with polymorphisms 
in drug metabolising enzymes, particularly CYPs (Pirmohamed et al., 2000; Wolken- 
stein et al., 2005), though also epoxide hydrolase (Gaedigk et al., 1994; Green et al., 
1995) and N-acetyl-transferase (Alfirevic et al., 2003; O’Neil et al., 2002), but the re­
sults have been disappointing. A small association between SMX-hypersensitivity with 
N-acetyl-transferase polymorphisms has been claimed (O’Neil et al., 2002), but at­
tempts to replicate this have failed (Alfirevic et al., 2003). Prospective studies have 
been performed in order to identify putative associations between exposure to reactive 
metabolites and hypersensitivity. In particular, a large-scale prospective clinical trial
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of N-acetyl cysteine as prophylaxis against SMX hypersensitivity was undertaken, but 
was unsuccessful (Walmsley et al., 1998).
1.3 .7  p-i concept o f T -cell activation  by drugs
More recently, a hypothesis known as the p-i, or pharmacological-interaction, concept 
has been proposed. The p-i concept posits that drugs can activate T-cells directly in 
the absence of metabolism, covalent binding, and antigen processing, (Pichler, 2002) 
through a reversible interaction between the TCR, MHC, and the drug. Several in­
dependent lines of inquiry have led to this conclusion. Firstly, both peripheral blood 
mononuclear cells (PBMCs) from hypersensitive patients and T-cell clones cultured 
from the same patients respond to parent drug in the absence of appreciable metabolism 
(Naisbitt et al., 2003a, 2005a; Schnyder et al., 1997; Zanni et al., 1997); second, washing 
the drug away from APCs prior to adding T-cells is sufficient to completely abrogate 
the T-cell response, irrespective of the length of time the APCs have been exposed 
to the drug (Depta et al., 2004; Schnyder et al., 1997; Naisbitt et al., 2003b); third, 
glutaraldehyde-fixed APCs are still competent to present drug to T-cell clones (Naisbitt 
et al., 2003b, 2005a; Schnyder et al., 1997), although they are incapable of antigen pro­
cessing (Schnyder et al., 1997; Shimonkevitz et al., 1983); and fourth, the time-course 
of activation of T-cell clones, as determined by several markers of T-cell activation, 
such as TCR downregulation (Zanni et al., 1998), ERK phosphorylation (Depta et al., 
2004), and Ca2+ mobilisation (Zanni et al., 1998), are too rapid to allow metabolism 
and antigen processing.
These findings have been demonstrated using ex vivo T-cell clones from patients hy­
persensitive to several drugs, including SMX (Schnyder et al., 1997), lidocaine (Zanni 
et al., 1997), lamotrigine (Naisbitt et al., 2003b), and phenindione (Naisbitt et al., 
2005a). However, in all these studies, the T-cells have been derived from in vitro ex­
pansion of drug-specific T-cells prior to cloning, which may well affect the apparent 
make-up of drug-specific T-cells. Recently, this point was addressed by Nassif et al. 
(2004), who identified SMX-specific T-cells directly from blister fluid in TEN patients. 
However, their interpretations regarding the lack of a role for metabolism remain con­
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troversial since blister fluid T-cells from all patients also responded to the reactive 
metabolite SMX-NO (Naisbitt et al., 2005b).
One of the main concerns with the theory is that while relatively low-affinity anti­
gens, as a non-covalently bound drug would presumably be, can activate memory T- 
cells, the initial T-cell priming event is more stringent with respect to TCR-antigen- 
MHC affinity. It has therefore been proposed that the drugs actually activate memory 
T-cells with unknown peptide-antigen specificity (Pichler, 2005). This may explain the 
propensity of certain compounds, such as radiocontrast media, to induce apparently 
immune-mediated hypersensitivity reactions within a few hours of the initial exposure 
to the compound (Christiansen et al., 2000). An interesting corollary of this hypothesis 
is that it removes the need for co-stimulation as a requisite element of hypersensitivity 
reactions, since this is only required for induction of a primary response. However, 
although certain hypersensitivity reactions occur extremely quickly and without prior 
exposure, this is not the case for the majority of reactions, which require a relatively 
long exposure (2-3 weeks) to the drug. This would suggest that in most cases, there 
is sufficient time for the induction of a primary immune response. In addition, Engler 
et al. (2004) successfully induced a primary T-cell immune response in vitro against 
SMX in PBMCs from drug-naive volunteers, but this required a significant period of 
incubation with the drug (3-4 weeks), which again does not appear to suggest a purely 
secondary response, and indeed suggests that non-covalently bound drug may indeed 
be able to act with sufficient affinity as an antigen to induce a primary response.
While the proposition that T-cells can recognise drugs as antigens in a non-covalent 
manner is still controversial, it is unquestionably recognised as the mechanism by which 
certain metal ions, such as nickel, are recognised. Nickel is one of the most commonly 
encountered contact sensitisers, and a common cause of allergy (Nielsen et al., 2002). 
Ni2+ ions readily dissolve in sweat and are absorbed through the skin (Menne, 1996), 
where they bind to carrier proteins via four- and six-coordinate binding to electron 
donors such as oxygen, nitrogen and free thiols (Zhang & Wilcox, 2002).
Nickel-specific T-cells have been cloned on a number of occasions (Moulon et al., 
1995; Pistoor et al., 1995; Sinigaglia et al., 1985), and these have allowed detailed
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investigations into the nature of the nickel antigen. It appears that for certain clones, 
nickel acts in a similar fashion to a classical hapten, in that it is not possible to wash the 
bound nickel away from antigen-presenting cells and eliminate T-cell reactivity (Moulon 
et al., 1995). In certain clones that react to nickel in this fashion, it appears that Ni2+ 
binds directly to the surface of a peptide-MHC complex (Lu et al., 2003), whereas a 
functional antigen-processing pathway is required for other clones, suggesting that Ni2+ 
remains bound to the peptide as it is processed (Moulon et al., 1995). In both of these 
cases, however, it is clear that the bonds Ni2+ forms to the MHC peptide are of sufficient 
strength to allow the ion to act as a hapten. Alternatively, certain clones appear to 
depend on the continual presence of free Ni2+ ions for activation, and in these clones it 
appears to act in a peptide-independent superantigen-like fashion (Gamerdinger et al.,
2003). In these cases, it seems likely that Ni2+ does not bind tightly to the MHC or 
peptide, but forms a relatively weak interaction that can be removed by washing.
An important implication of these findings is that it is not so much covalent vs. non- 
covalent which is the issue of importance, but more the summation of the interactions 
in question—certain non-covalent interactions, such as the co-ordinate linkages involved 
in nickel binding, can act either as haptens or as free compounds, depending on the 
T-cell clone which responds.
1.3.8 Exam ples o f  xen ob iotic  im m unogenicity
In order to further elucidate some of the previously discussed themes, we will briefly 
discuss four important paradigm compounds, namely, nitrohalobenzenes, penicillins, 
SMX and CBZ. This will illustrate the different possible ways by which the immune 
system can recognised drugs, and it also offers insights into the common features which 
they all share.
1.3.8.1 Dinitrohalobenzenes
The most widely studied classes of model chemical immunogens are the nitrohaloben­
zenes, particularly 2,4-dinitrochlorobenzene (DNCB), 2,4-dinitrofluorobenzene (DNFB), 
and 2,4,6-trinitrochlorobenzene. These are highly potent topical sensitisers, although
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they are rarely encountered amongst the population at large. However, their relatively 
simple chemistry and effectiveness for in vivo sensitisation has made them essential 
tools for the investigation of fundamental immunochemistry.
Nitrohalobenzenes are powerful electrophiles which readily react with nucleophilic 
residues on proteins, particularly cysteine and lysine groups, through an SjvAr nucle­
ophilic substitution mechanism (see figure 1.1A). This involves nucleophilic attack at 
the halogen-bonded carbon, which is stabilised by resonance structures involving the 
electron-withdrawing nitro groups, followed by preferential ejection of the halide ion as 
a good leaving group. This has been seen to occur with cysteine and lysine, both in 
vitro (Habig et al., 1974; Tingle et al., 1990) and in vivo (Kitteringham et al., 1985; 
Maggs et al., 1986). The biological relevance of chemical reactivity with other nucle­
ophilic amino acid residues, such as tyrosine and histidine, is less certain. Some studies 
have shown that DNFB reacts with these residues (Jackson & Young, 1986; Liu et al., 
1993), whereas a recent analysis found extremely limited reactivity for DNCB to histi­
dine (Gerberick et al., 2004). It is not known whether this reflects genuine differences 
between the two compounds or simply differences in experimental method. It may also 
reflect the variable reactivity of amino acid side chains in different proteins. Chemi­
cal reactivity of individual amino acid residues is a function of their microenvironment 
within the protein, which, in addition to steric effects, can have a profound influence on 
pKa (Bello et al., 1979). Importantly, all dinitrohalobenzenes generate the same dini- 
trophenyl adduct on proteins, although the residues to which they attach may differ, 
as can be seen by the controversy regarding their reactivity to histidine residues. Trini- 
trohalobenzenes generate trinitrophenylated derivatives of proteins, again typically on 
lysines and cysteines.
Early studies focused on the ability of nitrohalobenzenes to induce humoral immune 
responses to haptenated proteins. In a series of elegant studies, Landsteiner & Jacobs 
(1935, 1936) found that the sensitising potential of a series of nitrohalobenzenes in 
guinea pigs correlated with their chemical reactivity in vitro. Further work confirmed 
that in addition to the effects of the parent compounds, nitrophenylated cells and 
proteins were also potent immunogens (Soeberg et al., 1978a,b), although this was cell
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type and protein dependent.
T-cell responses to both nitrohalobenzenes and nitrophenyl-modified proteins and 
peptides have also been well characterised. T-cell clones have been generated from hy­
persensitive individuals which respond to DNCB in a processing and covalent binding- 
dependent manner (Pickard et al., 2007), suggesting that DNCB must be bound solely 
to the peptide. This is in keeping with several other studies which have found that 
trinitrophenyl-modified peptides are sufficient to activate in vivo primed CD4+ and 
CD8+ T-cells (Cavani et al., 1995; Martin et al., 1993). Additionally, trinitrophenyl- 
modified peptides have been shown to be capable of priming trinitrophenyl-specific 
T-cell responses in vivo (Kohler et al., 1995). These studies have found a precise re­
quirement for trinitrophenyl-modification of a specific residue, albeit on a given peptide. 
Whether this is a general feature of trinitrophenyl reactivity is not known at present.
An interesting development in our understanding of how contact hypersensitivity 
to sensitisers such as dinitrohalobenzenes occurs is the finding that they are capable 
of directly activating dendritic cells and supplying requisite co-stimulatory signals for 
primary T-cell activation (see earlier discussion (1.3.4); Aiba et al., 1997; Coutant et al., 
1999; Jugde et al., 2005; Manome et al., 1999).
Therefore, it is clear that dinitrohalobenzenes may activate the immune system 
both by acting as an antigen, in a haptenic fashion, and by direct activation of the 
innate immune system to drive active T-cell priming. Indeed, this newly discovered 
function may be the mechanism behind the therapeutic immunomodulatory effects of 
DNCB as used topically in dermatology (Holzer et al., 2006). A full consideration of 
the interactions of this class of compounds will allow an understanding of how it can 
act as a complete immunogen.
1.3.8.2 Penicillin
Penicillin is a directly reactive drug associated with a high incidence of allergic reactions. 
It has a reactive structure, with the capacity to modify amine, hydroxyl, mercapto and 
histidine groups on protein. The site and extent of protein modification is influenced 
by concentration (of penicillin and protein), pH and the presence of certain metal ions
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B
Dlmertsaion Nitro SMX
Figure 1.1: Mechanisms of protein-adduct formation by (A) dinitrohalobenzenes, (B) penicillin, and (C) SMX
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(Ahlstedt & Kristofferson, 1982).
Nucleophilic attack of the /3-lactam ring by free amino groups of protein leads 
to a covalently linked penicilloyl determinant, often referred to as a major antigenic 
determinant for antibodies and T-cells. This derivative represents greater than 90% 
of penicillin-modified protein. Other penicillin-related adducts are formed through the 
conversion of penicillin in solution to penicillenic or penicilloic acid, both of which are 
thought to modify cysteine residues in protein. Resultant penicillenyl and penicillamine 
conjugates, called minor antigenic determinants, are formed in low levels, but may 
contribute towards the induction of allergic reactions (see figure 1.1B).
T-cells from allergic patients are mainly CD4+ and stimulated with penicillin pre­
sented in the context of MHC class II (Padovan et al., 1996). T-cells are penicillin- spe­
cific (i.e. they are not stimulated with structurally unrelated drugs); however, certain 
clones accommodate small changes in the penicillin side chain which are not involved 
in penicillin binding to protein. T-cell clones also reacted both to free penicillin, in 
a processing-independent fashion, and to penicillin-modified albumin, in a processing 
dependent fashion (Brander et al., 1995). The requirement of penicillin modification 
of MHC-associated peptides and formation of a penicilloyl determinant for T-cell ac­
tivation has been demonstrated by the stimulation of specific TCRs with designer 
peptides containing appropriate anchor residues (Padovan et al., 1997). Importantly, 
only peptides containing lysine residues in precise positions were able to stimulate 
TCRs (Padovan et al., 1997). The ability of penicillenyl or penicillamine conjugates to 
stimulate T-cells has not been investigated.
More recently, the involvement of dendritic cells in penicillin allergy has been eval­
uated. Immature dendritic cells from amoxicillin-hypersensitive patients, but not those 
from penicillin-naive controls, were activated in response to amoxicillin, and were able 
to present processed peptides to autologous peripheral blood mononuclear cells and T- 
cells (Rodriguez-Pena et al., 2006). However, the mechanism behind this effect is not 
known at present, and will require further work to elucidate. Thus, while the primary 
focus on the mechanisms of penicillin hypersensitivity has been on the formation of the 
penicilloyl hapten, there is still the need to define the chemical basis of the generation
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of the co-stimulatory signals involved.
1.3.8.3 Sulfamethoxazole
SMX is a sulfonamide which was largely phased out of clinical practice because of 
rare but serious cutaneous hypersensitivity reactions. In recent years it has been more 
widely prescribed in combination with TMP as treatment for Pneumocystis carinii 
pneumonia in patients with AIDS. Unfortunately, the incidence of hypersensitivity 
reactions is greatly increased in this population (Pirmohamed & Park, 2001).
Many studies exploring the mechanisms of drug hypersensitivity have focused on 
SMX, because it is known to cause hypersensitivity and much is known about its 
disposition in the body (see figure 1.1C). SMX is metabolised by CYP2C9 in human 
liver to a pro-reactive hydroxylamine metabolite SMX-NHOH (Cribb et al., 1995; Gill 
et al., 1996; Mitra et al., 1996; van der Ven et al., 1994). This readily reacts with 
molecular oxygen to generate SMX-NO (Cribb et al., 1991; Naisbitt et al., 1996), which 
is unstable and reacts both with SMX-NHOH to generate azo- and azoxy- dimers, and 
with protein (Manchanda et al., 2002; Naisbitt et al., 2002) and nonprotein thiols 
(Cribb et al., 1991) to form both semimercaptal and sulfinamide adducts. Further 
oxidation can also generate nitro-sulfamethoxazole (SMX-NO2 ) (Naisbitt et al., 2002). 
Importantly, reduction of SMX-NO can occur either via interaction with nonprotein 
thiols (e.g., glutathione) or ascorbate, or enzymatically (Cribb et al., 1995; Kurian et al., 
2004). Thus, the critical balance between metabolic activation and detoxification in a 
given cell system ultimately determines the level of exposure to the reactive metabolite.
Studies with animal models of SMX hypersensitivity have found that SMX-NO is 
a potent immunogen (Naisbitt et al., 2002), and is capable of inducing hapten-specific 
T-cell responses similar to those generated by nitrohalobenzenes, i.e. both covalent 
binding and processing dependent (Farrell et al., 2003). Interestingly, a study demon­
strated that while administration of SMX was insufficient to induce a T-cell response, 
despite in vivo generation of SMX-NHOH, co-dosing with an adjuvant produced a 
T-cell response to SMX-NO (Naisbitt et al., 2001). This demonstrates that in vivo 
generated reactive metabolites may form antigens through haptenation, although ad­
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ditional activation of the innate immune system through danger signalling (Park et al., 
1998) is required to produce immunogenicity.
T-cells from hypersensitive patients have been isolated and cloned in order to ex­
plore the mechanisms by which SMX can act as an antigen in man. In contrast to 
animal studies, however, no T-cell clones have been found which respond to SMX-NO 
in a classical hapten-like fashion. Instead, in all patients studied so fax, T-cell clones 
have been found which respond to SMX-NO in a binding-dependent but processing- 
independent fashion, presumably by binding to the preformed MHC-peptide complex 
(Schnyder et al., 2000). This represents a vital distinction between immunogenicity in 
experimental animals, which is consistently observed, and hypersensitivity in a small 
subgroup of patients. However, the protein milieu in any given in vitro system will dif­
fer from that in the in vivo environment at the time of antigen encounter, so it may be 
premature to rule out the presence of T-cells responsive towards metabolite-modified 
endogenous proteins.
Unexpectedly, T-cell clones have been identified which also respond to SMX itself 
in the absence of covalent binding or antigen processing (Schnyder et al., 1997; Zanni 
et al., 1998). This T-cell activation is TCR dependent (Depta et al., 2004) and MHC 
restricted, but does not appear to depend on the presence of specific peptides (Burkhart 
et al., 2002), suggesting a reversible interaction between MHC-drug-TCR. Recently, 
studies with T-cells isolated from blister fluid in toxic epidermal necrolysis patients 
found a similar pattern of antigen specificity (Nassif et al., 2004), suggesting that these 
T-cells may also be important effector cells in drug hypersensitivity.
The differences between the nature of the antigen in SMX-immunogenicity between 
humans and animals axe as yet unexplained, but they suggest caution regaxding the use 
of animal models to investigate what is an idiosyncratic reaction in man, and one that 
is therefore patient-specific. It is important to note that the ability of SMX to function 
as an antigen with T-cells from susceptible individuals does not necessarily prove that 
SMX per se was the original immunogen in those patients.
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1.3.8.4 Carbamazepine
CBZ is a commonly used aromatic anticonvulsant, and like most drugs of this type, 
it has been associated with hypersensitivity reactions. These reactions often show a 
high degree of cross-reactivity between other, structurally unrelated, aromatic anti­
convulsants (Knowles et al., 1999). This propensity for cross-reactivity has not been 
satisfactorily explained, and hopefully a more detailed understanding of the precise 
determinants of hypersensitivity will identify the reasons for this.
There is good evidence that, at least in some populations, the individual suscep­
tibility to CBZ hypersensitivity is in part genetically controlled. Studies have looked 
for associations with polymorphisms in metabolic enzymes, such as epoxide hydrolase 
(Gaedigk et al., 1994; Green et al., 1995), with little success. However, certain haplo- 
types of immunological genes do appear to play a role. The presence of certain TNF-a 
polymorphisms (Pirmohamed et al., 2001) and specific HLA subtypes (Chung et al., 
2004; Hung et al., 2006; Man et al., 2007) correlate with the presence of CBZ hyper­
sensitivity, although the association is stronger for more severe cases. Interestingly, 
although one of these studies (Chung et al., 2004) found an extremely close linkage 
between HLA-B*1502 and Stevens-Johnson syndrome or TEN reactions to CBZ in a 
Han Chinese population (100% of hypersensitive patients; 3% of controls), this was not 
reproduced by two studies on Caucasian groups (Alfirevic et al., 2006; Lonjou et al., 
2006), suggesting that ethnicity may be important, presumably as a marker for further 
unidentified genetic differences. Interestingly, the association with B*1502 was only 
observed with bullous reactions such as TEN and Stevens-Johnson syndrome; there 
was no association with maculopapular eruption or hypersensitivity syndrome (Hung 
et al., 2006). The overall conclusion to be drawn from these studies is that, while ge­
netic factors can act as determinants of adverse reactions, our current understanding 
of both the interactions amongst the genome and the pathophysiology of the reaction 
itself mean that we should be very cautious before ascribing too much importance to 
individual genetic associations.
CBZ is composed of an iminostilbene moiety coupled via the nitrogen heteroatom 
to a carbamoyl side chain. CBZ undergoes complex oxidative metabolism (over 30
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metabolites have been extracted from urine; Lertratanangkoon & Horning, 1982, see 
figure 1.2), and has been found to form several distinct reactive species. The most 
abundant oxidative metabolite excreted is the 10,11 epoxide, which is formed by the 
action of CYP3A4 and, to a lesser degree, CYP2C8 (Kerr et al., 1994). Although this 
metabolite is largely stable in plasma, recent studies have suggested that it actually 
forms glutathionyl and protein adducts (Bu et al., 2005). The hydrolysis product of 
this epoxide, generated by the action of epoxide hydrolase, 10,11-dihydroxy-CBZ, is 
another major excreted metabolite (Eichelbaum et al., 1985). This is also believed to 
be produced by two separate hydroxylation steps, with 10-OH-CBZ as an intermedi­
ate. Ring contraction of either CBZ-10,11-epoxide or 10,11-dihydroxy-CBZ produces 
9-hydroxymethyl-10-carbamoyl acridan (Lertratanangkoon &; Horning, 1982).
Ring hydroxylation, producing a 2,3-epoxide allows direct reactions with GSH, and 
presumably with protein (Madden et al., 1996), and hydrolysis to 2,3-dihydroxy-CBZ, 2- 
OH-CBZ and 3-OH-CBZ (Lertratanangkoon & Horning, 1982). 2-hydroxy-CBZ, which 
is also a direct product from CBZ (multiple CYPs, but especially CYP2E1; Pearce et al., 
2002), can be further oxidised to form an iminoquinone, either following hydrolysis of 
the carbamoyl group to 2-OH-iminostilbene (Ju & Uetrecht, 1999) or directly from 
2-OH-CBZ (Pearce et al., 2005). This iminoquinone readily reacts with sulfhydryl- 
containing nucleophiles such as GSH or NAC, and so it is likely to be able to form 
cysteinyl adducts on protein.
MPO-mediated chlorination of CBZ leads to ring contraction and the generation of 
9-acridinecarboxaldehyde (Furst & Uetrecht, 1993), which can generate lysine adducts 
via schiff base formation (Furst et al., 1995). These are readily reversible adducts, 
although they can rearrange to amine adducts, which are more permanent. In addi­
tion, 9-acridinecarboxaldehyde can undergo loss of the carboxaldehyde moiety to form 
acridine, and this can further oxidise to acridone (Breton et al., 2005; Furst et al., 
1995).
A final route of phase I metabolism involves hydrolysis of the carbamoyl group to 
leave iminostilbene (Csetenyi et al., 1973). This can either undergo ring contraction 
to the 9-acridinecarboxaldehyde derivative described earlier (Furst et al., 1995), or can
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undergo oxidative metabolism as does CBZ itself. The formation of 2-OH-iminostilbene 
can clearly be seen as a precursor to the iminoquinone described earlier.
Little is known currently about the mechanisms by which CBZ activates the im­
mune system. One recent study (Naisbitt et ai, 2003a) found that T-cells isolated from 
patients following hypersensitivity reactions responded to CBZ ex vivo by both prolifer­
ation and cell-directed killing. Furthermore, clones isolated from the same individuals 
were also found to proliferate following CBZ treatment, and this was apparently in the 
context of HLA-DR or DQ. Cytokine secretion was also observed, although there was 
a degree of heterogeneity seen between clones: all 10 clones secreted IFN-y to varying 
degrees, whilst IL-4, 5 and 10 secretion was more variable. A range of structurally 
related and unrelated compounds were tested for their ability to cross-react with CBZ- 
‘specific’ clones. Of these, only the 10,11-epoxide and a 10,11-dihydro-CBZ were able 
to do so, and again there was significant heterogeneity between clones, with several 
only responding to CBZ itself.
It would be particularly interesting to develop these findings in order to gain a 
better understanding of both the mechanisms of CBZ presentation to T-cells, and the 
structural requirements which enable this.
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Figure 1.2: Known routes of oxidative CBZ metabolism. Dashed arrows represent formation of protein or GSH adducts.
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1.4 H ypotheses and aims
The overall aim of this thesis is to investigate the role of drug metabolism in the 
activation of the immune system by drugs, both as a source of signal 1 and signal 2. 
In particular, this thesis will focus on three compounds, SMX, CBZ and TMP, as they 
are commonly associated with hypersensitivity reactions.
The work in this thesis is intended to test two independent hypotheses, as sum­
marised in figure 1.3. The first hypothesis tested is that a reactive drug metabolite, 
in this case SMX-NO, can act to induce danger signalling in dendritic cells. To this 
end, the effect of SMX and SMX-NO on dendritic cells will be explored in Chapter 
2, along with the functional consequences of these direct effects. The mechanisms by 
which the compounds induce their effects will be further investigated in Chapter 3, and 
the metabolic capacity of dendritic cells evaluated and compared to other relevant cell 
types. In order to accurately evaluate the metabolism of SMX it will be necessary to 
define the bioanalytical requirements for SMX-NHOH quantification, and these findings 
will be presented in chapter 4.
The second hypothesis to be explored is that drug-specific T-cells isolated from CBZ 
and TMP hypersensitive patients respond both to the stable parent drug, via reversible 
interactions, and to reactive drug metabolites, via hapten formation. Data presented 
in chapter 5 will describe investigations intended to explore the nature of the antigen 
recognised by CBZ-specific T-cell clones and evaluate the hypothesis that stable and 
reactive CBZ metabolites play a role in the activation of T-cells. Finally, chapter 6 
will discuss similar investigations with T-cells from a patient both during and following 
severe TMP-induced hepatotoxicity.
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Drug * • Excretion
Figure 1.3: Different hypothetical routes by which a drug or drug metabolite can act to activate T-cells, and hence induce a hypersensitivity reaction
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2.1 Introduction
SMX hypersensitivity reactions have been extensively studied. There are several rea­
sons for this: first, SMX hypersensitivity is a significant clinical problem, particularly 
in the treatment of opportunistic infections in HIV-I- patients; second, SMX is relatively 
straight-forward and well-understood in terms of its metabolism (although it must be 
said that there are still several uncertainties), and the known reactive metabolites can 
be synthesised chemically; and third, these metabolites are immunogenic in vivo, which 
has allowed the development of animal models.
Most mechanistic studies of SMX hypersensitivity have focused on T-cells isolated 
from patients either during or following their reaction. While these have given in­
sights into the mechanism by which SMX is recognised by the immune system, they do 
not necessarily allow the mechanisms involved in the induction of the response to be 
explored.
For full induction of an immune response, the responding T-cell must receive two 
signals, as discussed previously (see 1.3.2).
The source of signal 1 in the induction of an immune response to SMX is often 
assumed (whether explicitly or not) to be related to the mechanism whereby activated 
and memory T-cells recognised SMX presented by APCs, but this is not necessarily the 
case (see the discussion in the previous chapter on avidity maturation; 1.3.1). We must 
therefore be careful not to assume that the antigen-specific T-cell repertoire present in 
patients either during or following a hypersensitivity reaction is perforce the same as 
that which was present during the induction phase.
Whilst the source of signal 1 is apparently well understood but still problematic, 
the source of signal 2, by contrast, is little understood. It has been postulated that 
the source of danger signals for the induction of hypersensitivity reactions is due to 
concurrent infection, either bacterial (Roth et al, 2003) or viral (Hashimoto et ai, 
2003; Pirmohamed et al., 2002), but there is little direct evidence for either of these 
propositions. In particular, there is no apparent epidemiological link between bacte­
rial infection and hypersensitivity, and while there is a clear association between viral 
infection and hypersensitivity, it does not appear to be essential, and there are al­
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ternative explanations, including impaired detoxification mechanisms (Naisbitt et al., 
2000b; Trepanier et al., 2004), depletion of regulatory cells (Eggena et al., 2005), or the 
presence of activated T-cells and/or inflammatory cytokines (Gerber & Pichler, 2006). 
Furthermore, although certain viral infections are certainly associated with danger sig­
nalling, this is by no means universal: certain infections, including those associated 
with hypersensitivity, have actually been shown to inhibit danger signalling and den­
dritic cell maturation (Majumder et al., 2005; Muthumani et al., 2005; Niiya et al., 
2006).
A further proposed source of signal 2 in the induction of SMX hypersensitivity is 
toxicity produced either by the drug itself or by reactive metabolites. Some support for 
this has come from the finding that lymphocytes from SMX-hypersensitive patients are 
more susceptible to toxicity induced by SMX reactive metabolites (Carr et al., 1993b; 
Rieder et al., 1989). However, this has not been universally observed (Reilly et al., 
1999), and, if it is the case, the mechanisms are not known, although several possibilities 
exist, such as impaired detoxification, altered patterns of protein binding, and/or drug- 
specific cell-mediated killing. In any case, the known toxicity of SMX-metabolites 
and their in vivo immunogenicity suggest that they may be able to directly activate 
dendritic cells and hence generate signal 2 for the induction of SMX hypersensitivity.
Therefore, in this study the effects of SMX and SMX-NO on the phenotype of 
monocyte-derived dendritic cells was determined. Furthermore, two models of SMX- 
NO immunogenicity were investigated in order to explore the role of co-stimulatory 
signalling.
2.2 M aterials and m ethods
2.2.1 M aterials
Recombinant human cytokines (IL-2, IL-4, GM-CSF) were obtained from Peprotech 
(London, UK). FITC-labelled mouse anti-human CDllc, CD14, CD40, CD80, CD83, 
and CD86 antibodies were obtained from Serotec (Oxford, UK). Anti-mouse CD154 
(MR1) was purchased from BD-Biosciences (Oxford, UK). Anti-human CD40 anti­
bodies 82111 and 82102 were supplied by R&;D systems (Abingdon, UK). [3H]-methyl
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thymidine was obtained from Moravek (California, USA). Lymphoprep was obtained 
from Nycomed (Oxford, UK). All other reagents, chemicals and components were sup­
plied by Sigma-Aldrich (Gillingham, UK).
2.2.1.1 C ultu re  m edium
A PC  m edium  consisted of Roswell Park Memorial Institute (RPMI) medium, sup­
plemented with 10% fetal bovine serum (FBS), N-2-hydroxyethylpiperazine-N’- 
2-ethanesulfonic acid (HEPES) buffer (25mM), L-glutamine (2mM), penicillin 
(lOOU/ml) and streptomycin (100/rg/ml).
T-cell m edium  consisted of RPMI with 10% human AB+ serum, HEPES buffer 
(25mM), L-glutamine (2mM), penicillin (lOOU/ml), streptomycin (100/rg/ml), 
and transferrin (25/xg/ml).
2.2.1.2 Synthesis of reactive SM X m etabolites
The SMX metabolites SMX-NHOH and SMX-NO were synthesised as described pre­
viously (see figure 2.1; Naisbitt et al., 1996). Nitro-sulfamethoxazole (SMX-NO2 ) 
was prepared by the reaction of 3-amino-5-methylisoxazole (20g; 203mmol) with 4- 
nitrobenzenesulfonyl chloride (45g; 203mmol) in 75ml ice-cold pyridine. The reaction 
mixture was stirred on ice overnight, and a brown precipitate was produced by the 
addition of excess distilled water (dH20). This precipitate was filtered, washed with 
further dH2 0  to remove remaining pyridine, recrystallised from an ethyl acetate:toluene 
mixture (1:3 v/v) and left overnight at 0°C. The final mixture was then collected by 
filtration and analysed for purity by nuclear magnetic resonance (NMR).
SMX-NHOH was synthesised from SMX-NO2 by reduction using sodium phos- 
phinite as a hydrogen donor and a two-phase solvent system (tetrahydrofuran /  wa­
ter) with a palladium /  carbon catalyst. 5% palladium carbon catalyst (O.lg) was 
added to a stirred solution containing sodium phosphinite (1.12g, llmmol) and SMX- 
NO2 (lg, 3.53mmol) in dH2O(10ml) /  tetrahydrofuran (100ml). The reaction mix­
ture was monitored by thin-layer chromatography (TLC), using a mobile phase of 
dichloromethane:ethyl acetate (65:35), until nearly all of the starting material had
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Figure 2.1: Synthesis of SMX-NHOH and SMX-NO
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reacted. This typically took ~20 mins. The product was filtered under vacuum to re­
move excess catalyst, extracted with ether and dried with MgSC>4 to give a pale orange 
oily product. This was then further dried on a rotary evaporator (Rotovapor, Biichi, 
Switzerland) to give a pale yellow solid. This product was then recrystallised from 
chloroform, and the purity of the final product assessed by NMR and high-performance 
liquid chromatography (HPLC).
Oxidation of SMX-NHOH by iron(III) chloride was performed to produce SMX-NO. 
SMX-NHOH(200mg, 0.743mmol) in ethanol (30ml) was added to a stirred solution of 
iron(III) chloride hexahydrate (1.5g, 5.549mmol) in dH2O(40ml) over a period of 10 
mins. This mixture was stirred at room temperature for 3h, during which time a yellow 
solid precipitated within the reaction mixture. This solid was filtered and dried under 
vacuum and the purity was analysed by NMR and HPLC.
2.2.1.3 Chem ical characterisation
Proton NMR spectra were obtained using a Bruker (400MHz) NMR spectrometer. 
Compounds were dissolved in deuterated dimethylsulfoxide (DMSO) and tetramethyl- 
silane was used as an internal standard.
The compounds were also analysed by HPLC with both UV and mass spectrometry 
(MS) detection. Samples were eluted from a Prodigy 5 ODS 2 column (150 x 4.6mm; 
Phenomenex) using an isocratic mobile phase of glacial acetic acid (1% v:v) and ace­
tonitrile (20% v:v) in dH20 at a flow rate of 1 ml.min-1 . UV absorbance was monitored 
at 254nm. Split flow of eluate to the mass spectrometer was 50pl/min. Full scanning 
spectra and selected ion monitoring data were acquired with a Quattro II tandem 
quadropole instrument (Micromass, Manchester, UK). The source temperature was 
70°C; the capillary voltage, 3.9xl0-3 V and the standard cone voltage 30 V. Data were 
processed via Mass Lynx 2.0.
2.2.2 Isolation  o f peripheral b lood m ononuclear cells
PBMCs were isolated from heparinised venous blood of healthy human volunteers by 
centrifugation on a density gradient of Lymphoprep. 15ml blood was carefully layered
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on 10ml of Lymphoprep and the tube was centrifuged at 750g for 25 min. PBMCs 
formed a distinct cloudy band between the plasma and the Lymphoprep layers, and 
could be aspirated with a sterile Pasteur pipette. The PBMCs were then washed twice 
in Hank’s balanced salt solution (HBSS) to remove residual Lymphoprep, and resus­
pended in 10ml HBSS. Cell yield was assessed using an improved Neubauer haemo- 
cytometer (Sigma) under a Wilovert microscope (Will Wertzlar, Germany), and cell 
viability determined by trypan blue dye staining. For this, trypan blue (10/j.I, 0.2%, 
w/v) was added to a suspension of cells (40/xl in HBSS). lOpl of the stained sample 
was placed on a Neubauer haemocytometer and 200 cells were counted. % viability 
was calculated as:
total number o f viable cells100 x --------- ;-------t—--- ;— r,------total number o f cells
and was typically > 95%.
2.2.3 D endritic cell generation
PBMCs were cultured at 2xl06/ml and lml/well in 24-well plates for 4 h followed by re­
peated washing to remove non-adherent cells. Adherent cells were then cultured at 37°C 
in an atmosphere of 5% CO2 in 1ml APC medium, supplemented with interleukin (IL)-4 
(800U/ml) and granulocyte-monocyte colony stimulating factor (GM-CSF) (800U/ml). 
Half of the medium was replaced with fresh complete media on days 1, 3 and 5, and im­
mature dendritic cells were ready for use on day 6. Purity of dendritic cell populations 
and loss of monocyte phenotype was determined by flow cytometry with anti-human 
CDllc and CD14 antibodies using an EPICS-XL flow cytometer (Coulter Electronics, 
Luton, Beds., UK).
2.2.4 Drug treatm ent and analysis o f cell surface markers
Phenotype analysis of drug-exposed dendritic cells was performed by flow cytometry. 
Immature dendritic cells were incubated with SMX, SMX-NO (both 0.5-4000/iM; made 
up in DMSO, final concentration <0.5%), LPS (E.Coli 0111; 1/xg/ml) or DMSO-only 
control for 24 h, before being washed and incubated with a fluorescein isothiocyanate
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(FITC)-labelled mouse anti-human CD40, CD80, CD83 or CD86 antibodies for 30 min 
at 4°C. Cells were washed repeatedly and fluorescence was measured by flow cytometry. 
Cells were gated according to forward and side scatter characteristics, and median FITC 
fluorescence determined. For some experiments polymyxin B (PMB) (20pg/ml) was 
pre-incubated with the drug for 30 min before addition to the cells.
2.2.5 D eterm ination  o f su lfam ethoxazole im m unogenicity  in th e  m ouse
Balb/C strain mice (Charles River; n=4 per group) were administered SMX-NO (1 
mg/kg) by subcutaneous injection into the nape of the neck on three consecutive days. 
Control animals received vehicle alone. A further group of mice were administered an 
anti-CD154 blocking antibody (MR1; 175/rg) via a single intraperitoneal injection 1 h 
prior to SMX-NO administration and subsequent subcutaneous doses (25/xg) with each 
dose of SMX-NO. After 5 days, draining lymph node cells were harvested and incubated 
(lxlO6; total volume 200/ul) in dendritic cell medium with [3H]-methyl thymidine (2pCi) 
for 24 h to measure proliferation. Cells were extracted to filter plates using a cell 
harvester (Tomtuk, Finland), and incorporated radioactivity was determined with a 
96-well /3-counter (Perkin-Elmer, US). Results are recorded as counts per minute (cpm).
2.2.6 Induction o f a prim ary T -cell response in  v itro  w ith  lym pho­
cytes from SM X  naive volunteers
Human naïve T-cells were primed with SMX-NO according to the technique of Engler 
et al. (2004). PBMCs were isolated from peripheral blood by density centrifugation 
as described earlier (2.2.2), and were frozen in 1ml FBS with 10% DMSO. Cells 
were defrosted and incubated at 2.5xl06 cells/ml in 2ml T-cell medium with either 
50pM SMX-NO or 250/xM SMX. Some wells contained either agonistic anti-CD40 
antibody (82111) or antagonistic anti-CD40 antibody (82102). On day 3 of culture, 
rhIL-2 (10U/ml) was added to the cultures, and on day 7 and weekly thereafter the 
cultures were stimulated with SMX-NO (50/xM) and irradiated (4500 rad) autologous 
PBMCs from frozen stocks. Antigen specificity was determined weekly by stimulation 
of an aliquot of T-cells (lx l06/ml) with SMX-NO (20-60pM) or SMX (50 - 500pM)
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and irradiated PBMCs (0.2xl06/ml) as antigen presenting cells, and measurement of 
proliferation was determined by [3H]-methyl thymidine incorporation. Proliferation 
was recorded as stimulation index (SI), calculated as,
cpm in drug — treated cultures cpm in cultures with DM  SO alone
Wells where the SI was reproducibly >2 with a given concentration of SMX or 
SMX-NO were designated positive.
2.2 .7  S tatistical analysis
Results are presented as mean ±  standard error of the mean. Normality of data was 
determined by the Shapiro-Wilks test and equality of variance by the Levene test. 
Data which were normally distributed were compared by means of a t-test, whereas 
nonparametric data were compared with the Mann-Whitney test for unpaired data or 
the Wilcoxon signed rank test for paired data. P-values < 0.05 were considered to be 
significant. All statistical analyses were performed on SPSS 13.0.
2.3 R esults
2.3.1 A nalysis o f  purity o f sulfam ethoxazole m etabolites
XH NMR spectra were obtained for SMX, as a reference, and for all metabolites syn­
thesised (all in d6-DMSO; 400MHz).
SM X 511.42 (s, 1H, S 02NH), 7.47 (d, 2H, J=8.64, ArH), 6.59 (d, 2H, J=8.7, ArH),
6.08 (s, 1H, ArH), 6.08 (s, 2H, NH2), 2.29 (s, 3H, CH3)
S M X -N 02 58.43 (d, 2H, J=8.73, ArH), 8.12 (d, 2H, J=8.75, ArH), 6.17 (s, 1H, ArH), 
2.31 (s, 3H, CH3)
SM X -N H O H  511.08 (s, 1H, S02NH), 9.07 (s, 1H, NHOH), 8.75 (s, 1H, NHOH), 7.61 
(d, 2H, J=8.72, ArH), 6.86 (d, 2H, J=8.8, ArH), 6.11 (s, 1H, ArH), 2.29 (s, 3H, 
CH3)
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SM X-NO <58.21 (d, 2H, J=8.47, ArH), 8.15 (d, 2H, J=8.5, ArH), 6.19 (s, 1H, ArH), 
2.31 (s, 3H, CH3)
Purity of compounds was determined by both NMR and LC/MS analysis. In all 
cases, purity of compounds selected for further use was >99%, with the only detectable 
contaminant being parent SMX.
2.3.2 A nalysis o f  purity  o f dendritic cell populations
Adherent PBMCs were washed and analysed, and found to be >95% monocytes (CD14+) 
Following 6 days culture in vitro with IL-4 and GM-CSF they were reanalysed and 
found to be >95% CDllc+/CD14- dendritic cells. This was accompanied by mor­
phological changes associated with the acquisition of the dendritic cell phenotype, and 
up-regulation of MHC-II and CD83.
2.3 .3  Effects o f S M X /S M X -N O  exposure on dendritic cell surface  
marker expression
Dendritic cells exposed to SMX (maximal effect: 250-500/xM) and SMX-NO (maximal 
effect: 1/xM) consistently displayed a concentration-dependent increase in CD40 expres­
sion (see figure 2.2), but no increase in CD80, CD83, or CD86 (see figure 2.3). This 
CD40-specific up-regulation was also seen with dendritic cell incubations with SMX and 
SMX-NO of up to 48 h (data not shown). In contrast, cells exposed to LPS showed 
an increase in expression of all the markers examined. Importantly, the response to 
SMX and SMX-NO was unaffected by preincubation with PMB (20/rg/ml), whereas 
the response to LPS was completely eliminated (see figure 2.4). No effect was seen on 
the expression of surface markers on dendritic cells with PMB alone (data not shown).
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Figure 2.2: Dendritic cell CD40 up-regulation in response to SMX and SMX-NO. Extent of up-regulation of CD40 in monocyte-derived dendritic cells, as measured by flow cytometry and recorded as the % of the increase with LPS over control, induced by varying concentrations of SMX (n=8) and SMX-NO (n=6) over a 24 h incubation period. Data are presented as mean ±  SEM. (*, Significantly different from untreated cells; p<0.05).
. Dendritic Cell Activation by SMX and SMX-NO
2. D endritic Cell A ctivation  by SM X  and SM X -N O
2.3 .4  I n  v ivo  im m unogenicity  o f SM X -N O
Subcutaneous dosing of Balb/C strain mice to SMX-NO was associated with a sig­
nificant increase in ex vivo lymph node cell proliferation when compared with mice 
exposed to vehicle alone. However, concurrent dosing with an antagonistic anti-CD154 
antibody completely eliminated the increased lymph node cell proliferation associated 
with SMX-NO treatment (see figure 2.5).
2.3.5 Prim ary induction  o f an im m une response to  SM X -N O  in  v itro
PBMCs isolated from SMX-nai’ve volunteers (n=5) were successfully sensitised in vitro 
to SMX-NO over the course of 4 weeks. When PBMCs from the same volunteers were 
co-cultured with an agonistic anti-CD40 antibody, a significantly enhanced SMX-NO 
specific response was seen (total positive wells: 11/20 vs. 3/20; average SI: 3.07 vs. 
1.26; see figure 2.6) after 4 weeks. Furthermore, the addition of an antagonistic anti- 
CD40 antibody prevented the sensitisation in all cases (total positive wells 0/20 vs. 
3/20).
However, in contrast to the results with SMX-NO, and to those previously published 
(Engler et a/., 2004), attempts to generate an in vitro primary response to SMX were 
unsuccessful, despite repeated attempts (data not shown).
2.4 Discussion
Little is known about whether drugs or drug metabolites may act to generate signals 
that lead to activation of dendritic cells. In order to address this, we studied the ef­
fects of SMX and SMX-NO on the surface expression of monocyte-derived dendritic 
cell co-stimulatory molecules, which are commonly used as markers of dendritic cell 
maturation. Dendritic cells were generated from healthy human drug-naive volunteers, 
incubated with SMX or SMX-NO, and expression was determined by flow cytometry. 
With both compounds an increase in surface CD40, but not CD80, 83 or 86, expression 
was seen after 24 h (see figure 2.2). A specific effect on CD40 expression was also seen 
following a longer term drug exposure of up to 48 h (results not shown). However, the 
positive control LPS readily induced up-regulation of all surface markers examined, ex-
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Figure 2.3: Selective dendritic cell up-regulation of CD40 by SMX-NO. Representa­tive flow cytometry histograms showing CD40, but not CD80, 83, or 86 up-regulation following incubation with 5/iM SMX-NO.
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Figure 2.5: CD40 blockade inhibits SMX-NO immunogenicity in mice. ***: signifi­cantly different to control p<0.001
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Figure 2.6: CD40 ligation enhances in vitro primary stimulation of naive PBMCs to SMX-NO. */**/***; significantly different to control p<0.05/0.01/0.001
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eluding the possibility that the dendritic cells used were simply abnormal. The maximal 
response to both SMX and SMX-NO was similar, at ~70% of the response seen with 
1/ig/ml LPS, and the only difference observed between the dendritic cells’ responses 
to SMX and SMX-NO was that the required molar concentration of SMX to induce 
maximal CD40 expression was ~250-fold higher. The concentrations of SMX which 
were maximally active are similar to those seen in vivo following high-dose therapy for 
P.carinii treatment (Stevens et ai, 1991), and the effective concentrations of SMX-NO 
were lower than those of SMX-NHOH in vivo (~3% of the ingested dose is excreted 
as SMX-NHOH; Cribb & Spielberg, 1992). However, as SMX-NO is too unstable to 
be successfully extracted from biological matrices, it is not known what proportion of 
SMX-NHOH is converted to SMX-NO at any one time, and so it is impossible to say 
with precision whether the concentrations used in this study are clinically relevant.
A selective up-regulation of CD40 against CD80/86 on dendritic cells in response 
to the hair-dye compound p-phenylenediamine (Coulter et ai, 2006) has been recently 
reported, although the implications of this are not yet fully understood. Dendritic 
cell regulation of CD40 and CD80/86 expression differs, and some of the upstream 
pathways are known. For instance, RelB deficient dendritic cells fail to upregulate CD40 
in response to LPS, but upregulate CD80 and CD86 normally, and induce tolerance 
rather than effective antigen-specific priming (Martin et al., 2003).
CD40 ligation by its natural ligand, CD154, leads to receptor trimérisation, which 
allows recruitment of TNF receptor-associated factors to the cytoplasmic tail (Pullen 
et al, 1998). These adaptor proteins produce a signalling complex which induces down­
stream events such as activation of the NF-/tB and MAPK pathways (Ouaaz et al, 
2002), reviewed in Quezada et al (2004). The overall effect of these signal trans­
duction pathways is to enhance dendritic cell survival (Ludewig et al, 1995), drive 
morphological changes, upregulate co-stimulatory markers, and induce cytokine release 
(Caux et al, 1994).
So-called semimature dendritic cells have been associated with the induction of 
tolerogenic T-cell responses (Lutz k  Schuler, 2002), either by induction of anergy (Sato 
et al, 2002) or by preferential activation of CD4+CD25+ regulatory T-cells (Verginis
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et al., 2005). However, this seems to be not so much a function of the dendritic cell than 
of the responding T-cell, as a recent study (Kleindienst et al., 2005) found that while 
semimature dendritic cells preferentially activated tolerogenic CD4+ T-cells, they were 
perfectly capable of inducing an effective CD8+ T-cell response to antigen. A major 
problem with establishing the physiological and pathological function of semimature 
dendritic cells is the lack of a stringent definition for what actually constitutes ‘semi­
mature’ in this sense: some papers use the term to refer only to dendritic cells which fail 
to secrete proinflammatory cytokines, others to refer to dendritic cells which actively 
release anti-inflammatory cytokines, and still others to those displaying an incomplete 
repertoire of surface markers. Furthermore, there is a wide discrepancy between the 
techniques used to generate semimature dendritic cells, which no doubt impacts heavily 
on their function.
Therefore, it is unclear whether our dendritic cells are genuinely semimature. It 
would be very interesting to investigate the effects of SMX and SMX metabolites on 
the pattern of cytokine release by dendritic cells, but this was not possible within 
this study due to time restraints. Importantly, one must also note that binding of 
the natural CD40 ligand CD 154 to dendritic cells expressing high levels of the CD40 
receptor stimulates further dendritic cell maturation (Caux et al., 1994) and as such 
the observed highly specific effect of SMX and SMX metabolites on CD40 may, in a 
mixed cell population, ultimately result in fully matured dendritic cells. Again, this 
will require continuing investigation to completely elucidate.
There are several possible sources of dendritic cell for in vitro investigations. Of 
these, monocyte-derived dendritic cells are the most commonly used because they are 
both easily available in relatively high numbers, and they are an excellent surrogate 
for in vivo dendritic cells. Alternative sources are dendritic cells derived from CD34+ 
cells, either from umbilical cord (Romani et al., 1994) or peripheral blood (Ohishi et al., 
2001), or from bone marrow (Bernhard et al., 1995). Although some studies have found 
slight differences between these different sources of cells (Bracho et al., 2003; Syme 
et al., 2005), these have typically been minor, and have been phenotypic rather than 
functional changes. A comparison of CD14+ vs. CD34+ derived dendritic cells found
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that they are both effective as a screening tool for contact sensitisers (Rustemeyer et al., 
2003).
It is possible that the effects which were observed on dendritic cells were in fact 
due to low-level contamination of SMX and SMX metabolite stocks by bacterial LPS. 
However, there are several reasons to believe this to be unlikely. First, the CD40- 
specific effects have not been previously described for any known microbial contaminant; 
second, the compounds were stored and used under sterile conditions, and endotoxin- 
free glass- and plasticware were continually used; third, the concentrations of SMX-NO 
at which the effects were observed were close in mass to the concentrations of LPS 
required for dendritic cell activation, indicating that any contamination of our SMX- 
NO stocks would have to constitute an implausibly large proportion of the stock; and 
fourth, and most convincingly, the addition of PMB, which binds to and inactivates 
LPS (Tsubery et al., 2000), and completely eliminated all effects produced by LPS 
in our system, had no impact on the dendritic cell activation induced by SMX or 
SMX-NO. It is worth noting that most studies use PMB for inactivation of LPS at 
10-25/ig/ml (Nikulina et al., 2004; Smiley et al., 2001), which concurs with our use of 
PMB at 20/xg/ml. A recent study has suggested that PMB has direct effects in inducing 
maturation of dendritic cells (Valentinis et al., 2005), restricted to up-regulation of 
MHC-1 and -2, and CD86, with no effects seen on CD40 expression. However, we saw 
no similar effects in the absence of drug, and the inhibition of LPS-mediated activation 
suggested that the PMB would have been successful in blocking any potential LPS 
contamination.
Activation of antigen presenting cells through CD40 signalling is known to precip­
itate animal models of autoimmune disease (Garza et al., 2000; Ichikawa et al., 2002), 
while CD40 blockade can prevent the progression of diseases such as systemic lupus 
erythematosus, cardiac allograft arteriopathy, and spontaneous autoimmune diabetes 
(Davidson et al., 2003; Nanji et al., 2006; Polese et al., 2002; Wang et al., 2002). How­
ever, the importance of CD40 signalling in drug hypersensitivity has not been consid­
ered previously. We have therefore utilised two experimental approaches to evaluate 
the role of CD40 signalling in SMX metabolite immunogenicity.
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First, we used the local lymph node assay. This is commonly used in industry to 
assess the sensitisation potential of novel drugs and chemicals (Gerberick et al., 2007; 
OECD, 2002). Compounds are applied either topically or subcutaneously and ex vivo 
lymph node cell proliferation is determined by [3H]-methyl thymidine incorporation. 
Inhibition of CD40:CD154 signalling by systemic pre-treatment with a blocking anti- 
CD154 antibody completely eliminated the SMX-NO induced increase in proliferation, 
demonstrating that CD40 signalling is essential for in vivo SMX-NO immunogenicity. 
SMX itself was not used as previous work in our laboratories has found that it is not 
directly immunogenic in this assay.
Secondly, we used a recently published protocol for in vitro primary stimulation of 
T-cells to SMX and SMX-NO (Engler et al., 2004). This involves alternated stimula­
tion of PBMCs from SMX-naive individuals with IL-2 and either SMX or SMX-NO. 
Sensitisation was determined by proliferation assays on a weekly basis. The addition 
of a CD40 agonistic antibody significantly enhanced the response to SMX-NO, while a 
CD40 antagonistic antibody eliminated the response in all cases.
However, we were unable to generate a primary response to SMX, when rechallenged 
either with SMX or SMX-NO. It is not clear why this was unsuccessful, although it is 
worth bearing in mind that the original paper only successfully induced responses in 
3/10 individuals. It is quite possible that only a small subset of individuals are suscep­
tible to in vitro primary sensitisation by SMX, either due to genetic, immunological or 
metabolic factors, and that, simply by chance, none of the 5 individuals tested herein 
were of this group. If this is the case, then further investigations may produce interest­
ing findings regarding the individual determinants of hypersensitivity. However, this is 
beyond the scope of this discussion.
These data indicate that CD40 plays an important role in the primary sensitisation 
of T-cells to SMX-NO in vitro. In addition, they support the thesis that this is a 
genuine primary sensitisation event, as opposed to a recall response with unknown 
original peptide specificity, as has been more recently proposed (Pichler, 2005).
In conclusion, these findings indicate that both SMX and the reactive SMX metabo­
lite SMX-NO can induce CD40 up-regulation on dendritic cells, and that CD40 plays
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an important role in the induction of a primary immune response to SMX-NO.
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3.1 Introduction
Dendritic cell activation in response to ‘danger signals’, and co-stimulatory signals in­
duced thereby, are requisite elements in the induction of an immune response. As 
discussed previously (see 1.3.2), in the absence of co-stimulatory signalling, novel anti­
gens are tolerogenic, rather than immunogenic. The source of these signals in drug 
hypersensitivity is not known, although several hypotheses have been proposed. In the 
previous chapter (see chapter 2) it was found, for the first time, that both a drug and 
its reactive metabolite are capable of inducing partial dendritic cell maturation, and 
that signalling through this pathway is essential for the immunogenicity of the reactive 
metabolite.
Danger signals can be broadly divided into exogenous, i.e. derived from foreign 
pathogens, and endogenous signals, i.e. derived from cellular damage within the or­
ganism. Dendritic cell activation in response to endogenous signals has been well- 
documented, although the mechanisms by which this happens are not as well under­
stood as the mechanisms by which dendritic cells activate in response to exogenous, 
pathogen-induced signals. While it is likely that many endogenous signals are also 
transduced by activation of TLRs, there have been several difficulties in identifying the 
precise TLR responsible—not least the risk of bacterial contamination of the endoge­
nous signalling molecules (for instance, see Gao & Tsan, 2003).
The best understood mechanism by which endogenous cell damage produces danger 
signals is via the induction of cell death. Originally, it was claimed that only necrotic 
cell death led to the production of danger signals (Gallucci et al., 1999), presumably 
via the uncontrolled release of intracellular contents such as uric acid (Shi et al., 2003), 
heat-shock proteins (Asea et al., 2000) or adenosine triphosphate (Bours et al., 2006), 
but recent work has found that apoptotic cells may also activate dendritic cells, albeit 
via a TLR-independent pathway (Janssen et al., 2006). As apoptosis is a normal
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function of homeostasis and development, it is not clear as yet whether this requires 
further discriminatory mechanisms to prevent unnecessary immune activation.
Compounds which produce cellular damage may also produce danger signals through 
the generation of reactive oxygen species and oxidative stress. Several lines of evidence 
led to this conclusion: firstly, direct application of either the reactive oxygen species 
donor hydrogen peroxide (Rutault et al, 1999) or the superoxide generating system 
xanthine-xanthine oxidase (Kantengwa et al., 2003) can induce dendritic cell activa­
tion; and secondly, the addition of anti-oxidants can prevent dendritic cell activation 
by toxic insults (Kantengwa et al., 2003)—including those generated by contact sensi- 
tisers (Bruchhausen et al., 2003). Interestingly, antioxidants have also been found to 
inhibit immune cell activation in response to other, apparently unrelated, stimuli, such 
as LPS (Matsue et al., 2003; Verhasselt et al., 1999), inflammatory cytokines (Tan et al., 
2005) and bacterial CpG-containing DNA motifs (Yi et al., 1996), and the generation 
of reactive oxygen species has been identified during dendritic cell activation (Maemura 
et al., 2005; Matsue et al., 2003; Yamada et al., 2006), suggesting that reactive oxygen 
species may be a common pathway for dendritic cell activation.
It has been postulated that all danger signals share a common theme: the presence 
or unmasking of hydrophobic residues on macromolecules (Seong &; Matzinger, 2004). 
In this light, it is interesting to reflect that denaturation of proteins through exces­
sive covalent modification is likely to result in the exposure of internal hydrophobic 
residues, potentially forming a linkage between covalent modification and generation of 
endogenous danger signals. While this has never been precisely demonstrated, many 
directly protein-reactive compounds have been found to activate dendritic cells, includ­
ing contact sensitisers such as dinitrohalobenzenes (Aiba et al., 1997; Manome et al., 
1999), oxazolone (Verheyen et al., 2005), trimellitic anhydride (Toebak et al., 2006), 
and paraphenylenediamine (Coulter et al., 2006), as well as drugs such as /3-lactam 
antibiotics (Rodriguez-Pena et al., 2006).
In this study, the mechanism by which both SMX and SMX-NO activate dendritic 
cells was investigated, and particular attention paid to the possibility that localised 
dendritic cell metabolism may allow the generation of SMX-NO from SMX in situ.
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3.2 M aterials and m ethods
3.2.1 M aterials
Hydroxylamine and nitroso metabolites of SMX were synthesised as described previ­
ously (see 2.2.1.2), and determined by HPLC, mass spectrometry, and nuclear magnetic 
resonance to be >99% pure. Rabbit anti-SMX IgG antibody was a kind gift of Dr M.J. 
Rieder (Department of Medicine, University of Western Ontario, Canada). rhIL-4, and 
rhGM-CSF were obtained from PeproTech. FITC-labelled anti-CD40, CD80, CD83, 
and CD86 Abs, and the leucoperm fixation and permeabilisation kit were all obtained 
from Serotec. Lymphoprep was obtained from Nycomed. The Annexin-V^iTC kit was 
obtained from Bender MedSystems. All rhCYP-expressing supersomes were obtained 
from BD Biosciences. DNase I and diethyl pyrocarbonate-treated water were obtained 
from Ambion. RiboGreen RNA quantification kit was obtained from Molecular Probes. 
RNeasy 96 total RNA extraction kit and RLT lysis buffer were obtained from Qiagen. 
Oligo(dT) 12-18 primer, 2’-deoxynucleoside 5’-triphosphate mix and the Superscript II 
reverse transcriptase kit were obtained from Invitrogen Life Technologies. Oligonu­
cleotide fluorogenic probes and TaqMan Universal PCR Mastermix were obtained from 
Applied Biosystems. All other chemicals, components, and oligonucleotide primers 
were obtained from Sigma-Aldrich.
3.2.2 D endritic cell generation
PBMCs and dendritic cells were generated as described previously (see 2.2.3) and anal­
ysed for purity as before.
3.2 .3  A nalysis o f  dendritic cell death  following S M X /S M X -N O  treat­
m ent
Immature dendritic cells were incubated with SMX or SMX-NO (0.01-1000/^M) for 24 h. 
Cells were counted on an improved Neubauer haemocytometer to determine cell recov­
ery. The populations were then analysed for apoptotic or necrotic cells using an annexin 
V-propidium iodide dual staining methodology (Vermes et al, 1995). Briefly, cells were
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stained with FITC-linked rhAnnexin V (lg/ml) for lOmin before being washed and in­
cubated with propidium iodide (PI) (35pM). The cells were then analysed for apoptotic 
and necrotic cell death by flow cytometry using an EPICS-XL flow cytometer (Coulter 
Electronics, Luton, Beds., UK). Cells were simultaneously analysed by forward scatter 
and side scatter characteristics, and a gated population defined to exclude cellular de­
bris. Cells within this gated population were simultaneously assessed for FITC and PI 
staining. Cells were then divided into four groups according to staining characteristics: 
F IT C -/P I- , viable; FITC+/PI- , early apoptotic; F IT C "/P I+, necrotic; FITC+/PI", 
late apoptotic, or secondary necrotic.
3.2 .4  D eterm ination  o f protein  quantity
Protein levels in samples were determined by the method of Bradford (1976). A stan­
dard curve of 0.25-5.Op,g bovine serum albumin (BSA) was prepared as per table 3.1 
using a stock solution of 0.5mg/ml BSA in dH^O. Samples were diluted as required 
and lOpl added to 10/d d t^O  in each well of a flat-bottomed 96-well plate. Bradford 
reagent was diluted 1:5 with dh^O and 200pl added to each well immediately prior to 
spectrophotometric analysis (MRX microplate reader running Revelation version 3.04 
software, Dynex Technologies, Billinghurst, W. Sussex) at 570nm. Blank wells were 
subtracted from all values, and linear standard curves were derived to allow quantifi­
cation of sample protein concentrations.
Final quantity (pg) Volume Stock (pi) Volume dtEO (pl)0 0 200.25 0.5 19.50.5 1.0 19.01 2.0 18.02 4.0 16.03 6.0 14.04 8.0 12.05 10.0 10.0
Table 3.1: Dilution of BSA standards for Bradford assay
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3.2 .5  A nalysis o f  g lutath ione dep letion  follow ing S M X /S M X -N O  treat­
m ent
Immature dendritic cells were incubated with SMX or SMX-NO (1-1000/xM) for 24 h. 
The cells were then washed and lysed with lOmM HC1, and an aliquot taken for protein 
content determination as described above (3.2.4). Total glutathione and GSSG levels 
were determined by a microtitre plate assay according to the method of Vandeputte 
et al. (1994). Reduced glutathione GSH levels were determined by subtracting GSSG 
from total glutathione, and were expressed as nmols GSH/mg protein.
3.2 .6  D eterm ination  of irreversible binding o f S M X /S M X -N O  to  den­
dritic cells by flow cytom etry
Antigen formation on dendritic cells was determined by a modification of Naisbitt et al. 
(1999). Immature dendritic cells were incubated with SMX (0.1-50/riVl), SMX-NO (50- 
4000//M) or vehicle for 24 h. Certain populations were fixed and permeabilized using a 
Leucoperm kit in order to identify intracellular binding. For this, cells were incubated in 
100/il of Reagent A (fixation medium; formaldehyde) for 15 min at room temperature, 
followed by washing and resuspension in 100/d Reagent B (permeabilisation medium) 
for 30 min at room temperature. The cells were then stained using a rabbit anti-SMX 
IgG antibody (1:500 in HBSS, 40/d) for 30 min at 4°C, washed repeatedly to remove 
excess antibody, and incubated with FITC-conjugated goat anti-rabbit IgG (1:50 in 
HBSS, 40/xl) for a further 30 min at 4°C, followed by further washes. Fluorescence 
was then measured by flow cytometry. Forward and side scatter characteristics were 
measured simultaneously, the cellular population of interest was gated with the for­
ward scatter threshold being raised to exclude cellular debris, and the median FITC 
fluorescence was recorded.
3.2 .7  D eterm ination  o f irreversible b inding o f S M X /S M X -N O  to  den­
dritic cells by ELISA
Protein SMX adducts were identified using a previously described enzyme-linked im­
munosorbent assay (ELISA) protocol (Roychowdhury et al., 2005). Dendritic cells were
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incubated with SMX (500/iiM), SMX-NO (10/xM) or vehicle for 0.1 or 24 h, washed re­
peatedly, resuspended in df^O  and lysed by repeated freeze-thaw cycles. The samples 
were spun to remove insoluble cell debris at 10,000rpm for 5 min, protein content of 
supernatants was determined as above (see 3.2.4) and standardised to 250/xg/ml. 100/d 
aliquots were then plated in triplicate on 96-well ELISA (BD Bioscience, Oxford) plates 
and left to adsorb for 16 h at 4°C. The wells were then washed repeatedly with casein- 
tris buffer (0.5% casein, 0.9% NaCl, lOmM tris-HCl, 0.01% thimerosal, pH 7.6), blocked 
for 2 h with casein-tris buffer, and incubated at 4°C with a rabbit anti-SMX antibody 
(1:500 in casein-tris buffer) for 24 h. The wells were then washed repeatedly with casein- 
tris buffer and incubated with a goat anti-rabbit alkaline phosphatase linked antibody 
(1:250) for 16 h. Finally, the wells were washed repeatedly and incubated for 1 h with 
alkaline phosphatase yellow liquid substrate. The optical density of the wells at 405nm 
was then determined by spectrophotometric analysis (MRX microplate reader running 
Revelation version 3.04 software, Dynex Technologies, Billinghurst, W. Sussex). For 
some experiments ImM SMX was added to the primary antibody 1 h before addition 
to the wells to confirm hapten-inhibition of the primary antibody binding. The ELISA 
protocol does not require cells to be fixed before analysis and thus a possible interaction 
between SMX and formaldehyde can be excluded.
3.2 .8  D esign  of prim ers and probes for qR T -PC R  analysis o f m etabolic  
enzym e expression
Primers and probes for quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) analysis were designed for quantification of metabolic enzyme ex­
pression in selected cell types. Sequences were identified from AceView (http://www. 
n c b i. nlm. n ih . gov/IEB/Research/Acembly/index. html), GnxWeb (GlaxoSmithKline) 
and Entrez Gene (http://www.ncbi.nlm.nih.gov/HomoloGene), and consensus se­
quences generated by aligning with LaserGene (DNAStar, Wisconsin, USA). Poly­
morphisms were identified with GnxWeb, intron-exon boundaries with GeneCruiser 
(GlaxoSmithKline) and repetitive sequences with RepeatMasker (f tp ://f tp .g e n o m e . 
washington.edu/cgi-bin/RepeatM asker). The target complementary DNA (cDNA)
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and exon were then entered into BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) 
and Easy Blast 2 (GlaxoSmithKline) to identify any competing targets.
Potential single-exon primers and probes were designed from the chosen exon by 
Primer Express (Applied Biosystems, California, USA), and selected according to the 
following criteria:
For probes,
• G-C content between 30-80%
• Avoid runs of identical nucleotide
• Avoid guanine at 5’ end
• Ensure C>G
• Tm between 68-70° C 
For primers,
• Design as close to probe as possible
• G-C content between 30-80%
• Avoid runs of identical nucleotide
• Tm between 58-60° C
• The final five nucleotides at 3’ end should have no more than 2 G/C bases
• Amplicons should be 50-150bp in length
The selected primer/probe sets were then inserted into BLAST and Easy Blast 
2 again to confirm the lack of competing targets. The sensitivity and specificity of 
the primer/probe sets was determined experimentally by running a polymerase chain 
reaction (PCR) with genomic DNA and analysing the PCR product on an agarose gel
The primer/probe sets selected are listed below (see table 3.2).
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Table 3.2: Primer/probe sets used for qRT-PCR analysis of metabolic enzyme expressionGene Forward primer Reverse primer ProbeCYP1A2 A G C A C G C C C G C T G T G ACYP1B1 C C A G C T T T G T G C C T G T C A C T A TCYP2A6 C T T C T G G T G G C C T T G C T G G TCYP2B6 T C C C C G C C T C T G T A G A C A A TCYP2C8 T C T G A A G A A T G C T A G C C C A T C T GCYP2C9 A T C T C A C A T T T T C C C T T C C C T G A ACYP2C19 G T C C C T G C A G C T C T C T T T C C TCYP2D6 C A C C A TC C C G G C A G A G A ACYP2E1 G T G C C A T T T T G C A G C A T T T T A ACYP3A4 T C T G G T G T T C T C A G G C A C A G ACYP3A5 T T T A T T G A C T C C G T T G A A A T C T C T G G T G T TCYP3A7 A A A G G C T G A G TC A A G G G A T G A GCYP4A11 G T A A A T T G T G T G C T T A A T G C A A C A G TMPO T G C A T T G A A C C T G G C T T C C TCOX-2 A C A T C T T C T G T A A C A G A A G T C A G T A C T C C TGAPDH C A A G G T C A T C C A T G A C A A C T T T G
G G T G T C T T C T T C A G T T G A T G G A G A A  5 ’ 
G G G A A TG TG G TA G C C C A A G A  5 
A G C T G C A G G T A G T T T C C A A T G A A  5' 
C T G G C T T G T A G C A G G T C T C T C A  5 ’ 
T G G G A A TA TC C TTG A TA A A A A A A G A  5 ’ 
G CA A C TG TTA CA G A G TA TG G A G A A TA G C A  5 ’ 
G G G A A G G G A A A A TG TG A G A T G A  5 
T G A G A G C A G C TT C A A TG A T G A G  A 5 ’ 
C A A TA TG T A T A G G G C TG A G G T C G A T  5 
C A A C C A G A A A A A C C C G T T G T T C  5 
A A A C C C A T T G T T C T A A A G G T G G A T  5 
A G C TT TC T TA A A G A G C A A A C C A G A A  5 ’ 
G C C C C G A G C T C T G G A A G T  5 ’. 
A TA C C C C T C A C TG C T G C A C C  5 
TC C A A A C TTA A C A G C A A C A G C A A  5 ’. 
G G G C C A T C C A C A G T C T T C T G  5
FA M -C A T G T C C A G G C G C G G C T G C -T A M R A -3’ 
-F A M -C T C A TG C C A C C A C T G C C A A C A C C T -T A M R A -3’ 
-FA M -A G C T G C C T C C G G G A C C C A C C -T A M R A -31 
F A M -C T C T G A C T C C C C G C A A C T T C C T -T A M R A -3’ 
FA M -C T G C C G A T C T G C T A T C A C C T G C -T A M R A -31 
-F A M -T C G A C C T C C A T T A C G G A G A G T T T C C T A T G T T T C A -T A M R A -S ’ 
-F A M -T G G T C C A A A T T T C A C T A T C T G T G A T G C T T C T T C T -T A M R A -31 
-FA M -A G G T C A G C C A C C A C TA TG C G C A G G -T A M R A -3’ 
-F A M -T T G A A G C C T C T C G T T G A C C C A A A G G A -T A M R A -3’ 
-F A M -C G G T G C C A T C C C T T G  A C T C A A C C T-T A M R A -3’ 
-FA M -T G G T C T T C A A G A A A G C T G T G C C C C A -T A M R A -3’ 
FA M -C C G T A A G T G G A G C C T G A T T T C C C T A A G G A -T A M R A -3’ 
-FA M -C A C C A C C T G T T T C T T T G T T T G A T C A C C A A T A A A -T A M R A -3’ 
-F A M -C C T T A C C T G G C C T C T A G G A G G C T T C C C T -T A M R A -31 
F A M -A A G T C T T C A C A A G T A T G A C T C C T T T C T C C G C A A -T A M R A -3’ 
-FA M -A C C A C A G T C C A TG C C A TC A C T G C C A -TA M R A -3’
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3.2 .9  qR T -PC R  analysis o f m etabolic enzym e expression
Expression of a panel of metabolic enzymes (CYP1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 
2C19, 2D6, 2E1, 3A4, 3A5, 3A7, 4A11, MPO, COX-2) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was measured by qRT-PCR. Firstly, total ribonucleic acid 
(RNA) was extracted from dendritic cells (n=10) generated as described above (2.2.3), 
PBMCs (n=10) generated as described above (2.2.2), and human hepatocytes (n=8) 
using a Qiagen RNeasy 96 kit. Genomic deoxyribonucleic acid (DNA) contamination 
was removed with DNAse treatment with 0.5U DNAse I in a thermocycler (Eppendorf, 
Cambridge), at 37°C for 10 min followed by 75°C for 5 min. Total RNA was quantified 
by fluorescent measurement with RiboGreen (excitation 480nm /  emission 520nm). 
cDNA was synthesised with DNAse treated RNA as a template using Superscript II 
bulk mix according to the manufacturer’s protocol. qRT-PCR was performed on the 
resulting cDNA in a 96-well optical reaction plate on an ABI Prism 7900 Sequence 
Detection System (Perkin-Elmer-Applied Biosystems). The reaction conditions were 
as follows: 2 min at 50°C, 15 min at 95°C, and 40 PCR cycles of 15 s at 95°C and 
1 min at 60°C. Standard curves of human genomic DNA were set-up under identical 
conditions for quantitative purposes, and cycles to threshold (Cx) values used to derive 
absolute copy numbers, which were standardised by total RNA content.
3.2 .10 I n  v itro  m etabolism  o f sulfam ethoxazole
Cytochrome P450 (CYP)-expressing Supersomes (CYP1B1/2B6/2C8/2C9/2D6/3A4; 
20pmols P450) were incubated in 50mM TYis buffer (pH 7.4) with SMX (800/xM), MgCl 
(3.3mM), ascorbic acid (ImM), and NADPH (ImM) for 30 min. Alternatively, some 
incubations were set up with SMX (800pM), myeloperoxidase (MPO; 1.56U/ml) and 
ImM ascorbic acid with H2 O2 (200/xM). Reactions were terminated and protein was 
precipitated by addition of 1ml ice-cold acetonitrile. The supernatant was analysed 
for SMX-NHOH formation by HPLC analysis as described below (4.2.4, condition 4). 
In certain experiments ImM 1-aminobenzotriazole (ABT) was preincubated with the 
enzyme and cofactors for 1 h prior to addition of the drug and additional cofactors.
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3.2.11 T im e-dependent enzym e inhib ition  by 1-am inobenzotriazole
E. Coli bactosomes expressing CYP enzymes (25fig protein) were incubated with fluo­
rescent substrates (ethoxyresorufin [50/iM; CYP1A2], 7-methoxy-4-trifluoromethylcoumarin- 
3-acetic acid [12.5mM; CYP2C9], 3-butyryl-7-methoxycoumarin [2.5mM; CYP2C19], 4- 
methylaminomethyl-7-methoxycoumarin [2.5mM; CYP2D6], 7-benzoquinoline [100/iM; 
CYP3A4] and diethoxyfluorescein [2.5mM; CYP3A4]) and ABT (0-1000/xM). ABT-free 
incubations were used as negative controls. Plates were incubated at 37°C for 5 min and 
25/u.l of an NADPH-generating system (5.53mM glucose-6-phosphate; 0.44mM oxidised 
nicotinamide adenine dinucleotide phosphate (NADP); 1.2 U/ml glucose-6-phosphate 
dehydrogenase) was added to initiate the reaction. Fluorescence was measured at 5 
min intervals for 60 min on a Cytofluor Series 4000 Plate Reader running Cytofluor 
v4.2 software (Applied Biosystems, Warrington). Initial blanks were subtracted from 
data, and inhibition was calculated as a % decrease from drug-free CYP activity.
3.2 .12 E nzym e inh ib ition  o f dendritic cell activation
Immature dendritic cells were generated as described previously (2.2.3), incubated with 
ABT (ImM) or vehicle (DMSO; final concentration < 0.5%) for 1 h, and exposed 
to SMX (25-2000/xM), SMX-NO (5-lO^M), or LPS (E.Coli 0111; Ifig/mi) for 24 h.
Cells were then washed and incubated with FITC-labelled mouse anti-human CD40, 
CD80, CD83 or CD86 antibodies for 30 min at 4°C. Cells were washed repeatedly and 
fluorescence was measured by flow cytometry.
3.2 .13 S tatistica l analysis
Results are presented as mean ±  standard error of the mean. Normality of data was 
determined by the Shapiro-Wilks test and equality of variance by the Levene test.
Data which were normally distributed were compared by means of a t-test, whereas 
nonparametric data were compared with the Mann-Whitney test for unpaired data or 
the Wilcoxon signed rank test for paired data. P-values < 0.05 were considered to be 
significant. All statistical analyses were performed on SPSS 13.0.
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3.3 R esults
3.3.1 D endritic  cell death  following S M X /S M X -N O  exposure
Initially, cell populations were counted, and cell recovery was determined to be con­
sistently > 95%. Proportions of necrotic and apoptotic cells were then determined 
using an annexin-V /  propidium iodide staining methodology. There was no significant 
necrotic or apoptotic cell death when dendritic cells were incubated with SMX at any 
concentration below 4mM, at which point the limited solubility became a problem, 
whereas significant quantities of necrotic cells were observed with SMX-NO only at 
concentrations above 500/iM (see figure 3.1). No increase in apoptotic cell death was 
observed at any concentration.
3.3.2 D ep letion  o f g lutath ione in dendritic cells following S M X /S M X -  
N O  exposure
GSSG levels were consistently at or below the level of detection, so total glutathione 
has been used as a surrogate for GSH concentrations. No significant GSH depletion 
was seen with SMX at any concentration studied (data not shown), whilst significant 
dendritic cell GSH depletion was seen with SMX-NO only at concentrations of 500/j.M 
or higher (see figure 3.2.)
3.3 .3  D etection  o f SM X -adducts in dendritic cells following S M X /S M X -  
N O  exposure
Incubation of dendritic cells for 24 h with SMX-NO (0.5-50/ixM), but not SMX (50- 
4000), resulted in the formation of surface adducts, as determined by flow cytometry 
(see figure 3.3.)
Dendritic cells were then permeabilized in order to identify total (i.e. both intra­
cellular and surface) SMX adducts by flow cytometry. As before, significant adduct 
formation was seen in SMX-NO-treated dendritic cells (10/iiM). In addition, however, 
SMX-treated (50-4000pM) dendritic cells also displayed significant formation of SMX 
adducts at concentrations above lOOpM (see figure 3.4.
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Figure 3.1: Apoptotic and necrotic dendritic cell death in response to increasing con­centrations of SMX-NO. The gray region corresponds to the range of concentrations associated with dendritic cell activation. Data are presented as mean ±  s.e.m. **: significantly different to control p<0.01
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Figure 3.2: Depletion of GSH by increasing concentrations of SMX-NO. The gray region corresponds to the range of concentrations associated with dendritic cell activation. Data are presented as mean ±  s.e.m. **: significantly different to control p<0.01
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Figure 3.3: Cell surface covalent binding seen following incubation with SMX-NO, but not with SMX. Data are presented as mean ±  s.e.m. *: significantly different to control p<0.05
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Figure 3.4: Total adduct formation seen following incubation with SMX-NO, but not with SMX, as determined by flow cytometry following permeabilisation. Data are presented as mean ±  s.e.m. */**: significantly different to control p<0.05/0.01
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Additionally, protein-SMX adducts could be identified using an ELISA methodology 
following either SMX-NO (100/xM) incubation for 0.1 h or 24 h, and SMX (500/iM) 
incubation for 24 h (see figure 3.5). Importantly, incubation of SMX (500/xM) for 
0.1 h did not led to apparent adduct formation. The addition of ImM SMX to the 
primary antibody (to saturate antibody binding sites) prior to its addition to the wells 
completely abrogated any binding to adsorbed protein, demonstrating that the binding 
was SMX-specific (data not shown).
3.3 .4  I n  v itro  m etabolism  o f sulfam ethoxazole
Several metabolic enzymes were investigated for their ability to bio-activate SMX in 
vitro. The cytochrome P450s 1B1, 2B6, 2D6, and 3A4, and COX-2 were all incapable 
of catalysing SMX N-hydroxylation. In contrast, CYP2C8, CYP2C9 and MPO all 
catalysed the reaction, with relative activities CYP2C9>MPO>CYP2C8 (see table 
3.3)
Table 3.3: Selected enzyme expression and SMX metabolism
Enzyme Dendritic cells
Expression (copies/ng mRNA) PBMCs Hepatocytes
SMX-NHOH formation (nmols/ml)- ABT i  ABTCYP1B1 591.1±82” * 11.62Ü.7 10.19i3.99 ND NDCYP2B6 0.04T0.02 5.98i0.83 67.23Ü8.2 ND NDCYP2C8 0.39T0.06 12.58Ü.8 2465T381 0.308 NDCYP2C9 0.30±0.20 12.48Ü.2 7400Ü600 0.780 NDCYP2D6 0.93T0.11 6.79Ü.3 39.10Ü3 ND NDCYP3A4 ND 0.45i0.21 3367Ü060 ND NDMPO 9.73i3.2*** 0.13i0.12 ND 0.394 NDCOX-2 0.08T0.03 23.1Ü2.6 1.75Ü.28 ND ND
: significantly different to expression in PBMCs/hepatocytes p<0.001; ND: Not de­tected.
3.3.5 E xpression o f m etabolic enzym es in dendritic cells, h epatocytes, 
and P B M C s
qRT-PCR analysis of dendritic cell mRNA from 10 healthy donors was performed 
to quantify the expression of several metabolic enzymes, and this was compared to
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*
0 SMX SMX-NO (500|jM) (100mM)
Figure 3.5: Protein-SMX adducts detectable in dendritic cell lysate following 0.1 or 24 h incubation with SMX-NO (1 0 0 /iM) or 24 h incubation with SMX (500/iM). Data are presented as mean ±  s.e.m. *: significantly different to control p<0.05
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expression in both PBMCs from the same individuals and commercially available human 
hepatocytes from 8  donors (see table 3.3; figure 3.6).
As expected, CYP expression was high in human hepatocytes, and considerably 
lower in both PBMCs and dendritic cells. High levels of both CYP1B1 and MPO were 
detected in dendritic cells compared to both PBMCs (fold differences: 50; 60) and 
hepatocytes (fold differences: 80; no MPO detected in hepatocytes), but expression of 
other metabolic enzymes was considerably lower in dendritic cells when compared with 
either PBMCs (average fold difference: 90) or hepatocytes (average fold difference: 
7800). GAPDH expression was comparable between cell types (dendritic cells: 84 
copies/ng total RNA; PBMCss: 111 copies/ng total RNA; hepatocytes: 170 copies/ng 
total RNA).
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Figure 3.6: Dendritic cells express MPO and CYP1B1, although other metabolic enzymes are expressed at low levels. Expression of metabolic enzymes in dendritic cells, PBMCs (both n=10) and human hepatocytes (n=8 ) was determined by quantitative real-time RT-PCR using cDNA library generated from RNA extracted from immature dendritic cells. The results are presented as mean ±  s.e.m copies/ng total RNA.
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3.3.6 T im e-dependent inhibition  o f enzym e activ ity  by 1-am inobenzotriazole
Inhibition of enzyme activity by ABT in vitro was studied both using a time-dependent 
inhibition assay with fluorescent probes and by direct inhibition of SMX-NHOH for­
mation as determined by HPLC.
Time-dependent inhibition studies over 1 h demonstrated that ImM 1-aminobenzotriazole 
(ABT) was a non-specific time-dependent inhibitor of all CYPs and peroxidases studied 
(inhibition after 1 h: 98.5-100%; see figure 3.7). Although there was a degree of selec­
tivity (see figure 3.8), all enzymes were significantly inhibited by ImM ABT following 
1 h incubation.
In addition, SMX-NHOH formation catalysed by either MPO, CYP2C8 or CYP2C9 
was completely inhibited by 1 h preincubation of the enzymes with ImM ABT (see 3.3).
3.3 .7  Inhibition o f dendritic cell activation  by 1-am inobenzotriazole
When ABT was incubated with dendritic cells 1 h prior to addition of drugs the response 
to SMX was completely abrogated, whereas the responses to both SMX-NO and the 
positive control LPS were unaffected (see figure 3.9).
3.4 Discussion
As discussed in the previous chapter 2, both SMX and its reactive metabolite SMX-NO 
have been found to induce dendritic cell maturation, as measured by an up-regulation 
of the co-stimulatory molecule CD40. The concentration of SMX required for maximal 
effect was found to be ~250-fold greater than that of SMX-NO required for a maximal 
response (see figure 2 .2 ).
Therefore, it was important to determine whether metabolism by the dendritic 
cells was an obligatory step in the observed up-regulation of CD40 expression. It is
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Figure 3.7: ABT acts as a potent inhibitor of a wide range of metabolic enzymes. Time-dependent inhibition of several metabolic enzymes was determined by inhibition by ImM ABT of fluorogenic substrate turnover by expressed enzymes over 1 h. Results were calculated as the % inhibition at various time points.
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Figure 3.8: ABT shows a degree of enzyme selectivity. Time-dependent inhibition of several metabolic enzymes was determined by inhibition by 0-1000/iM ABT of fluo- rogenic substrate turnover by expressed enzymes after 1 h incubation. Results were calculated as the IC 5 0  of ABT for inhibition of specific enzymes.
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Figure 3.9: ABT inhibits CD40 up-regulation with SMX, but not SMX-NO or LPS. Monocyte-derived dendritic cells were pre-incubated with lmM ABT or vehicle for 1 h, followed by incubation with SMX or SMX-NO for 24 h (n = 3). CD40 up-regulation was determined by flow cytometric analysis, and is presented as the % increase in median fluorescence over control. Data are presented as mean ± SEM. *, Significantly different from vehicle treated (p < 0.05).
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possible that both the compounds in question could stimulate dendritic cell maturation 
directly. For instance, the increased CD40 expression may be due to direct interaction 
of SMX itself with receptors found on the surface of dendritic cells such as TLRs. A 
precedent for this already exists: the imidazoquinoline, imiquimod, has been shown to 
activate macrophages through TLR7 and thereby induce the production of cytokines 
(Hemmi et al., 2002). Alongside this direct activation by SMX, SMX-NO could induce 
maturation by toxicological pathways, for instance producing cell death, GSH depletion 
or covalent binding.
However, the evidence suggests that it is the intracellular metabolic activation of 
SMX in dendritic cells that is responsible for the increased CD40 expression. Using 
a highly specific anti-SMX antibody (Naisbitt et al., 1999; Manchanda et al., 2002; 
Roychowdhury et al., 2005), haptenated intracellular proteins were detectable by both 
flow cytometry and ELISA when SMX was incubated with dendritic cells at similar 
concentrations to those which stimulated increased CD40 expression (see figures 3.4 
and 3.5). Importantly, the formation of haptenated proteins was time dependent and 
not observable immediately after incubation of SMX with cells (see figure 3.5). By 
contrast, SMX-NO bound rapidly to both intra- and extracellular proteins, consistent 
with previous work from several laboratories (Manchanda et al., 2002; Naisbitt et al., 
1999, 2001, 2002; Reilly et al., 2000; Roychowdhury et al., 2005). A recent study 
(Roychowdhury et al., 2007) has looked for similar adduct formation in dendritic cells 
(albeit of a different source to those used in this study) exposed to SMX (250/xM for 3 h), 
dapsone and both of their hydroxylamine metabolites. While the authors’ conclusions 
were that dapsone, but not SMX, was metabolised to form adducts, the primary data 
presented appears to suggest a small degree of binding, though considerably less than 
that found in this study. However, it is hard to draw comparisons with the present study 
considering the number of methodological differences: for instance, the concentration 
of drug, time of exposure, and source of cells all differed significantly.
Because analytical techniques are not sufficiently sensitive to detect dendritic cell- 
mediated SMX metabolism directly, a series of enzyme inhibitor studies were performed 
to substantiate a causal relationship between SMX metabolism by dendritic cells and
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increased cell surface CD40 expression. ABT, a suicide inhibitor of haemoxygenases, 
which acts via alkylation of the enzyme-associated haem group by a benzyne radical 
(Ortiz De Montellado et al., 1984), was shown to inhibit 1) activity of all recombinant 
metabolic enzymes studied over the course of 1 h (see figure 3.7); 2) metabolism of SMX 
to SMX-NHOH catalysed by CYP2C8, 2C9 and MPO (see table 3.3); and 3) SMX- 
induced, but not SMX-NO- or LPS-induced, increased CD40 expression on dendritic 
cells (see figure 3.9) . Taken together, our observations suggest that increased CD40 
expression following exposure of dendritic cells to SMX is dependent on oxidative drug 
metabolism.
It is possible that the reactive species generated by metabolism of ABT (a highly 
reactive benzyne radical) binds to and inactivates SMX, and hence inhibits dendritic cell 
activation by SMX in a manner independent of its enzyme inhibitory activity. However, 
considering the near complete degree of enzyme inhibition following 1 h preincubation, 
it seems unlikely that there would still be sufficient enzymatic activity to produce 
enough benzyne to completely eliminate the response to SMX. It is worth bearing in 
mind that the range of active concentrations span a whole order of magnitude, and 
so at least 90% inactivation of SMX would be required at the highest active dose to 
produce the complete inhibition seen—at a 1:1 SMX-ABT reaction stoichiometry, this 
would require 90% of the ABT to be converted to benzyne, and all of that to bind to 
SMX.
There is some degree of variation between different studies with regard to the po­
tency and selectivity of ABT, although much of the variation can be ascribed to dif­
ferences in the incubation conditions—in particular, variations in the length of prein­
cubation. One study, in which enzymes were not preincubated with ABT prior to the 
addition of the substrate, found considerable variation, with little or no inhibition of 
certain enzymes, including CYP2C9 (Emoto et al., 2003). However, a later study by 
the same group (Emoto et al, 2005) found considerably greater inhibitory potency and 
reduced selectivity following 30 min preincubation, in line with both the current work 
and other published studies (Balani et al., 2002).
To explore further the role of metabolism in this process, expression of metabolic
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enzymes in dendritic cells was determined, and contrasted with those seen in other 
cell types (PBMCs and hepatocytes). Dendritic cells expressed the majority of CYPs 
studied (see figure 3.6), albeit at a low level compared with both PBMCs and hepato­
cytes. The sole exception was CYP1B1, which was expressed at a significantly higher 
level than that seen in either alternative cell type. A previous study has looked at 
CYP expression in dendritic cells (Sieben et al., 1999), but the data presented herein 
are the first which have both quantified the expression and compared this to other 
cell types of known metabolic capacity. CYP1B1 is a polymorphic enzyme that plays 
an important role in the activation of carcinogens (Watanabe et al., 2000). However, 
our data suggests that it does not catalyse SMX metabolism (see table 3.3) and thus 
an association between CYP1B1 expression and SMX hypersensitivity seems unlikely. 
There is a degree of controversy surrounding the expression of MPO in dendritic cells, 
and it is possible that MPO is differentially expressed depending on the source and 
phenotype of the dendritic cells in question (Pickl et al., 1996; Scholz et al., 2004). 
In this study, it was apparent that dendritic cells generated from 10 donors expressed 
consistently high levels of MPO mRNA (see table 3.3), and that this was significantly 
higher than that in PBMCs (fold difference: 58.9; p<0.0001). CYP2C9 and MPO, 
consistent with previous literature (Cribb et al., 1990, 1995; Gill et al., 1996), but also 
CYP2C8, were found to be capable of SMX-NHOH generation (see table 3.3). All 
other enzymes studied were inactive. Based on this, and the CYP expression data, 
it seems plausible that MPO is, at least in part, responsible for the SMX metabolic 
activation observed in dendritic cells. Additionally, dendritic cells expressed low levels 
of COX-2; however, in contrast to early reports, COX-2 has recently been shown not 
to play a direct role in SMX oxidation (Vyas et al., 2006c). However, it is important 
to bear in mind that there are several enzymes which may be able to metabolise SMX 
for which we did not attempt to determine the expression levels in our cell types, not 
least FMO-3 (Vyas et al., 2006b) and several peroxidases, such as lactoperoxidase or 
thyroid peroxidase. Finally, it is well-known that the presence of the mRNA message 
for a given protein does not automatically allow the expression of the protein to be 
deduced. Further work is currently underway in order to identify the presence of MPO
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protein in dendritic cells, as opposed to simply detecting the presence of MPO mRNA.
MPO has previously been linked to several idiosyncratic reactions as a result of its 
ability to locally bioactivate drugs within the immune system. In particular, several 
drugs which are associated with agranulocytosis, a deficiency of granulocytes within 
the blood, have been found to be metabolised to reactive species by MPO, including 
SMX (Cribb et al., 1990), clozapine (Williams et al., 1997), ticlopidine (Liu &: Uetrecht, 
2000), amodiaquine (Naisbitt et al., 1997), and indomethacin (Ju & Uetrecht, 1998). 
However, these are likely to be due to direct toxicity within the neutrophil rather than 
immunologically driven (Williams et al., 2000). It is known that MPO is typically 
stored in an inactive form within the cell, and is only activated upon cellular activa­
tion. It is possible therefore, that localised bioactivation and the resultant dendritic 
cell activation is dependent on a certain background level of cellular activation. Fur­
ther work is underway in order to test this, and to explore the possibility that further 
activation of the cells enhances the degree of turnover within the system. It is not 
known whether MPO expressed by dendritic cells is released through degranulation, 
in the same manner as that produced by neutrophils. If so, it seems possible that 
SMX turnover in this system may have been initially produced extracellularly. When 
dendritic cells were treated with SMX, no surface adducts were detectable by flow 
cytometry, suggesting that SMX-NO haptenation was largely confined to the intracel­
lular milieu, although the relative stability of SMX-NO would be expected to allow it 
to migrate across cell membranes. It might be instructive to examine the degree of 
modification of extracellular serum proteins in order to fully explore this issue.
There are several possible hypotheses by which reactive drug metabolites could in­
duce increased CD40 expression on dendritic cells, which will be addressed sequentially. 
Firstly, release of cell contents from both necrotic (Barker et al., 2002; Sauter et al., 
2000) and apoptotic (Janssen et al., 2006) cells stimulates dendritic cell activation. In­
deed, in a recent study it was demonstrated that dendritic cell activation in response to 
contact sensitisers is dependent on low levels (~ 10-20%) of necrotic cell death (Hulette 
et al., 2005), although this has been challenged (Coulter et al., 2006). However, in 
the present work, there was no significant increase in necrotic or apoptotic cell death
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observed with SMX at any concentration tested, and for SMX-NO only at concentra­
tions that were ~500-fold higher than required for increased CD40 expression. This is 
comparable to the concentrations of SMX-NO found to be toxic in vitro to a variety 
of immune-derived cell types by previous investigators (Lavergne et al, 2006; Naisbitt 
et al., 2 0 0 2 ).
Secondly, depletion of glutathione has also been shown to be associated with den­
dritic cell maturation, particularly increased expression of co-stimulatory receptors 
(Verhasselt et al., 1999; Yamada et al., 2006). However, depletion of glutathione was 
only seen at concentrations of SMX-NO ~ 2 0 0 -fold higher than required for increased 
CD40 expression, and was not seen at all with SMX. Additionally, the level of oxidised 
glutathione was below the limit of detection at all times, and no increase in oxidised 
glutathione was observed.
Thirdly, it is possible that the association is due to the generation of reactive oxygen 
species. This hypothesis was not explicitly tested, although previous studies have found 
that low concentrations of SMX-NHOH produce detectable quantities of reactive oxygen 
species (Vyas et al., 2005). However, considering the evidence that reactive oxygen 
species generation is a requisite event in the activation of dendritic cells (Matsue et al., 
2003), it would be very hard to be certain that any reactive oxygen species identified in 
dendritic cells exposed to either SMX or SMX-NO were causative rather than secondary 
to the dendritic cell activation. For this reason, and due to time constraints, it was 
decided not to investigate this possibility further.
Finally, covalent binding to intracellular macromolecules could potentially generate 
danger signals for the induction of dendritic cell maturation. As discussed above, 
SMX adducts were detected by means of different immunochemical methodologies (flow 
cytometry, ELISA) and that this binding occurred with concentrations of SMX and 
SMX-NO that were associated with dendritic cell activation. Again, this is in line with 
findings from previous investigators, which found that covalent binding can be detected 
with significantly lower concentrations of SMX-NO than that which produces toxicity 
(Manchanda et al., 2002; Naisbitt et al., 2002).
In conclusion, these data reveal that activation of dendritic cells by SMX is sec­
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ondary to local bioactivation of SMX to SMX-NO, at least in part through MPO, and 
that both compounds appear to transduce their effects through covalent binding to 
cellular macromolecules. The site and nature of SMX metabolite modification, and 
indeed whether specific proteins are modified, has yet to be deciphered.
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4.1 Introduction
The antimicrobial SMX is associated with a relatively high risk of immune-mediated 
hypersensitivity reactions (see 1.3.8 .3; 2.1). This is believed to be, although defini­
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tive proof is lacking, due to the enzymatic generation of the hydroxylamine metabo­
lite (SMX-NHOH), and subsequent auto-oxidation to a protein-reactive nitroso species 
SMX-NO (Cribb et al., 1991). The cellular distribution (Naisbitt et al., 1999), toxicity 
(Lavergne et al., 2006) and immunogenicity (Naisbitt et al., 2001) of SMX metabolites 
have been well-studied.
SMX-NHOH generation has been found both in vitro (Cribb & Spielberg, 1990; 
Cribb et al., 1995) and in vivo (Cribb k, Spielberg, 1992; Gill et al., 1996). Sev­
eral enzymes have been demonstrated to bioactivate SMX to SMX-NHOH, including 
CYP2C9 (Cribb et al., 1995) and MPO (Cribb et al., 1990, see also 3.3.4). Although it 
was believed that COX could also activate SMX, a recent study has claimed that this 
is actually secondary to hydrogen peroxide (H2 O2 ) in the reaction mixture (Vyas et al., 
2006c). Importantly, however, most studies in this area use co-chromatography with an 
authentic standard using relatively simple HPLC conditions as a means of identifying 
SMX-NHOH formation.
In this study we identified a novel non-enzymatically formed hydroxylated SMX 
derivative, investigated the mechanism of formation, and determined the minimum 
bioanalytical requirements for accurate SMX-NHOH identification.
4.2 M aterials and m ethods
4.2.1 M aterials
SMX-NHOH was synthesised as described previously (2.2.1.2), and its purity was con­
firmed by NMR and LC/MS to be >99%. Unless specified otherwise, all other reagents 
were purchased from Sigma-Aldrich Ltd. (Gillingham, UK).
4.2 .2  M icrosom al ox idation  of sulfam ethoxazole
Human liver microsomes were incubated in tris buffer (50mM; pH 7.4) with SMX 
(800/xM), ascorbate (ImM), MgCl (3.3mM) and NADPH (ImM) at 37°C. Additional 
reactions were set up with either desferrioxamine (25mM) or mannitol (0.5M). Con­
trol incubations contained SMX in the absence of either ascorbate or H2 O2 , or with 
boiled microsomes (30 min at 95°C). Following 1 h incubations the metabolites were
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extracted, separated by HPLC using one of the conditions below, identified by MS-MS, 
and quantified by UV detection.
4.2 .3  H 20 2 oxidation  o f sulfam ethoxazole
SMX (800/xM), ascorbate (ImM), and H2 0 2 (ImM) in tris buffer (50mM; pH 8.00) 
were incubated at 37°C for 1 h. Additional incubations contained either desferriox- 
amine (25mM), mannitol (0.5M), or FeS0 4  (lOOmM) and ethylenediamine tetraacetic 
acid (EDTA) (lOOmM). Control incubations contained SMX in the absence of either 
ascorbate or H2 0 2. Metabolites were extracted and separated by HPLC using one of 
the conditions given below, identified by MS-MS, and quantified by UV detection.
4 .2 .4  H PLC  conditions
Different protocols were used to attempt to separate the hydroxylated species from an 
authentic SMX-NHOH standard, both to try to identify suitable conditions for analysis 
and to determine if any previous studies may have failed to adequately separate the 
two compounds. These conditions are listed below, and numbered sequentially.
1. As described in Gill et al. (1996), samples were eluted from a Prodigy 5 ODS 2 
column (150 x 4.6mm; Phenomenex) using an isocratic mobile phase of glacial 
acetic acid (1% v:v) and acetonitrile (20% v:v) in dH20  at a flow rate of 1 
ml.min-1.
2. As described in Vyas et al. (2006c), samples were eluted from a Nova-pak 4/xm 
C-18 column (150 x 3.9mm; Waters) using a isocratic mobile phase of acetonitrile 
(18.95% v:v), glacial acetic acid (1% v:v), and triethylamine (0.05% v:v) in dH20  
at a flow rate of 1 ml.min-1 .
3. As described in Cribb & Spielberg (1990), samples were eluted from an Ultra­
sphere C18 ODS 5^m column (150 x 4.6mm; Beckman Instruments) using an 
isocratic mobile phase of acetonitrile (25% v:v), glacial acetic acid (1% v:v) and 
triethylamine (0.05% v:v) in dH20  at a flow rate of 1 ml.min-1 .
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Furthermore, an additional method was developed in order to ensure complete res­
olution of the hydroxylated SMX derivatives:
4 Samples were loaded onto an Ultrasphere C18 ODS 5/xm column (250 x 4.6mm; 
Beckman Instruments) using 10% acetonitrile in 50mM formic acid and washed 
for 5 minutes at a flow rate of lml.min-1 . The acetonitrile content was then 
increased linearly from 10-70% over 20 min and from 70-100% over 2 min. The 
column was re-equilibrated with the starting buffer for 1 0  min prior to any further 
runs.
4.2 .5  U V  d etection
A BioTek 560 UV detector (Sci-Tek, Bucks, UK) was used to determine UV absorbance 
at 254p.m. Metabolite quantification was performed by comparison to an internal stan­
dard of lOpM sulfadimethoxine.
4.2 .6  M ass spectrom etric analysis
A Deca-XPp*us ion-trap mass spectrometer (ThermoFinnigan, Hemel Hempsted, UK) 
was used to detect SMX and its metabolites via negative ion electrospray ionisation. 
Data dependant MS-MS experiments provided collision-induced dissociation spectra of 
the fragment ions of the compounds of interest.
4.3 R esults and D iscussion
4.3 .1  Identification o f th e  novel SM X -O H  derivative
Although standard microsomal incubations of SMX with the continuous presence of 
ascorbate produced a single peak corresponding to a hydroxylated metabolite ([M-H]-  
m/z:268), this peak was also present, albeit reduced, in control incubations without 
NADPH. Further investigations found that although the peak present in these in­
cubations coeluted with an SMX-NHOH authentic standard (see figure 4.1 A) under 
previously used HPLC conditions (condition 1; see 4.2.4), it had a distinct fragmen­
tation pattern under MS-MS (see figure 4.2 for all fragment allocations), lacking the
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characteristic neutral loss of 17 seen with SMX-NHOH. In all other respects it re­
sembled SMX-NHOH. Unlike the previously identified metabolite 5-OH SMX (Vree 
et al, 1994), the neutral loss of 96 (loss of the methylisoxazole ring) was unchanged 
from the parent SMX molecule, demonstrating that the hydroxylation must be on the 
benzene ring, although the precise location was not determinable. Changes to the 
chromatography conditions (condition 4) produced good separation of the novel com­
pound (hereafter referred to as SMX-OH) from an SMX-NHOH standard (see figure 
4.IB). The continued presence of SMX-OH in microsomal incubations both without 
NADPH and in incubations using boiled microsomes demonstrates that it is generated 
non-enzymatically.
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Figure 4.1: (A) SMX-OH generated by addition of ascorbate following termination of a microsomal incubation (grey trace) co-elutes with an SMX-NHOH authentic standard (black trace) under previously used HPLC conditions (condition 1); (B) SMX-OH gen­erated by addition of ascorbate following termination of microsomal incubation (grey trace) separated effectively from a SMX-NHOH standard (black trace) by novel chro­matographic conditions (condition 4); (C,D) SMX-OH (grey trace) and SMX-NHOH (black trace) display chromatographic similarities under two previously used HPLC conditions (conditions 2 and 3). All traces are representative of 3 independent experi­ments.
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Figure 4.2: HPLC-MS-MS spectra of SMX, SMX-NHOH and SMX-OH with diagnostic fragment ions
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4.3 .2  Investigation  o f th e  m echanism  o f SM X -O H  form ation
Further investigations found that an incubation of SMX with H2 O2 and ascorbate in 
tris buffer generated a single hydroxylated metabolite with an MS-MS fragmentation 
pattern identical to SMX-OH. Contrary to previous reports (Vyas et al., 2006c), when 
SMX was incubated with H2 O2 and ascorbate, SMX-NHOH was not detected. This 
non-enzymatic reaction was further investigated. In initial experiments, the kinetics 
of SMX-OH formation were investigated in an SMX/H2 0 2 /ascorbate incubation. As 
appreciable quantities were detected within 0 .1  h, it was not possible to determine the 
minimum required time for formation. Maximal quantities of SMX-OH were found 
following 1.5 h, which stayed stable for at least 4 h (see figure 4.3). Incubations with 
either H2 O2 or microsomes only generated SMX-OH in the presence of ascorbate. Fur­
thermore, the addition of the iron chelator desferrioxamine completely inhibited the 
generation of SMX-OH, whereas the hydroxyl radical scavenger mannitol had no effect, 
even at high concentrations. Addition of FeS0 4  and EDTA to the peroxide reaction 
increased the amount of SMX-OH formed over 1 h (see table 4.1). These data are 
consistent with the synthesis being via an Fe2+/ascorbate / 0 2  oxidising complex, as 
first described by Udenfriend et al. (1954), rather than via hydroxyl radical genera­
tion from Fenton reactions. Although there have been conflicting reports regarding the 
role of hydroxyl radicals in this reaction (Hamilton, 1962; Ito et al., 1993), the lack of 
inhibition following mannitol addition suggested no role for radical involvement here.
Table 4.1: Generation of SMX-OH under varying conditions.
Condition SMX-OH generation*
1 SMX (800/zM) 0
2 1 + H2 0 2 (100/xM) 03 2  +  ascorbate (1 0 0 /dVl) 0.2624 3 + Fe2+ (lOOmM) + EDTA (lOOmM) 1.2585 3 + mannitol (0.5M) 0.283
6 3 + desferrioxamine (25mM) 0.053
* Calculated as ratio of SMX-OH: sulfadimethoxine peak area
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Figure 4.3: Time-course of SMX-OH formation in an SMX/H2 0 2 /ascorbate incubation
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4.3 .3  V alidation of previously used  analytical techniques
With a very few exceptions (Cribb k  Spielberg, 1990; Cribb et al., 1990), all previous 
studies to have quantified SMX-NHOH formation in microsomal or peroxidase systems, 
or in clinical samples, have used HPLC separation with either UV or MS detection, 
and identified SMX-NHOH by co-chromatography with an absolute standard. We 
tested three sets of previously-used conditions, designated 1, 2 and 3, for their ability 
to separate SMX-OH from SMX-NHOH, but all three systems were not suitable (see 
figure 4.1). Furthermore, the use of UV detection is clearly insufficient for accurate 
metabolite verification, given the chromatographic similarity of SMX-NHOH to SMX- 
OH. The minimum requirements for accurate identification and quantification should 
be confirmed separation from SMX-OH, and either MS-MS fragmentation analysis or 
conversion to SMX-NO2 by addition of excess base (Rieder et al., 1988). While there 
is no question that the major oxidative metabolite in microsomal incubations is SMX- 
NHOH, previous studies have insufficiently separated this from the non-enzymatically 
generated SMX-OH, and as a result may not have accurately identified or quantified the 
generation of SMX-NHOH. These data have major implications for designing future 
analyses of SMX metabolite formation.
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5.1 Introduction
CBZ is a commonly used anti-epileptic which has been associated with the induction of 
hypersensitivity reactions. These typically involve rash, eosinophilia, fever and systemic 
organ involvement, most commonly hepatitis. Several lines of evidence indicate that 
these reactions are immune-mediated, particularly the initial sensitisation period from 
first exposure, followed by rapid relapse of symptoms on rechallenge. Furthermore, 
several investigators have found T-cell involvement, including T-cell proliferation ex 
vivo when exposed to CBZ (Naisbitt et al., 2003a), and the presence of T-cell infiltration 
in the dermis and epidermis in CBZ-hypersensitive patients with TEN and erythema 
multiforme (Friedmann et al., 1994). T-cells from both peripheral blood and skin of 
patients with CBZ-induced TEN express the skin-homing marker cutaneous lymphocyte 
antigen, and this returns to normal as the clinical situation improves (Leyva et al.,
2000).
T-cell cloning is a powerful technique for generating clones of T-cells, i.e. popula­
tions of T-cells which have been grown in vitro from a single precursor cell. As all mem­
bers of these clones share an identical T-cell receptor, these populations axe ideal tools 
for exploring antigen-specificity and distinguishing genuine intraclonal cross-reactivity 
from mere interclonal diversity. This technique has been used to investigate hyper­
sensitivity reactions to several drugs, in particular SMX (Schnyder et al., 1997, 2000), 
penicillins (Brander et al., 1995; Padovan et al., 1997) and trinitrohalobenzenes (von 
Bonin et al., 1992; Ortmann et al., 1992), and has been instrumental in distinguishing 
T-cell reactions to hapten-modified peptides from reactions to the unmodified parent 
drug (Zanni et al., 1998).
CBZ, structurally N-carbamoyl-iminostilbene, undergoes a complex pattern of metabolism 
within the body, including formation of several structurally distinct reactive species.
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The major oxidative metabolite is CBZ-10,11-epoxide, the formation of which is catal­
ysed by CYP3A4, with minor involvement of CYP2C8 (Kerr et al., 1994). The 10,11- 
epoxide was for some time believed to be non-protein reactive as it is stable in plasma, 
although recent studies have actually identified glutathionyl and protein conjugates de­
rived from it (Bu et al., 2005). This metabolite is readily hydrolysed in vivo by epox­
ide hydrolase to 10,11-dihydrodiol-CBZ. In addition, several reactive species have also 
been identified, including CBZ-2,3-epoxide (Madden et al., 1996), CBZ-iminoquinone 
(Pearce et al., 2005), and 9-acridine carboxaldehyde (Furst et al., 1995). For a more 
detailed treatment of this issue, see 1.3.8 .4 and figure 1 .2 .
The structurally related CBZ analog oxcarbazepine (oxCBZ), used clinically for 
epilepsy and mood disorders, is keto-substituted on the unsaturated 1 0 -carbon of the 
iminostilbene structure. This alters its main route of metabolism such that the major 
oxidative metabolite is 10-OH-CBZ, which is also believed to be the active component 
(Theisohn k  Heimann, 1982). Previous studies have investigated the possibility that 
oxCBZ may be tolerated in patients hypersensitive to CBZ (Pirmohamed et al., 1991; 
Troost et al., 1996; Zakrzewska k  Ivanyi, 1988), although clinical studies are rare 
(Beran, 1993; Misra et al., 2003). One of the key issues regarding clinical cross-reactivity 
is that both oxCBZ and CBZ produce 10-OH-CBZ, and therefore if any of the initial 
T-cell response is directed towards this stable metabolite, clinical cross-reactivity seems 
almost inevitable.
One of the main unanswered questions regarding the aetiology of drug hypersen­
sitivity is the ultimate nature of the antigen which T-cells respond to, both in the 
primary sensitisation event and in the secondary effector response. It has long been 
believed that small molecules (molecular weight <1000Da) become immunogenic by 
coupling to a carrier macromolecule, most likely protein, a proposal known as the hap­
ten hypothesis (Park et al., 1998). However, more recent studies have suggested that 
drug-specific T-cells may actually be activated by the soluble drug itself, presumably 
via a reversible three-way interaction between the MHC, drug and TCR (the p-i con­
cept; Schnyder et al., 1997; Zanni et al., 1998). This has been demonstrated with 
several important drugs with relatively high incidences of immune-mediated adverse
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reactions, including SMX (Schnyder et al., 2000), lamotrigine (Naisbitt et al., 2003b), 
lidocaine (Zanni et al., 1997), and phenindione (Naisbitt et al., 2005a). Importantly, 
however, for SMX this was not the only mechanism by which T-cell clones could be 
stimulated by the drug—the protein-reactive metabolite SMX-NO could also activate 
T-cells when bound directly to the MHC molecule. It is quite possible that the only 
reason that this finding is not seen with a wider range of drugs is because few drugs 
have protein-reactive metabolites as easy to work with as SMX-NO. However, it is im­
portant to be clear that these findings are only able to inform us about the antigens 
which can activate T-cells following an adverse event—they do not, and indeed, cannot, 
inform us about the antigens involved in the initial sensitisation event. For one, there is 
good evidence that the antigenic repertoire changes both during and after an immune 
reaction, both via shifts in the population frequencies of responsive clones (Amrani 
et al., 2000), and through the alteration of antigen-specificity of the TCR on a given 
clone (McMahan & Fink, 2000; Serra et al., 2002). Caution is therefore required when 
drawing conclusions from studies on T-cells isolated post-event.
In this chapter, studies intended to explore the specificity of lymphocytes isolated 
from CBZ or oxCBZ-hypersensitive patients towards both CBZ and oxCBZ and a range 
of stable, circulating metabolites of the two compounds will be described. Furthermore, 
the mechanism by which CBZ is recognised by T-cell clones will be discussed, in order 
to give some insights into the nature of the antigen involved in the clinical response.
5.2 M aterials and M ethods
5.2.1 M aterials
Lymphoprep was obtained from Nycomed (Oxford, UK). Recombinant human IL-2 was 
obtained from Peprotech (London, UK). Anti-CD4, Anti-CD8 , anti-CD3, and anti-V/3 
antibodies were all obtained from Serotec (Oxford, UK). [3 H]-methyl thymidine was 
obtained from Moravek (California, USA). 10-OH-CBZ, 2-OH-CBZ, 3-OH-CBZ, CBZ- 
1 0 ,1 1 -irans-diol, and CBZ-10,ll-cis-diol were obtained from Novartis (Basel, Switzer­
land). All other reagents, chemicals and components were supplied by Sigma-Aldrich 
(Gillingham, UK).
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N-acetyl-iminostilbene was prepared by reacting iminostilbene (2.0g, 10.4mmol) 
with acetic anhydride (15ml) at 100°C for 5 h. After cooling to room temperature, 
the reaction mixture was added to an ice/water mix (150ml) and stirred for 30 min. 
The crude product was extracted into ethyl acetate and the extracts stripped once 
with water. The organic phase was dried over Na2 SC>4 and solvents were removed in 
vacuo. The crude material was re-crystallised from ethyl acetate/n-hexane to give the 
desired N-acetyl-iminostilbene as a white solid (yield, 1.98g, 81%; 1H-NMR spectrum, <5 
(ppm) (d6-acetone): 7.23-7.47 (m, 8 H, aromatic); 6.90-6.99 (AB qt, 2H, H-C aromatic); 
1.86 (s, 3H, H3-CO); 13C-NMR spectrum, 5 (ppm) (d6-acetone): 170.82 (CO); 140.55 
(C13); 140.31 (C15; aromatic). Accurate mass calculated: 236.10753, found: 236.10760. 
Melting point: 110-112°C. This synthesis was performed by Dr Elizabeth Bowkett 
(Dept of Chemistry, University of Liverpool).
5.2.1.1 Culture medium
T-cell and APC culture media were prepared as described previously (see 2 .2 .1 .1 ).
5.2.1.2 Isolation of PBM Cs
PBMCs were isolated and viability was analysed as described previously (see 2.2.2).
5.2 .2  C linical details
Blood was obtained and lymphocytes isolated from 12 patients hypersensitive to CBZ 
and 1 patient hypersensitive to oxCBZ. Approval for the study was obtained from 
Liverpool local research ethics committee, and informed consent was obtained. The 
clinical details of the patients are shown in table 5.1.
2  groups of volunteers were also recruited: individuals who had been exposed to 
CBZ without overt hypersensitivity, and drug naive individuals (n=5 for both groups).
5.2 .3  D eterm ination  o f lym p h ocyte  proliferation
Lymphocyte proliferation was measured by means of the lymphocyte transformation 
test (LTT), as described previously by Nyfeler & Pichler (1997). Freshly isolated
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Table 5.1: Clinical details of CBZ hypersensitive patients
Age
(y)
Sex Days to re­action Details of reaction Monthssincereac­tion
Rechallenge
1* 70 M 21 Widespread maculopapu- lar eruption with tissue eosinophilia
28 No
2 66 F 42 Maculopapular rash, fever, eosinophilia, abnormal LFTs 84 No3 33 M 21 Exfoliative dermatitis, fa­cial swelling, fever and eosinophilia
180 No
4 67 F 6 Widespread erythematous rash, lymphocytosis and eosinophilia
180 No
5 31 M 28 Erythematous rash, jaun­diced, hepatomegaly 160 No6 33 M 21 Widespread severe skin rash 21 No7 27 M 21 Widespread rash with fever, history of allergy to multiple drugs
36 No
8 40 F 21 Widespread maculopapular erythematous rash 6 No9 55 F 21 Widespread maculopapular rash, similar reaction to lamotrigine
12 No
10 65 F Rechallenge Desquamating rash with fever on inadvertent rechal­lenge, history of rash on initial exposure
<1 Positive
11 28 F Rechallenge Widespread maculopapular rash with fever/eosinophilia after 1 dose, history of allergy to antibiotics
2 Positive
12 31 M 12 Widespread severe macu­lopapular rash with fever 229 No13 67 F 22 Generalised maculopapular rash 23 No
Number assigned to patient throughout chapter (patient 13 sensitive to oxCBZ).
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PBMCs (1.5 x 105; total volume 0.2ml) were incubated with CBZ, oxCBZ, CBZ-10,11- 
epoxide, 10-OH-CBZ, 2-OH-CBZ, 3-OH-CBZ, CBZ-10,11-trans-diol and CBZ-10,11- 
as-diol, iminostilbene (all 10-50/itg/ml; for structures of all of the above, see figure 
5.1) and tetanus toxin (1 0 /xg/ml) as a positive control in 96-well U-bottomed tissue 
culture plates for 6  days (37°C; 5% CO2 ). Proliferation was measured by the addition 
of [3 H] thymidine (0.5/xCi) for the final 16 h of the incubation). Cells were harvested, 
and counted as cpm on a /5-liquid scintillation and luminescence counter (PerkinElmer 
Life Sciences, Boston, MA). Proliferative responses were calculated as SI calculated as 
described previously (see 2 .2 .6 ).
5.2 .4  G eneration  o f E B V -transform ed B -lym phoblastic  cell lines
Epstein-Barr virus (EBV)-transformed B-lymphoblastic cell lines (B-LCLs) were gener­
ated from the CBZ-allergic patients by transformation of freshly isolated PBMCs with 
supernatant from the EBV-producing cell line B9-58. B9-58 cells were maintained in 
APC medium, and the supernatant was 0 .2 /xrn filtered to remove remaining cells prior 
to use. For transformation, 2xl06 PBMCs were incubated in 5ml B9-58 supernatant, 
supplemented with cyclosporin A (1 /ig/ml) to prevent T-cell mediated suppression of 
B-cell infection. EBV-transformed B-cell cultures were maintained in APC medium.
5.2.5 T -cell cloning
T-cell cloning involves three major stages: firstly, PBMCs are bulk cultured with the 
antigen in question in order to enrich their initially low precursor frequency, so as to 
make generation of antigen-specific T-cell clones more feasible. Secondly, T-cells are 
serially diluted from enriched bulk cultures so as to allow the setting up of incubations 
containing, on average, a single T-cell. Finally, these incubations are allowed to grow 
in the presence of IL-2, and are tested for antigen specificity by antigen challenge and 
assessment of proliferation, and tested for clonality by analysis of V/5 expression.
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Figure 5.1: CBZ analogs used for LTT
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5.2.5.1 Generation of T-cell clones
For the generation of T-cell clones, freshly prepared PBMCs were incubated as bulk 
cultures with CBZ or CBZ metabolites (10-100pg/ml) in 0.5ml T-cell medium in 48- 
well tissue culture plates. Cultures were supplemented with IL-2 (60U/ml) on days 6  
and 9 to maintain drug-specific proliferation. On day 14, T-cell clones were prepared 
by serial dilution (Schnyder et al, 2000). T-cell bulk cultures were serially diluted so 
as to leave 0.3, 1 or 3 cells to be incubated in 96-well round-bottomed tissue culture 
plates in 100/ul T-cell medium, supplemented with 5xl04 allogenic irradiated (3000 rad) 
lymphocytes, 5p,g/ml phytohaemagglutinin and 60U/ml IL-2. T-cells were expanded in 
T-cell medium with 60U/ml IL-2 and restimulated every 14 days with irradiated (3000 
rad) allogenic lymphocytes and 5/xg/ml phytohaemagglutinin.
5.2.5.2 Specificity of T-cell clones
CBZ-specific T-cell clones were identified by proliferation assay. 0.5xl05 T-cells were in­
cubated with autologous irradiated (4500 rad) B-LCLs (O.lxlO5) and CBZ (10, 25/xg/ml) 
in a final volume of 200pl in a 96-well round-bottomed tissue culture plate. After 48 
h, [3H]-thymidine was added (0.5pCi), and 16 h later proliferation was determined as 
described earlier. T-cell lines with a positive proliferative response (as determined by 
SI > 2.5) were taken to be drug-specific and maintained in IL-2 containing medium.
5.2.5.3 Phenotypic analysis of T-cell clones
Clonality of T-cell lines was determined by V/3 analysis. T-cells were incubated with 
a panel of FITC-labelled anti-V/3 antibodies, washed repeatedly, and V/3 expression 
was determined by flow cytometry by comparison to isotype matched controls. CD4/8 
phenotype was determined by dual staining with FITC-labelled anti-CD4 and PE- 
labelled anti-CD8  antibodies followed by flow cytometry.
5.2 .6  R ole o f m etabolism  in T -cell activation  by CBZ
Three variations of the standard proliferation assay were used in order to explore the 
role of CBZ metabolism in T-cell activation.
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5.2.6.1 T-cell and B-cell pulsing with CBZ prior to proliferation assays
The role of covalent binding in T-cell activation with CBZ was explored by pulsing 
of T-cells or APCs with CBZ prior to combining the two cell types, as previously de­
scribed (Schnyder et al., 1997, 2000). These experiments involved the incubation of 
CBZ (25/xg/ml) with either T-cells (0.5xl05) or irradiated (4500rad) B-LCLs (O.lxlO5) 
for 2  h, followed by repeated washes to remove non-covalently bound drug, and incu­
bation in fresh medium (0.2ml) with additional irradiated (4500rad) B-LCLs or T-cells 
respectively, and proliferation determined by thymidine incorporation as described pre­
viously.
5.2.6.2 Enzyme inhibition by aminobenzotriazole in proliferation assay
The role of localised metabolism in T-cell activation by CBZ was explored by the 
addition of ABT, a mechanism based inhibitor of haemoxygenases (Ortiz De Montellado 
et al., 1984), to the proliferation assay. ImM ABT was pre-incubated with T-cells 
and irradiated (4500rad) B-LCLs 1 h prior to the addition of CBZ for a standard 
proliferation assay.
5.2.6.3 Addition of glutathione to proliferation assay
T-cells and irradiated (4500rad) B-LCLs were incubated with GSH (2mM) for 35 min 
prior to the addition of CBZ for a standard proliferation assay. GSH irreversibly binds 
to CBZ reactive metabolites and hence inhibits covalent modification of protein (Ju & 
Uetrecht, 1999; Madden et al., 1996).
5.2 .7  R ole o f antigen  processing in T -cell activation  by CBZ
A potential requirement for antigen processing in T-cell activation by CBZ was deter­
mined as described below.
5.2.7.1 CBZ presentation by fixed EBV-transformed B-cells
Chemical fixation of B-LCLs by glutaraldehyde was performed to evaluate the pos­
sibility of antigen processing in T-cell activation by CBZ. B-LCLs (2xl06 in 0.5ml
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HBSS) were fixed by the addition of glutaraldehyde (0.05%) for 30 sec at room temper­
ature. The reaction was terminated by the addition of glycine (0.2M) for 45 sec. Fixed 
B-LCLs were washed repeatedly, and used in proliferation assays as described previ­
ously. Glutaraldehyde inhibits antigen processing but does not alter MHC expression 
or presentation of preprocessed antigens (Shimonkevitz et al., 1983; Zanni et al, 1997).
5.2.7.2 Determination of minimum time requirement for T -cell/B -cell ex­
posure to CBZ
To determine the minimum time requirement for T-cell activation by CBZ, T-cells 
and B-LCLs were incubated with CBZ (25^g/ml) in 1ml T-cell medium for 0.1, 1, 
2, 4 and 16 h, followed by repeated washing, resuspending in fresh T-cell medium, 
and incubation for the remainder of 48h prior to the addition of [3 H]-thymidine and 
determination of proliferation as before.
5.2.7.3 Evaluation of time-course of T-cell activation by CBZ
The kinetics of T-cell activation by CBZ was determined by analysis of TCR internal­
isation. TCR-internalisation is one of the first detectable stages in T-cell activation, 
and is believed to act to prevent excessive T-cell activation and activation-induced cell 
death. T-cells (0.5xl05) were incubated with B-LCL (0.25xl05) in a final volume of 
0 .2 ml with CBZ (10, 25/xg/ml). After 1 , 4 or 16 h, the cells were harvested, washed, and 
stained for CD3 expression with a FITC-labelled anti-CD3 antibody. Fluorescence was 
then determined by flow cytometry as described previously, and values were calculated 
as a % decrease from the baseline expression..
5.2.8 S tatistica l analysis
Results are presented as mean ±  standard error of the mean. Normality of data was 
determined by the Shapiro-Wilks test and equality of variance by the Levene test. 
Data which were normally distributed were compared by means of a t-test, whereas 
nonparametric data were compared with the Mann-Whitney test for unpaired data or
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the Wilcoxon signed rank test for paired data. P-values < 0.05 were considered to be 
significant. All statistical analyses were performed on SPSS 13.0.
5.3 R esults
5.3.1 L ym phocyte proliferation in response to  CBZ and CBZ m etabo­
lites
PBMCs from 11/12 CBZ-hypersensitive patients proliferated in vitro when exposed to 
CBZ (5-50/iig/ml; see figure 5.2 and table 5.2). CBZ concentrations of 7 5 p.g/ml and 
above did not induce proliferation, presumably via direct toxic effects on lymphocyte 
function.
Additionally PBMCs from 1/1 oxCBZ patient proliferated when exposed to oxCBZ. 
PBMCs from CBZ-hypersensitive patients (5/5 tested) were also stimulated in vitro 
by the major CBZ oxidative metabolite CBZ-10,11 epoxide, and by oxCBZ and its 
major oxidative metabolite 10-OH-CBZ, but not by other oxidative CBZ metabolites 
(2-OH-CBZ, 3-OH-CBZ, CBZ-10,11 -as-diol, CBZ-10,11-irans-diol, or iminostilbene). 
Figure 5.3 shows proliferation of PBMCs from 6  hypersensitive patients in response to 
all positive compounds. In addition, all 5 hypersensitive individuals tested responded 
weakly to the stable CBZ-analog, N-acetyl-iminostilbene (see figure 5.4).
No increased proliferation was seen by either drug-naive (SI: 1.1±0.2) or drug- 
tolerant (SI:1.2±0.4) individuals in response to CBZ, although they all responded to 
the positive control tetanus toxin (data not shown).
5.3.2 G eneration and characterisation o f CBZ and C B Z -m etabolite  
specific T -cell clones
More than 1000 T-cell clones isolated from 6  CBZ-hypersensitive patients were tested 
for CBZ-reactivity, and over 100 CBZ-reactive clones were thereby detected (control 
incubations, 4981.5±5846.4 cpm; CBZ [25 ¡xg/mL], 17721.4±15964.9 cpm; patients 1, 
2, 3, 4, 6  and 7). The majority of these clones were CD4+, with 11 being either CD8 + 
(n=7) or CD4-I-CD8-)- dual positive (n=4), and all clones expressed a single a¡3 TCR,
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Figure 5.2: Proliferation of lymphocytes from 10 CBZ hypersensitive patients. Drug specific proliferation was determined by LTT. Lymphocytes were incubated with CBZ for 5 days, followed by [3H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean SI of triplicate cultures. Bold bars indicate mean SI.
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Table 5.2: CBZ-specific proliferation of lymphocytes from hypersensitive patients
Carbamazepine (¿¿g/ml)cpm in control 5 1 0 25 50 1 0 0
1 584 5.2* 7.5 9.8 3.3 1 .0
2 289 8.5 44.3 42.1 2 2 .8 2 .13 1003 3.1 14.3 18.7 29.8 5.14 1443 6 .0 12.5 10.5 13.5 2 .15 1078 2 .8 8.4 6.4 4.9 0.5
6 1321 1.5 2.3 3.0 1 .6 0.37 687 8 .1 7.1 7.6 4.2 1.5
8 399 9.2 17.6 23.4 18.9 4.29 881 11.5 13.8 24.7 9.9 1 .2
1 0 670 22.5 69.4 42.3 38.7 3.2
1 1 1004 16.4 28.6 23.2 6.4 1.4
1 2 1294 1 .1 0.9 1 .2 1 .0 1 .113 920 2 .8 4.8 5.3 4.2 1.7Mean 7.6 17.8 16.8 1 2 .2 2 .0
* : Data presented as SI: stimulation index.
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Figure 5.3: Proliferation of lymphocytes from hypersensitive patients stimulated with CBZ, oxCBZ and major oxidative metabolites. Drug specific proliferation was de­termined by incubating lymphocytes with CBZ for 5 days, followed by [3 H]-methyl- thymidine for the final 16 h of incubation. Results are expressed as the mean SI of triplicate cultures. *: p < 0.05 compared to control incubations
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Figure 5.4: Proliferation of lymphocytes from hypersensitive patients stimulated with CBZ or N-acetyl iminostilbene. Drug specific proliferation was determined by incubat­ing lymphocytes with CBZ for 5 days, followed by [3 H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean SI of triplicate cultures. *: p < 0.05 compared to control incubations
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although there was no clear pattern of expression. All clones responded to CBZ in a 
dose-dependent manner, with maximal responses at concentrations between 5-50/ig/ml. 
As with PBMC cultures, concentrations above 75/rg/ml inhibited proliferation. Figure
5.5 shows proliferation data from 8  representative clones.
5.3.3 R ole o f m etabolism  in T -cell activation  by CBZ
Three modifications of the basic proliferation assay were used to explore the role of CBZ 
metabolism and covalent binding in T-cell activation, which we will discuss sequentially.
Firstly, either T-cell clones or irradiated B-LCLs were incubated with CBZ for 2 
h prior to the addition of irradiated B-LCLs or T-cells respectively. In no case was 
T-cell proliferation observed following pulsing of cells (see figure 5.6), indicating that 
the simultaneous presence of CBZ, T-cells and B-LCLs was an absolute prerequisite 
for T-cell activation. This indicates that covalent binding of CBZ to either T-cells or 
B-LCLs cannot substitute for, and cannot be the essential result of, the role of free 
CBZ in CBZ-induced T-cell activation.
Secondly, ABT was used as a nonspecific inhibitor of oxidative metabolism. ABT 
inhibits a wide range of haemoxygenases, including all CYPs and myeloperoxidase 
(Ortiz De Montellado et al., 1984, see 3.3.6). The addition of ABT to T-cell/B-LCL 
cultures 1 h prior to the addition of CBZ had no effect on the proliferative response 
induced, whereas ABT alone had no effect (see figure 5.7).
Thirdly, GSH was added to the cells 35 min prior to the addition of CBZ. GSH is 
known to bind to and detoxify all known CBZ-reactive metabolites (Bu et al., 2005; Ju 
& Uetrecht, 1999; Madden et al., 1996; Pearce et al., 2005), and so the failure of this 
pre-treatment to reduce T-cell activation compared to control incubations (see figure 
5.8) was taken to be further evidence that CBZ-reactive metabolites do not play an 
important role in this in vitro CBZ-induced T-cell activation.
5.3 .4  R ole of antigen  processing in T -cell activation  by CBZ
In addition, several approaches were undertaken in order to explore the possibility that 
antigen processing by APCs is an essential step in the activation of T-cells by CBZ.
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Figure 5.5: Proliferation of 8  representative T-cell clones isolated from CBZ hyper­sensitive patients stimulated with CBZ. Drug specific proliferation was determined by incubating T-cell clones with CBZ and B-LCLs as APC for 48 h, followed by the ad­dition of [3H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures.
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Figure 5.6: CBZ-specific T-cell clones do not proliferate in the presence of B-LCLs or T-cells pulsed with CBZ for 2 h. Drug specific proliferation was determined by incubating lymphocytes with CBZ for 48 h, followed by [3H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures. *: p < 0.05 compared to control or pulsed incubations
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Figure 5.7: The addition of ImM ABT does not affect the T-cell proliferative response induced by CBZ. Drug-specific proliferation was determined by incubating lymphocytes with CBZ for 48 h, followed by [3 H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures. *: p < 0.05 compared to control incubations
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Figure 5.8: The addition of 2mM GSH does not affect the T-cell proliferative response induced by CBZ. Drug-specific proliferation was determined by incubating lymphocytes with CBZ for 48 h, followed by [3 H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures. *: p < 0.05 compared to control incubations
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Firstly, B-LCLs were chemically fixed with glutaraldehyde prior to addition of CBZ 
and T-cells. This is known to inactivate the internal antigen processing and presenta­
tion machinery, although it does not eliminate MHC expression. In previous studies 
(Schnyder et al., 1997) it was sufficient to eliminate processing of protein antigens, but 
did not prevent presentation of pre-processed protein antigens, nor did it prevent the 
presentation of small molecules in a metabolism- and processing-independent fashion. 
In this study, it was found that glutaraldehyde fixation was insufficient to prevent CBZ 
presentation (see figure 5.9), suggesting that CBZ is presented directly on the MHC 
molecule, without being processed as part of a peptide antigen.
Secondly, the minimum time requirement for effective T-cell activation was deter­
mined by incubating T-cells, B-LCLs and CBZ for various periods (0.1, 1, 4, 16 h), 
followed by washing away soluble drug and resuspending cells in fresh medium for the 
remainder of 48 h in culture. T-cell clones did appear to be heterogenous in response, 
but in 4/5 cases activation was observed with as little as 1 h exposure, and in 2/5 cases 
only 5 mins. In the remaining clone, 4 h exposure was sufficient for activation (see 
figure 5.10.
Thirdly, an early marker of T-cell activation, TCR internalisation, was used as a 
surrogate of T-cell activation in order to identify the earliest point that T-cell acti­
vation can be detected following incubation with B-LCLs and CBZ. Significant TCR 
internalisation was detectable in all clones within 1 h of T-cell exposure to CBZ (see 
figure 5.11).
Since antigens which require processing takes a minimum of 4-6 h exposure to 
induce T-cell activation (Panina-Bordignon et al., 1991; Zanni et al., 1998), and since 
they cannot be presented by fixed APCs (Schnyder et al., 1997), these data demonstrate 
that, for the clones under study, CBZ is presented in a processing-independent fashion.
5.4 Discussion
Many of the adverse reactions to CBZ are believed to be immunological in nature, 
although convincing final evidence is still lacking. In this study, PBMCs and T-cell 
clones from patients with apparent CBZ hypersensitivity were studied both in order
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Figure 5.9: Fixation of B-LCLs does not affect the T-cell proliferative response induced by CBZ. Drug-specific proliferation was determined by incubating lymphocytes with CBZ and fixed B-LCLs for 48 h, followed by [3H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures. *: p < 0.05 compared to control incubations
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Figure 5.10: Determination of the minimum required period of exposure to CBZ for activation of CBZ-specific T-cell clones. T-cells and B-LCLs were incubated with CBZ (25/xg/ml) for 0.1-16 h, prior to washing and incubated in drug-free medium for the remainder of 48 h. Proliferation as determined by measuring [3 H]-thymidine incorpo­ration. *: p < 0.05 compared to control incubations
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Figure 5.11: Kinetics of T-cell receptor internalisation following CBZ exposure. T- cells were exposed to CBZ (10, 25/xg/ml) for varying periods (1, 4, 16 h), followed by staining with FITC-labelled anti-CD3 antibody and fluorescence determination by flow cytometry. Data show one representative clone.
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to explore both the cross-reactivity patterns to a panel of stable and reactive CBZ 
metabolites and analogs, and in an attempt to identify the mechanism by which CBZ 
is presented to CBZ-specific T-cells, in particular, whether localised drug metabolism 
or antigen processing are essential parts of the response.
PBMCs from CBZ-hypersensitive patients have been shown previously to proliferate 
in the presence of CBZ (Mauri-Hellweg et al., 1995; Naisbitt et al., 2003a; Zakrzewska 
k  Ivanyi, 1988), although little work has been done to investigate the potential for 
CBZ metabolites to also act as antigens. CBZ is primarily metabolised by oxidative 
reactions, largely through the formation of the stable 1 0 ,1 1 -epoxide and subsequent 
hydrolysis products. In addition, oxidation of the benzene rings both to a 2,3-epoxide 
and 2-OH products has been associated with the formation of reactive species. The 
technique used to investigate PBMC reactivity to CBZ, the LTT, has been previously 
used as a aid to diagnosis, or in order to differentiate the culprit drug in cases of 
polypharmacy (Pichler &; Tilch, 2004). In one major study (Nyfeler k  Pichler, 1997), 
over 900 past patients who had had an LTT performed during their treatment were 
retrospectively analysed, and the accuracy of the test was determined. Sensitivity and 
specificity values of 74% and 85% were obtained, although the preponderance of (3- 
lactam antibiotics amongst the culprit drugs makes it hard to extrapolate too far from 
these findings. Other studies have found wide variation in sensitivity, which may reflect 
differences in the drugs studied, the clinical characteristics required for enrolment, 
methodological differences, or the technical skill of the individuals performing the test.
In this study, 11/12 CBZ-hypersensitive patients and 1/1 oxCBZ patient were found 
to be positive in an LTT, whereas none of the 10 control individuals demonstrated 
increased proliferation. Importantly, the concentrations associated with PBMC prolif­
eration were comparable with those expected in vivo in patients receiving therapeutic 
doses (5-10pg/ml; Tomson et al., 1980). The response was surprisingly stable over 
time, with two of the individuals who responded most vigorously having had their 
initial reaction some 15 years previously.
Studies with T-cell clones have previously been used to elucidate the mechanism by 
which T-cells are stimulated by antigens. In particular, the use of T-cell clones rather
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than whole blood lymphocytes allows the investigator to reduce the complexity which 
a polyclonal response necessarily produces, and hence allows greater insight into the 
fundamental mechanisms in play.
Studies with T-cell clones from SMX-hypersensitive patients have suggested that 
they can respond to SMX in a metabolism- and processing-independent fashion (Schny- 
der et al., 1997; Zanni et al., 1998), and similar results also have been found with several 
other drugs (Naisbitt et al., 2003b, 2005a; Zanni et al., 1997). In order to investigate 
the possibility that CBZ acts on T-cells in a similar fashion, various functional assays 
were used to explore the mechanisms of antigen processing and presentation.
Previous studies have shown that pulsing APCs with protein-reactive compounds 
can allow T-cell activation when T-cells are added following washing of the APCs 
(Naisbitt et al., 2001; Schnyder et al., 2000; Zanni et al., 1998). However, non-protein 
reactive compounds appear to require the continual presence of the soluble drug, sug­
gesting that covalent binding to the cells, as may potentially occur through the action 
of enzymes expressed by either of the cell types present, is not an essential or sufficient 
step (Burkhart et al., 2002; Schnyder et al., 1997, 2000) for a low molecular weight 
compound to act as an antigen. In these studies, 2 h pulsing of either T-cells or APCs 
by CBZ, followed by incubation with the other cell type in fresh medium, was always 
insufficient for T-cell stimulation. It remains possible that 2 h is not a long enough 
period of time for exposure, and that longer pulses might have given different results. 
However, this seems unlikely in light of some of the later results, which found that puls­
ing combined T-cells and APCs with CBZ for as little as O.lh was sufficient to activate 
the T-cells. These data appear to suggest that CBZ-specific T-cell clones respond to 
CBZ in a covalent-binding-independent fashion.
The broad-spectrum metabolic enzyme inhibitor ABT was added to proliferation 
assays in order to further explore the role of oxidative metabolism in T-cell activation by 
CBZ. ABT is a suicide inhibitor of haemoxygenases which functions by alkylating the 
haem group via a benzyne radical (Ortiz De Montellado et al., 1984). Data presented 
previously showed that ABT inhibited all CYPs and peroxidases studied (see 3.3.6), 
yet it had no effect on the T-cell proliferative response when preincubated with APCs
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for 1 h prior to the addition of T-cells and CBZ. Again, this offers evidence that the 
T-cell response to CBZ is truly to the parent drug and not to metabolites formed in 
situ.
The addition of GSH would also be expected to inhibit T-cell responses to CBZ- 
derived protein reactive metabolites, as indeed it does with SMX-NO specific T-cells 
(Farrell et ai, 2003; Burkhart et al., 2001). All reactive metabolites derived from CBZ 
which have been characterised are detoxified by the formation of conjugates with GSH 
(Bu et al, 2005; Ju &; Uetrecht, 1999; Madden et al, 1996; Pearce et al, 2005), and so 
the fact that prior incubation of APCs with GSH was unable to prevent, or even reduce, 
CBZ-specific T-cell activation must be seen as further evidence that CBZ-specific T- 
cells respond directly to the parent drug without any requirement for metabolism and 
covalent binding.
Further studies were undertaken in order to explore the requirements for antigen 
processing. In the first instance, glutaraldehyde-fixed B-LCLs were used as APCs as 
they are known to be incapable of antigen processing (Schnyder et al, 1997; Shimonke- 
vitz et al, 1983). In all of the clones tested, fixed APCs were still able to present 
CBZ to T-cells, suggesting that antigen-processing is not a necessary step in antigen 
presentation. Glutaraldehyde fixation involves the formation of multiple cross-linkages 
between free amino groups on protein, and it has been suggested that fixation could 
therefore allow CBZ-protein covalent adducts via a glutaraldehyde linker binding to 
the terminal amine group of CBZ. While this is a concern, there are some reasons to be 
cautious about this critique. Firstly, the fixation process involves quenching with excess 
glycine prior to addition of the drug. Though this is unlikely to completely eliminate 
the possibility of covalent interactions, it will greatly reduce the number of potential 
binding sites. Furthermore, since the processing machinery is inactivated, immunolog- 
ically relevant adducts will have to be very specifically placed, presumably either on or 
very close to the peptide within the MHC cleft, further limiting the potential number 
of binding sites. Secondly, the structure of the postulated CBZ-glutaraldehyde-protein 
adduct will be quite different from any probable non-covalent interaction of CBZ with 
protein. Further work on CBZ-reactive T-cells (Wu et al, 2006) found that several of
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the clones investigated herein were extremely specific with regards to their structural 
requirements for binding, with some failing to cross-react with any structural analog 
tested. It is possible that these clones do in fact cross-react with CBZ-glutaraldehyde- 
protein adducts despite their apparent stringency, but it seems implausible. However, 
this criticism does carry some force, and so further experiments were undertaken to 
explore the kinetics of T-cell activation in order to better understand the process of 
antigen presentation within this in vitro system.
Firstly, the minimum period of T-cell exposure to CBZ was assessed by use of a 
combined pulse methodology. There was some degree of heterogeneity between clones, 
but in no case was more than 4 h exposure required for a full proliferative response, 
and in some cases the time required was as low as 0.1 h. It was not clear why the 
heterogeneity was observed, but repeated experiments demonstrated that it was true 
clonal variation rather than experimental error. It may be related to the quantity of 
receptors which need to be triggered in order to induce a full response, as both this 
and the density of receptors may vary between clones (Depta et al., 2004).
Secondly, the kinetics of TCR internalisation in response to CBZ stimulation was 
studied. TCR internalisation for all clones was detectable within 1 h of CBZ exposure, 
and maximal within 4 h. This further suggests that the T-cell response to CBZ is 
too rapid to allow for the process of antigen processing, which is believed to take a 
minimum of 4-6 h (Panina-Bordignon et al., 1991; Zanni et al., 1998).
Taken together, these data all support the hypothesis that CBZ is presented to 
T-cell clones in a metabolism- and processing-independent fashion, as has been shown 
previously for several drugs, and in keeping with the p-i concept.
While some studies have explored PBMC proliferation in response to some stable 
CBZ metabolites or analogs (CBZ-10,11-epoxide, oxCBZ; Naisbitt et al., 2003a; Za- 
krzewska & Ivanyi, 1988), no previous study has investigated a wide range of known 
CBZ and oxCBZ metabolites or structural analogs. Of the compounds studied here 
(see figure 5.1), only CBZ, oxCBZ, CBZ-10,11-epoxide, 10-OH-CBZ and N-acetyl- 
iminostilbene were capable of inducing a PBMC proliferative response in vitro. Fig­
ure 5.12 summarises these findings. It is worth bearing in mind that these find-
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Table 5.3: Non-covalent molecular interactions
Type Energy* Relationship between strength and distanceIon-ion 20-40 1 /dIon-dipole 8 - 2 0 1 /d 2Dipole-dipole 4-20 1 /d 3Hydrogen 5-30 1 /d 4Van der Waals forces Hydrophobic interactions 0.5-53.4+ 1 /d 5—1 /d 8
* : kJ/mol+ : per methylene group
ings relate solely to proliferation of mixed PBMC cultures, and so cannot inform us 
about whether these results indicate different responding populations or genuine cross­
reactivity amongst individual clones. For a fuller study, involving analysis of cross­
reactivity within clones, please see Wu et al. (2006), in which genuine cross-reactivity 
of T-cell clones to several patterns of CBZ structural variations was identified.
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For a full understanding of the implications of these findings, it is briefly worth 
recapping the non-covalent interactions which may be involved in CBZ binding to 
TCR/MHC. The interactions which are known to mediate non-covalent molecular 
binding are summarised in 5.3. The strongest non-covalent interactions which are 
commonly involved in small-molecule binding to proteins are ionic interactions, but 
these are unlikely for CBZ binding, as the only potentially ionisable atom of the CBZ 
molecule, the primary amine of the carbamoyl moiety, is extremely hard to ionise (a 
weak acid with a pKa of 14; Scheytt et al, 2005). Weaker, but more likely to be in­
volved with CBZ binding, are hydrogen bonds, of which CBZ contains one acceptor, 
the oxygen of the carbamoyl group, and one donor, the amine. It is possible there­
fore, that these are involved in the binding of CBZ to the TCR/MHC complex, a 
suggestion supported by the finding that iminostilbene was completely ineffective with 
regard to PBMC stimulation. However, since replacement of the carbamoyl side chain 
with an acetyl moiety (effectively switching the primary amine with a methyl group), 
restored some (but not all) of the activity of the compound, it is also apparent that 
this is not essential in its entirety. Dipole-dipole and dipole-induced-dipole interac­
tions also require this side chain, as there are no other dipole moments within the 
remainder of the molecule. Interactions through this part of the molecule will therefore 
need to be through either Van der Waals forces (otherwise known as induced-dipole- 
induced-dipole interactions or London dispersion forces) as a consequence of transient 
dipoles, or through hydrophobic interactions, in which reordering of molecules to ex­
clude water becomes thermodynamically more stable. While individually weak, these 
are potentially quite powerful in summation, and CBZ binding is likely to rely heav­
ily on them, as the tricyclic core of the molecule is a large hydrophobic region (log 
P of whole molecule, 2.45; Physprop online database, Syracuse Research Corporation, 
h t t p : //www. s y rre s . com/esc/physprop. htm). Therefore, it is interesting to note that 
modifications of these regions can have major impacts on the ability of the compound 
to be recognised by CBZ-specific T-cells. In particular, the MHC-drug-TCR inter­
action appears able to accommodate some degree of modification of the unsaturated 
10,11 bond, although both cis and trans diol modifications were inactive. This may
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be due to changes in the electron density of the region, which may affect the ability of 
the compound to form hydrophobic interactions with the MHC or TCR, or to direct 
steric hindrance at the site of binding, or indirect steric hindrance through realign­
ment of the aromatic regions, both of which which would prevent the close alignment 
required for multiple Van der Waals forces. Hydroxylation of the aromatic rings led 
to complete inactivity. Work is underway to attempt to synthesise CBZ analogs with 
halogen-substitutions on the rings, which should allow insights into whether this lack 
of activity is due to steric alterations or modified electrochemical properties, and in 
turn should allow predictions to be made as to the bonds of importance involved in 
non-covalent interactions within the TCR-CBZ-MHC complex.
An important consideration when interpreting the data presented here is that it 
is not necessarily the case that T-cell clones isolated ex vivo are a good model for 
T-cells in vivo. For one thing, the extended period of enrichment in vitro prior to 
serial dilution may introduce an artificial stimuli which could induce artifactual T- 
cell specificities to develop (see, for instance, Engler et ai, 2004). Additionally, it is 
known that the process of avidity maturation (see 1.3.1 for details) leads to shifts in the 
pattern of T-cell specificity over the course of a reaction, and so potentially could lead 
to significant differences between the antigen-specificity of the initial T-cell population, 
and the antigen-specificity of the T-cell population at the time of PBMC isolation. 
However, seen simply as an exercise in exploring the possibilities of TCR binding, 
these studies demonstrate that the postulated molecular weight cut-off for antigenicity 
is not necessarily the case. A stronger case can be made for this being analogous 
to the pathological situation when one recalls the studies by Nassif et al. (2004), in 
which considerable cytotoxicity was observed within 4 h when T-cells isolated directly 
from blister fluid were incubated with target cells and SMX. In this study, essentially 
similar findings were obtained from T-cells at the time of the reaction without ex vivo 
stimulation or enrichment. However, further work is certainly required in order to test 
the suitability of ex vivo enriched T-cell clones post-reaction as models for effector 
T-cells during a drug hypersensitivity reaction.
A further potential criticism of this current work is that the it does not encompass
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the whole potential range of CBZ-derived antigens. Remember that SMX is presented 
in a similar fashion (Schnyder et al., 1997), and without further information, one would 
be tempted to assume that reactive metabolites play no role in SMX antigenicity (to 
leave aside the issue of immunogenicity for a moment). Of course, further studies have 
found that SMX-NO is also antigenic for T-cells derived from hypersensitive patients 
(Schnyder et al., 2000), leaving open the question of the ultimate antigen in hypersen­
sitivity. To extend the analogy, it may be the case that while CBZ can be presented 
directly, as it appears to be doing so here, CBZ reactive metabolites may also be able to 
act as antigens. However, it has not been possible as yet to fully explore this, although 
some attempts have been made. It has been claimed that the addition of microsomes to 
an LTT with CBZ led to proliferation and cytokine release which was not detectable in 
the absence of microsomes (Merk, 2005), although it has not been possible to identify 
the primary data to support this claim. Additionally, it has been found that PBMCs 
from hypersensitive patients proliferate in response to cell-free supernatant contain­
ing CBZ which has been incubated with PBMCs (and, it is claimed, has therefore 
been metabolised), but not to CBZ alone or to the washed cells thus exposed (Acharya 
et al., 2001; Strickland et al., 1996). However other studies (this chapter; Naisbitt et al., 
2003a) have found that PBMCs from CBZ-hypersensitive patients readily respond to 
the parent drug alone without this initial step, and so these findings are of uncertain im­
portance. A further major study explored the possibility that either CBZ-metabolites 
generated by a microsomal system in situ or CBZ-iminoquinone could activate T-cells, 
but was unable to demonstrate this (Wu, 2006). In any event, there is a strong case to 
be made for the extracellular application of reactive metabolite being sufficiently dif­
ferent from the intracellular generation of reactive metabolite in terms of the ultimate 
antigen as to make the exercise unviable. A more promising approach would be to use 
APCs which are sufficiently metabolically active to generate intracellular antigen. As 
dendritic cells are known to be metabolically active, at least regarding MPO (see chap­
ter 3), a previous study from our group did attempt to investigate them as APCs in 
CBZ proliferation assays (Wu, 2006). However, they were unable to identify any differ­
ences between them and B-LCLs with regards to the mechanism of presentation; CBZ
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was presented in a mechanism- and processing-independent fashion by both cell types. 
However, as dendritic cells appear to primarily express MPO rather than CYPs, this 
does not allow us to rule out the possibility that CYP-competent APCs (for instance, 
keratinocytes) could present CBZ in a metabolism-dependent fashion.
In conclusion therefore, it is important to bear in mind that whilst these studies 
do have limitations—not least, the important distinction between antigenicity, which 
these studies can address, and immunogenicity, which they cannot—they do also allow 
an insight into the mechanisms of T-cell activation, and show that the intricacies of 
TCR-specificity and mechanisms of presentation can be elucidated.
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6.1 Introduction
TMP is an antibiotic, most commonly used in conjunction with SMX in the formulation 
co-trimoxazole. This combination therapy has been associated with the induction of 
apparently immune-mediated adverse reactions, including delayed-type hypersensitivity 
reactions with skin rash and internal organ involvement. However, since both the 
components of the formulation are known to induce hypersensitivity reactions, it is 
often hard to determine the precise culprit drug in any given reaction. Most work 
on the subject has focused on the SMX component, although one study found ~20% 
of co-trimoxazole hypersensitive individuals responded to rechallenge with TMP alone 
(Bonfanti et al., 2000), and a recent case study reported a fatal case of TEN upon 
inadvertent rechallenge with TMP alone (Mortimer et al., 2005).
The structure of TMP consists of a trimethoxybenzene ring connected via a methyl 
group to a diamine-substituted pyrimidine structure. It is excreted largely unchanged 
(50-60%) in urine, but several metabolites have also been detected. Of these, the most 
prominent stable oxidative metabolites are two demethylated species, 3’-OH-TMP and 
4’-OH-TMP, a hydroxylated derivative, a-OH-TMP, and two N-oxides, 1-NO-TMP and 
3-NO-TMP (van ’t Klooster et al., 1992). In addition, it has been found that TMP 
can form a reactive iminoquinone methide species following oxidation by a MPO/H2 O2 
oxidising complex (Lai et al., 1999). It has been postulated that this occurs through 
N-chlorination of the para-amino group, although complete proof for this is lacking. See 
figure 6.1 for a summary of these known metabolites. The initial study which identified 
the iminoquinone methide species found NAC adducts via both the a-methyl group 
and the 4-position on the pyrimidine ring, while a later study (Dieckhaus et al., 2005), 
found GSH adducts only through the pyrimidine ring. This may be due to the increased 
pH at which the reaction was performed, or may be due to intrinsic differences between 
the reactivity of the two model nucleophiles.
The nature of the ultimate antigen responsible for the activation of T-cells in TMP 
hypersensitivity has not previously been explored. In this study, the immune response 
in a patient who had experienced severe hypersensitivity with hepatic involvement 
following TMP administration was explored by means of ex vivo rechallenge of PBMCs
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OMeTMP-iminoquinonemethide
Figure 6.1: Known routes of oxidative TMP metabolism. *: sites of NAC adduct formation
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and T-cell clones, in order to explore the requirements for T-cell activation by TMP.
6.2 M aterials and M ethods
6.2.1 M aterials
Lymphoprep was obtained from Nycomed (Oxford, UK). Recombinant human IL-2 was 
obtained from Peprotech (London, UK). Anti-CD4, Anti-CD8 , anti-CD3, anti-V/3 and 
anti-chemokine receptor antibodies were all obtained from Serotec (Oxford, UK). [3 H]- 
methyl thymidine was obtained from Moravek (California, USA). All other reagents, 
chemicals and components were supplied by Sigma-Aldrich (Gillingham, UK).
6.2.1.1 Culture medium
T-cell and APC culture media were prepared as described previously (see 2.2.1.1).
6.2.1.2 Isolation of PBM Cs
PBMCs were isolated and viability was analysed as described previously (see 2.2.2).
6.2 .2  Clinical D eta ils
A 20-year old female was prescribed TMP at 300mg b.d. for acne. 2 weeks after 
the initial treatment, she developed a maculopapular rash, starting in the legs and 
spreading to affect the trunk and upper limbs. The TMP was stopped 1 week later (3 
weeks from onset of treatment) as the rash was worsening.
She was admitted to a local hospital in the 4th week after onset of treatment with 
fever, desquamating rash and pruritis. Initial haematology results on admission were 
white cell count of 24.9xl06/m l (reference range: 4-11) with eosinophilia of 13% (0-7); 
and liver function test results as in table 6.1. A blood film performed at the time of 
initial admission showed atypical lymphocytes with eosinophilia.
She was later transferred to Queen Elizabeth Hospital in Birmingham when her liver 
tests continued to deteriorate, with aspartate transaminase >6000. Clinical assessment 
in Birmingham showed ongoing exfoliating rash with facial swelling. Liver function 
tests on admission in Birmingham were as given in table 6.1.
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Table 6.1: Liver function test results
Test Reference range On admission On referral On dischargeBilirubin (/¿M) 2-14 13 283 177AST (IU/L) 10-34 399 3407 116ALP (IU/L) 44-147 183 599 358INR 0.9-1.2 NP 2.4 1
Abbreviations in this table, ALP: alkaline phosphatase, AST: aspartate transaminase, INR: international normalised ratio, IU: international unit, NP: not performed.
Treatment was largely symptomatic, alongside N-acetylcysteine given as a lmg/kg 
infusion over 24 h. Steroids were not given, and a liver biopsy sample was not ob­
tained. Eosinophilia peaked 6  days after admission to Birmingham, despite all other 
haematological tests indicating decreases, and the patient was discharged 8  days af­
ter Birmingham admission, with liver function test results as given in 6.1. Blood test 
results were normal on a 2  month follow-up.
Blood samples for this study were taken upon referral to the Queen Elizabeth 
Hospital and 3 months after recovery.
6.2 .3  D eterm ination  o f lym p h ocyte  proliferation
Lymphocyte proliferation was measured by means of the LTT, as described previously 
(Nyfeler & Pichler, 1997, see 5.2.3;). Freshly isolated PBMCs (1.5 x 105; total vol­
ume 0.2ml) were incubated with TMP (0.1-500/ig/ml; either with or without 2mM 
NaOCl), SMX (1-1000/iM), SMX-NO (0.1-50/xM) or tetanus toxin (10/ug/ml) as a 
positive control in 96-well U-bottomed tissue culture plates for 6  days (37° C; 5% CO2 ). 
Proliferation was measured by the addition of [3 H] thymidine (0.5pCi) for the final 16 
h of the incubation. Cells were harvested, and counted as cpm on a /3-liquid scintilla­
tion and luminescence counter (PerkinElmer Life Sciences, Boston, MA). Proliferative 
responses were calculated as SI as described previously (see 2.2.6).
In addition, LTTs were performed with two separate modifications: firstly, GSH 
(ImM) was added to the incubations 30 min prior to addition of the drugs; and sec­
ondly, PBMCs (0.5xl05 or 1.5xl05 /incubation) were either modified with a TMP imi- 
noquinone methide generating system (1-50/jg/ml TMP and 2mM NaOCl) or TMP 
alone (1-50/ig/ml), or were left untreated, then were irradiated (3000 rad) and added
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to a standard LTT with further PBMCs in fresh media.
6.2 .4  G eneration o f E B V -transform ed B -lym phoblastic  cell lines
EBV-transformed B-LCLs were generated from the TMP-allergic patient by transfor­
mation of freshly isolated PBMCs with supernatant from the EBV-producing cell line 
B9-58. B9-58 cells were maintained in APC medium, and the supernatant was 0 .2 pm 
filtered to remove remaining cells prior to use. For transformation, 2xl06 PBMCs were 
incubated in 5ml B9-58 supernatant, supplemented with cyclosporin A (lpg/ml) to pre­
vent T-cell mediated suppression of B-cell infection. EBV-transformed B-cell cultures 
were maintained in APC medium.
6.2.5 G eneration o f T -cell clones
For the generation of T-cell clones, freshly prepared PBMCs were incubated with TMP 
(10-100pg/ml) in 0.5ml T-cell medium in 48-well tissue culture plates. Cultures were 
supplemented with IL-2 (60U/ml) on days 6  and 9 to maintain drug-specific prolif­
eration. On day 14, T-cell clones were prepared by serial dilution (Schnyder et ai, 
2000). 0.3, 1 or 3 cells were incubated in 96-well round-bottomed tissue culture plates 
in lOOpl T-cell medium, supplemented with 5xl04 allogenic irradiated (3000 rad) lym­
phocytes, 5pg/ml phytohaemagglutinin and 60U/ml IL-2. T-cells were expanded in 
T-cell medium with 60U/ml IL-2 and restimulated every 14 days with irradiated (3000 
rad) allogenic lymphocytes and 5/ig/ml phytohaemagglutinin.
6.2 .6  Specificity o f T -cell clones
TMP-specific T-cell clones were identified by proliferation assay. 0.5x10s T-cells were 
incubated with autologous irradiated (4500 rad) B-LCLs (0.1x10s) and TMP (10, 
25/ig/ml) in a final volume of 200¡A in a 96-well round-bottomed tissue culture plate. 
After 48 h, [3 H]-thymidine was added (0.5/iCi), and 16 h later proliferation was de­
termined as described earlier. T-cell lines with a positive proliferative response (as 
determined by SI > 2.5) were taken to be drug-specific and maintained in IL-2 con­
taining medium.
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6.2 .7  P henotypic analysis o f T M P -specific  T -cell clones
Monoclonality of T-cell lines was determined by V/3 analysis. T-cells were incubated 
with a panel of 25 FITC-labelled anti-V/3 antibodies which detect more than 75% of 
all known V/3 families, washed repeatedly, and V/3 expression was determined by flow 
cytometry by comparison to isotype matched controls.
CD4/8 phenotype was determined by dual staining with FITC-labelled anti-CD4 
and PE-labelled anti-CD8  antibodies followed by flow cytometry.
6.2.7.1 Chemokine receptor expression on TMP-specific T-cell clones
Chemokine receptor expression was determined by comparison of fluorescence as de­
termined by flow cytometry with a panel of FITC-labelled anti-chemokine receptor 
(CXCR3, CCR4, CXCR4, CCR5, CXCR6 , CCR8 ) antibodies versus FITC-labelled 
isotype controls.
6.2.7.2 Cytotoxicity of TM P-specific T-cell clones
TMP-induced T-cell mediated cytotoxicity was investigated through use of a 4-hour 
[51 Cr]-release assay. To measure immune-mediated killing, autologous B-LCLs (lxlO6) 
were labelled with 51 Cr (50/xCi) for 1 h. B-LCLs were washed repeatedly to remove 
free 51Cr and incubated (2.5xl03; total volume 0.2mL) with T cells at effector: tar get 
ratios of 3:1, 10:1, and 30:1 in the presence and absence of TMP (10, 25/xg/ml) for 
4 h. Spontaneous release was determined by parallel incubations without TMP, and 
maximal release was determined by repeated freeze-thaw cycles to lyse remaining cells. 
Specific lysis was therefore calculated as
1 0 0 % x experimental release — spontaneous release maximal release — spontaneous release
Direct toxicity of TMP was excluded by incubating TMP (50/ag/ml) with [5 1Cr]- 
loaded B-LCLs (2.5xl03) for 4 h in the absence of T cells.
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6.2 .8  R ole o f m etabolism  and processing in th e  activation  o f T -cell 
clones
Three modifications of the standard proliferation assay were used to explore the role of 
metabolism, covalent binding, and processing in the activation of TMP-specific T-cell 
clones.
6.2.8.1 Additional pulse with TMP-modified B-LCLs
The ability of TMP-covalently-modified cells to act as sources of antigens was explored 
by means of an additional pulsing methodology. In this, B-LCLs were exposed to a 
TMP-iminoquinone methide generating system (1 0 0 /ig/ml TMP, 2mM NaOCl; from 
Lai et al., 1999), irradiated (4500 rad), and added to fresh T-cells and irradiated (4500 
rad) B-LCLs. Proliferation was determined 48 h later as for a standard proliferation 
assay.
6.2.8.2 T-cell and B-cell pulsing with TM P prior to proliferation assays
The role of covalent binding in T-cell activation with TMP was explored by pulsing 
of APCs with TMP prior to combining them with T-cells, as previously described 
(Schnyder et al., 1997, 2000). These experiments involved the incubation of TMP 
(25/ig/ml) with irradiated (4500rad) B-LCLs (O.lxlO5) for 2 h, followed by repeated 
washes to remove non-covalently bound drug, and incubation in fresh medium (0 .2 ml) 
with additional T-cells and proliferation determined by thymidine incorporation as 
described previously.
6.2.8.3 Addition of glutathione to proliferation assay
T-cells and irradiated (4500rad) B-LCLs were incubated with GSH (2mM) for 35 min 
prior to the addition of TMP for a standard proliferation assay. GSH irreversibly binds 
to TMP iminoquinone methide and hence can inhibit covalent modification of protein 
(Dieckhaus et al., 2005).
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6.2.8.4 TM P presentation by fixed EBV-transformed B-LCLs
Chemical fixation of B-LCLs by glutaraldehyde was performed to evaluate the pos­
sibility of antigen processing in T-cell activation by TMP. B-LCLs (2xl06 in 0.5ml 
HBSS) were fixed by the addition of glutaraldehyde (0.05%) for 30 sec at room temper­
ature. The reaction was terminated by the addition of glycine (0.2M) for 45 sec. Fixed 
B-LCLs were washed repeatedly, and used in proliferation assays as described previ­
ously. Glutaraldehyde inhibits antigen processing but does not alter MHC expression 
or presentation of preprocessed antigens (Shimonkevitz et ai, 1983; Zanni et al, 1997).
6.2 .9  S tatistica l analysis
Results are presented as mean ±  standard error of the mean. Normality of data was 
determined by the Shapiro-Wilks test and equality of variance by the Levene test. 
Data which were normally distributed were compared by means of a t-test, whereas 
nonparametric data were compared with the Mann-Whitney test for unpaired data or 
the Wilcoxon signed rank test for paired data. P-values < 0.05 were considered to be 
significant. All statistical analyses were performed on SPSS 13.0.
6.3 R esults
6.3 .1  L ym phocyte transform ation test
Lymphocytes from the TMP-hypersensitive patient proliferated in response to either 
TMP (maximal response 10-25/Ug/ml; cpm of control incubations, 1222.7±652.5, cpm of 
test incubations, 6950±5468, 5779±4279; see figure 6.2) or the positive control tetanus 
toxoid (cpm, 7058±4319), but not to any of the other compounds tested (SMX, SMX- 
NO). In addition, lymphocyte cultures with ImM GSH and TMP demonstrated compa­
rable proliferation to lymphocyte cultures with TMP alone. No noteworthy difference, 
besides a small increase in magnitude, was seen between experiments performed on 
lymphocytes isolated at the time of the reaction and those undertaken on lymphocytes 
isolated 3 months subsequently (see figure 6.2).
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Figure 6.2: Proliferation of lymphocytes from a TMP-hypersensitive patient stimulated with TMP either during or 3 months after the hypersensitivity reaction. Drug specific proliferation was determined by incubating lymphocytes with TMP for 5 days, followed by [3 H]-methyl-thymidine for the final 16 h of incubation. TT: tetanus toxin. Results are expressed as the mean SI of triplicate cultures.
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When lymphocytes were incubated with a TMP-iminoquinone methide generating 
system (TMP with 2mM NaOCl), proliferation was completely eliminated. However, 
this is likely due to a toxic mechanism related to the presence of the hypochlorite, 
so further experiments used this system simply as a source of antigen generation. In 
these experiments PBMCs were modified either with the metabolite generating system 
or TMP alone prior to being irradiated, washed, and added to fresh lymphocytes. A 
previous study has found that similarly metabolite-modified dead cells can represent 
a potent source of antigen (Naisbitt et al., 2002). However, although this did not 
inhibit proliferation to the positive control tetanus toxoid (indicating the absence of 
a functional inhibition), this was incapable of inducing T-cell proliferation (see figure 
6.3).
6.3.2 G eneration and characterisation o f T M P -specific  T -cell clones
Over 336 T-cell clones were investigated for TMP reactivity, of which 58 were found to 
respond to TMP (maximal response 50-100/xg/ml; cpm of control incubations 1115±215, 
cpm of test incubations 8553±2930, 10125±2922; see figure 6.4). All of the clones thus 
identified were found to be CD4+, and all clones expressed a single, though varying, 
TCR V/3 chain, confirming the clonality of the lines. Only 3 of the clones expanded 
sufficiently to allow chemokine receptor analysis to be performed. Of these clones, 
3/3 expressed both CXCR3 and CCR4, and 2/3 additionally expressed CCR8  (fold 
increase in median fluorescence >1.4; Wu et al., 2007). None of CXCR4, CCR5 or 
CCR6  were expressed by any of the clones examined. See figure 6.5 for flow cytometry 
traces from one representative clone. The 5 clones examined did not demonstrate any 
immune-mediated killing, even at the highest effector:target ratio of 30:1.
6.3.3 R ole o f m etabolism  and antigen  processing in th e  activation  of 
T M P -specific  T -cell clones
The addition of TMP-iminoquinone methide modified B-LCLs to the standard pro­
liferation assay was not able to induce a response in any of the T-cell clones tested, 
although they responded normally to the addition of free TMP (see figure 6 .6 ). Simi-
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TMP (|jg/ml)
Figure 6.3: Proliferation of lymphocytes from a TMP-hypersensitive patient stimu­lated with either TMP (diamonds) or TMP-iminoquinone-methide-modified PBMCs (0.5xl05, squares; 1.5xl05, triangles). Proliferation was determined by incubating lym­phocytes with TMP for 5 days, followed by [3H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean SI of triplicate cultures.
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Figure 6.4: Proliferation of 12 T-cell clones isolated from a TMP hypersensitive patient and stimulated with TMP. Drug specific proliferation was determined by incubating T-cell clones with TMP and B-LCLs as APC for 48 h, followed by the addition of [3 H]-methyl-thymidine for the final 16 h of incubation. Results are expressed as the mean cpm of duplicate cultures.
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Figure 6.5: Flow cytometry traces from one representative T-cell clone demonstrating expression of CXCR3, CCR4 and CCR8 . T-cell clones were incubated with labelled anti-chemokine receptor antibodies (filled histograms) or isotype-matched controls (un­filled histograms), and expression determined by comparison.
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larly, B-LCLs pulsed with TMP and washed were incapable of activating T-cell clones 
which responded to free TMP (see figure 6 .6 ). These data indicate that the T-cell 
clones required the simultaneous presence of T-cells, B-LCLs and free TMP to induce 
T-cell proliferation, in line with the p-i concept of T-cell activation by small molecules 
(Pichler, 2002). Furthermore, the addition of GSH, which would be expected to reduce 
the formation of protein adducts by the iminoquinone methide metabolite, had no effect 
on the proliferation of clones to TMP.
B-LCLs fixed with glutaraldehyde were found to be equally effective in the induction 
of T-cell proliferation as viable B-LCLs (see figure 6 .6 ), suggesting that functional 
internal machinery for antigen processing is not required, and hence that the drug is 
presented on the surface of peptide/MHC molecules in the absence of antigen processing 
(Schnyder et al, 1997).
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6.4 Discussion
While TMP is known to be associated with delayed-type hypersensitivity reactions, 
little work has been done on the mechanisms behind these reactions. As TMP is often 
used in conjunction with SMX, which induces very similar adverse reactions, in many 
cases it is hard to be sure which drug is the actual culprit. This case was particularly 
interesting as it not only offered a case where the culprit drug was unquestionably TMP, 
as the patient was solely exposed to this, but it also encompassed severe liver damage. 
While this is not unusual in drug hypersensitivity, it often requires transplantation 
and consequent immunosuppression, making future investigations of immune function 
difficult to perform and harder to interpret. Therefore, investigations into this case 
should shed some light on T-cell responses to TMP, as well as the mechanisms by 
which liver involvement is induced.
The clinical triad of fever, rash and systemic involvement is characteristic of drug 
hypersensitivity syndrome, and is often observed in conjunction with an elevated white 
cell count and eosinophilia. It is believed that these reactions have an immunological 
aetiology, although this has never been unquestionably demonstrated. T-cells isolated 
from the patient readily proliferated in response to ex vivo rechallenge with TMP, with 
a maximal response to TMP at ~10-25pg/ml. This is in keeping with several previous 
studies with similar drugs (Naisbitt et al, 2003a,b; Schnyder et al, 1997), and with the 
studies with CBZ described earlier (see chapter 5). Furthermore, T-cell clones derived 
from the patient’s PBMCs were also capable of reacting to TMP when cultured with 
autologous B-LCLs as antigen-presenting cells. These data, in conjunction with the 
clinical case history discussed earlier, strengthen the case that the adverse reactions 
experienced by the patient were immunological in nature.
One interesting facet of the LTT data was that a proliferative response to TMP 
was observed both during and, more strongly, following the reaction. This is unusual, 
as LTTs performed on PBMCs isolated at the time of the reaction are often unsuc­
cessful (Naisbitt, D.J., unpublished observations). It is not known why this should be 
the case, despite speculation that it might be related either to extravascular compart- 
mentalisation of drug-reactive T-cells or to excessive background activation of T-cells
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leading to overwhelming of the drug-specific response, nor why this case in particular 
was unusual. However, attempts to clone T-cells from the PBMCs taken during the 
reaction were unsuccessful, and so all of the data generated from clones was performed 
with clones isolated post-reaction.
While the stable routes of oxidative TMP metabolism are relatively well under­
stood (see figure 6.1), less is known about how TMP reactive metabolites are formed. 
One study identified a iminoquinone methide through oxidation of the pyrimidine ring, 
which reacted with biological nucleophiles to form cysteinyl adducts. Therefore, a 
metabolite-generating system was derived from this paper, consisting of TMP and 
NaOCl. This was intrinsically toxic, and was unsuitable for addition directly to lym­
phocyte assays, so an additional pulse methodology was attempted, based on previous 
findings that SMX-NO modified cells, both alive and dead, can act as a source of 
antigen for the activation of T-cells from SMX-NO treated animals (Naisbitt et al, 
2002). In this study, this involved modification of PBMCs or B-LCLs with TMP and 
NaOCl so as to use as a source of antigen in an incubation with either fresh PBMCs 
or T-cell clones and B-LCLs. However, this approach was unsuccessful at inducing a 
TMP-metabolite specific T-cell response. More work is required to determine if this 
is simply due to a failure of the experimental system to generate the appropriate, in 
ww-equivalent, antigen (quite apart from any other consideration, the antigens in this 
case would be in large part localised on the surface rather than intracellularly), or was a 
more general failure of the experimental methodology, or actually reflected the genuine 
lack of antigenicity of TMP-modified proteins.
The addition of GSH had no effect on the proliferation of lymphocytes in response to 
TMP, giving further weight to the suggestion that the T-cells recognise the drug in the 
absence of metabolism. However, the reactions of GSH with TMP reactive metabolites 
have not been explored in sufficient detail to know whether this addition could be sure 
to completely eliminate all TMP-metabolite adduct formation.
Studies with T-cell clones isolated from the patient allow greater manipulation 
of the processes of T-cell activation than those performed with PBMCs, albeit at the 
expense of some proximity to the in vivo situation. The universal CD4+ status and lack
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of cytotoxicity of the clones extracted was not unexpected, as CD4+ clones typically 
make up the majority of all clones isolated in this way. This is likely to be an artefact 
of the methodology; in particular, the requirement for ex vivo enrichment, which will 
give selective advantages to those clones which proliferate more rapidly in response to 
phytohaemagglutinin, and the use of TMP-specific proliferation as a marker of TMP- 
selectivity. A recent study by Wu et al. (2007) on CBZ hypersensitivity has attempted 
to address these concerns by various alterations to the cloning methodology, and was 
successful in generating significant numbers of drug-specific CD8 + clones. It might 
therefore be interesting to apply these methodologies to this case, in order to explore 
the antigen-specificity of TMP-specific CD8 + T-cells, as these are likely to be the final 
effector cells of the reaction.
Chemokines form a large family of >50 small proteins (8-10kDa), which play an 
important role in the migration, adhesion, and tissue infiltration of immune cells. In 
particular, chemokines presented on the luminal surface of the endothelium induce 
arrest of rolling lymphocytes and promote transendothelial migration. Once within the 
tissue, the cells undergo positive chemotaxis along a chemokine gradient towards the 
site of inflammation (Lalor k, Adams, 2002). In the resting state, tissue infiltration is 
controlled both by reductions in the quantity of chemokines released from the tissue, 
but also through limited expression of chemokine receptors on the surface of resting 
T-cells. T-cell clones, as used in this study, are permanently activated, as they are 
maintained in medium containing IL-2, and so their chemokine receptor expression can 
be used as a marker to identify their particular tissue-homing characteristics.
All of the clones which were examined expressed the liver-homing chemokine recep­
tor CXCR3, although not CCR5 or CXCR6 , both of which are known to act as liver 
homing receptors (Lalor et al., 2002). Furthermore, the skin homing receptor CCR4 
was uniformly expressed, and 2 out of 3 clones examined expressed the skin homing re­
ceptor CCR8 . This is in keeping with the known clinical characteristics of the reaction, 
with both skin and liver involvement. However, too few clones expanded sufficiently in 
vitro to allow solid conclusions to be drawn from this data, and further work is required, 
both to confirm the initial findings, and to contrast this pattern with those known from
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both hypersensitivity reactions with different patterns of organ involvement, and from 
non-hypersensitive control individuals.
The nature of the antigen presented to TMP-specific T-cell clones was explored 
in a series of modifications to the standard proliferation assay. In these, TMP was 
successfully presented to T-cells on the surface of glutaraldehyde-fixed B-LCLs, and B- 
LCLs pulsed either with TMP alone or a TMP-iminoquinone methide generating system 
were found to be incapable of activating TMP-specific T-cell clones. These experiments 
are reminiscent to those performed earlier with CBZ-specific T-cells (see chapter 5), 
and many of the specific points raised in the discussion to that chapter relate equally 
to these experiments. Further work to determine the time-course of clonal activation 
would be interesting with regards to confirming the lack of dependence on processing, 
but this caveat notwithstanding, the data generated suggest that the clones respond 
to the parent drug via reversible interactions, as per the p-i concept, and as has been 
demonstrated both above, for CBZ, and previously, for a wide range of structurally 
unrelated drugs (Naisbitt et al., 2003b, 2005a; Schnyder et al., 1997; Zanni et al., 
1998).
There are several possibilities by which reversible interactions could be formed be­
tween TMP and cellular macromolecules such as MHC-peptide or TCR complexes (see 
the discussion in 5.4 and table 5.3 for a fuller discussion of these interactions). These 
include the strong interactions afforded by ionic bonding, as TMP is a weak base with 
a pKa of 7.3 (Nowak et al., 1985) and hence the primary amine groups will be ap­
proximately 50% ionised at physiological pH; hydrogen bonds, both accepted by the 
nitrogen of the primary amines and the oxygens of the methoxy groups, and donated 
by the primary amine hydrogens; and Van der Waals forces, which require a close 
structural fit between the molecule and the 3-dimensional configuration of the macro­
molecule in question. Unlike for CBZ, it is unlikely that hydrophobic interactions will 
play a large role in this binding, as the two aromatic rings within the molecule are 
somewhat shielded by polar groups. A previous study has explored the fine specificity 
of TMP-specific antibodies using hapten inhibition studies (Pham et al., 1996), and has 
found that the sera from different patients fell into 3 groups: 2/8 responded solely to
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the whole molecule, 1/8 recognised only TMP and diaveridine, a desmethoxy derivative 
of TMP, and the remaining 5/8 specifically recognised just the 3,4-dimethoxybenzene 
determinant. However, there are significant differences between the stringency of anti­
body binding and that of T-cell binding, and these data were produced from patients 
following immediate, type I immune reactions. Therefore, it would be interesting to 
use a similar panel of structural analogues of TMP in order to explore the precise 
specificities of ‘TMP-specific’ T-cell clones.
It is again worth mentioning that these findings relate solely to the antigen speci­
ficity of T-cell clones subsequent to the initiation of the reaction, and therefore can only 
inform us as to the antigenicity of TMP, not its immunogenicity. In other words, we are 
still left uncertain about the initial antigenic trigger which induced the reaction, and 
further work, with novel and innovative methodologies will be required in order to delve 
deeper into the fundamental mechanisms involved in the initiation and propagation of 
hypersensitivity reactions.
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Final Discussion
Adverse drug reactions axe a major healthcare problem, both directly—that is to say, 
in the clinic—and indirectly, as regards drug development. Large-scale epidemiological 
studies place the total financial burden of adverse reactions on healthcare in this coun­
try at approaching / ’400m per annum, and claim that as many as 5% of all hospital 
inpatient episodes are directly due to them (Pirmohamed et ai, 2004). While the ma­
jority of these reactions are dose-dependent (i.e. Type A according to the Rawlins & 
Thompson (1991) scheme; see 1.1.1), a significant proportion (~20%) are idiosyncratic 
(Type B). While these are less common than type A reactions, they are often more 
serious, and have been the cause of several recent drug withdrawals (such as troglita- 
zone or trovafloxacin). It is important to gain an immunotoxicological understanding 
of these reactions in order to better predict and prevent them. In order to advance 
this understanding, the aims of this study were to explore the possibility that drug 
metabolism and the generation of reactive drug metabolites play an important part 
either in the induction or propagation of drug hypersensitivity reactions.
In order to do this, three paradigm drugs with known associations with hypersen­
sitivity reactions, SMX, CBZ and TMP, were investigated as sources of signal 1 or 
signal 2. This discussion will briefly recap the findings and conclusions drawn by the 
individual studies, and attempt to synthesise these so as to draw more wide-ranging 
conclusions about the impact these findings may have on our understanding of drug 
hypersensitivity reactions in general.
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Firstly, SMX was studied in order to explore the possibility that either it or its 
known reactive metabolite SMX-NO can supply the requisite signal 2 for the induction 
of an immune response. In Chapter 2, this hypothesis was investigated through incu­
bating monocyte-derived dendritic cells, used as a model of an antigen-presenting cell, 
with either SMX or SMX-NO, and looking for changes in the expression of surface co­
stimulatory markers which are associated with maturation and activation of dendritic 
cells. These changes are an essential part of a full immune response to antigen, and in 
their absence, antigen presentation is tolerogenic, not immunogenic. It was found that 
incubation of dendritic cells with either SMX or SMX-NO, at concentrations within the 
therapeutic range, induced up-regulation of a key co-stimulatory molecule, CD40. This 
surface marker acts as the natural receptor for the CD154 ligand, which is expressed 
on the surface of activated T-cells, and induces full maturation of the dendritic cell 
affected (see 1.3.3 for a fuller treatment of these responses). Up-regulation of CD40, 
therefore, is believed to be an important step in the induction of an immune response. 
This proposition, with regards to SMX hypersensitivity, was tested by means of two 
models of SMX-NO immunogenicity: the murine local lymph node assay; and an in 
vitro primary stimulation assay. In both cases inhibition of CD40 signalling prevented 
the generation of a primary T-cell response to SMX-NO, and enhancement of CD40 
signalling led to a significantly enhanced primary stimulation in vitro. These data pro­
vide compelling reasons to believe that CD40 signalling plays an important role in the 
transduction of co-stimulatory signals between T-cells and APCs, and therefore that 
the observed modulation of the expression of these molecules by SMX and SMX-NO 
may have immunotoxicological consequences.
The mechanism by which this phenomenon occurs was explored in a later study 
(see Chapter 3). Here, three possible mechanisms were systematically considered and 
tested: cell death, either necrotic or apoptotic; glutathione depletion; or covalent mod­
ification of protein. Of the mechanisms tested, two, glutathione depletion and cell 
death, required greatly increased concentrations of SMX-NO and were not observed 
at any concentration of SMX examined. Protein adduct formation, by contrast, was 
observed both with SMX and SMX-NO, and both at concentrations comparable to
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those which had earlier been found to induce CD40 up-regulation on dendritic cells. 
As SMX is incapable of directly binding to protein, this is indirect evidence of ox­
idative metabolism within the incubation. In addition, the preincubation of dendritic 
cells with ABT, a metabolic enzyme inhibitor with a broad specificity was found to 
inhibit the CD40 up-regulation induced by SMX, but not that produced by SMX-NO 
or LPS, offering further evidence that the response to SMX was secondary to oxidative 
metabolism within the cell. It is also possible that production of reactive oxygen species 
as a consequence of SMX metabolism may play an additional role, and further work is 
required to investigate this possibility.
In order to explore the possibility of dendritic cell metabolism, the dendritic cell ex­
pression of a panel of metabolic enzymes, including several CYPs and peroxidases, was 
determined, along with the activities of the enzyme to catalyse SMX N-hydroxylation 
(although this was not as clear-cut as previous studies might have suggested—see Chap­
ter 4 for details). It was found that the only enzyme on the panel which was expressed 
in dendritic cells, active with respect to SMX N-hydroxylation, and readily inhibited by 
ABT, was MPO. This does not preclude the possibility that an unexamined enzyme, 
for instance, FMO-3 or lactoperoxidase, may also be expressed in dendritic cells and 
be active in this regard, but it does demonstrate that MPO is likely to be the enzyme 
responsible, at least in part.
The main conclusion from these studies is that localised bioactivation and metabolism 
can induce dendritic cell maturation, and hence has the potential to supply the req­
uisite signal 2 for a immune reaction. We have demonstrated this for SMX, however, 
further work is now needed to see if this concept extends to other drugs: importantly, 
many other drugs which are associated with immune-mediated adverse reactions are 
also known to be metabolised to reactive intermediates by MPO, such as, inter alia, 
CBZ (Furst & Uetrecht, 1993), TMP (Lai et ai, 1999), phenytoin (Uetrecht & Zahid, 
1988), and lamotrigine (Lu & Uetrecht, 2007). This work will explore the possibility 
that these compounds have similar effects to SMX when incubated with dendritic cells. 
Were it to be the case, then it is not hard to see how this would be useful for the pur­
poses of drug discovery, as tests for the potential to cause hypersensitivity are poor at
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present. For instance, in vitro testing for the ability of novel drugs or drug metabolites 
to activate dendritic cells may offer insights into their potential to induce hypersen­
sitivity reactions. A parallel for this would be the recent studies into the possibility 
of using dendritic cell activation as a marker for the potential of a chemical to cause 
contact sensitisation, and hence to replace in vivo testing for cosmetics and related 
household goods (Python et al., 2007; Sakaguchi et al, 2006). However, it is likely 
that the complexity of hypersensitivity reactions will continue to confound attempts to 
accurately predict them for the near future.
While these studies have concentrated on the possibility that localised SMX metabolism 
and covalent binding by dendritic cells can provide a source of signal 2  in the induction 
of an immune response, they have not addressed the equally compelling question of 
whether or not this localised metabolism and covalent binding might be able to gen­
erate sufficient covalent adducts to act as a source of antigen, or signal 1. SMX-NO 
has been found to activate T-cells isolated from SMX-hypersensitive patients, and so, 
if the quantity of SMX-NO generated in dendritic cells is sufficient, it appears quite 
plausible that dendritic cells incubated with SMX might be able to activate T-cells 
via a covalent-binding-dependent hapten-like mechanism. However, the only time this 
proposition has been tested, dendritic cells were found to present a drug (CBZ) to T- 
cells in a metabolism- and processing-independent fashion (Wu, 2006), indistinguishable 
from that observed with EBV-transformed B-LCLs. In this study, the clones used were 
derived by ex vivo enrichment with parent CBZ, and so it could be argued that they 
do not satisfactorily reflect the in vivo scenario. Further work is clearly required in 
order to thoroughly test this proposition. In particular, this work will require the as­
sessment of parallel in vitro and in vivo metabolism and immunogenicity, including 
analysis of MHC-presented peptide antigens, and their use in order to interrogate the 
T-cell response in vivo. Analysis of such low-abundance peptides presents significant 
technical difficulties, and advances in proteomic technologies may be required in order 
to isolate and identify them, but this will potentially answer many of the important 
questions about drug hypersensitivity. A recent study (Yang et al., 2007) has attempted 
to explore these issues with regard to CBZ hypersensitivity by looking for differences
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between the antigenic peptide library presented by an HLA-B*1502 transgenic B-LCL 
both with and without CBZ treatment, including attempts to identify CBZ-modified 
peptides. Although this study was unsuccessful, it stands as an example of the kind of 
study which will be required in order to truly explore the fundamental mechanisms of 
drug hypersensitivity.
One of the key unanswered questions in the field of drug hypersensitivity reactions 
concerns the nature of the antigen(s) involved, and whether the original antigen— 
that to which the immune reaction is first stimulated—and the ultimate antigen— 
that which stimulates propagation of the response, and is involved in rechallenge— 
are necessarily identical. Chapters 5 and 6  describe studies which were performed to 
explore the characteristics of the ultimate antigen involved in cases of CBZ and TMP 
hypersensitivity.
CBZ was found to activate T-cells in a metabolism- or covalent binding-independent 
fashion, as pulsed APCs were unable to present antigen and neither ABT or GSH 
inhibited the response. The response also appeared to be processing-independent, as it 
happened more rapidly than the time required for the internal processing machinery and 
was not inhibited by fixation of the APCs. This has been postulated for several drugs 
previously, but rarely with such a detailed study of the mechanisms as was performed 
in chapter 5. TMP was also found to activate T-cells in a processing- and metabolism- 
independent fashion, and TMP-iminoquinone methide modified cells, used as a source 
of antigen, were ineffective at T-cell activation. This demonstrates that, like CBZ, and 
several previously studied drugs, TMP can activate T-cells in the absence of covalent 
binding and hapten formation. However, these findings only offer guides as to what 
the initial antigen might be, as in all similar cases they require T-cells isolated from 
patients subsequent to the initiation of the reaction.
These studies allow a greater knowledge of the range of potential antigens the 
immune system can ‘see’. This is important, since early arguments for the hapten hy­
pothesis relied upon the perceived impossibility of TCR recognition of small molecules. 
Clearly then, if the conclusions from these studies—that small molecules can be recog­
nised by specific TCRs—are valid, then these arguments for the importance of the hap­
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ten hypothesis are not. Of course, there are many other arguments for the importance 
of covalent binding in drug hypersensitivity, such as the considerable immunogenic- 
ity of many reactive metabolites in vivo, the existence of SMX-NO reactive T-cells in 
SMX-hypersensitive patients, and the associations between metabolite exposure and 
hypersensitivity, and so these data can only be seen as a step towards a greater under­
standing, but this story still illustrates how these findings can have implications, even 
if questions remain about their relevance to the in vivo situation at the initiation of a 
reaction.
The chemical requirements for binding of CBZ to the TCR or MHC-peptide complex 
were also investigated in chapter 5 through structure-activity relationship analysis. 
The findings here suggested that certain regions of the molecule, such as the aromatic 
rings, appeared to predominate with respect to this binding, in that modifications there 
were less well tolerated than other sites of modification such as the unsaturated bond 
within the iminostilbene moiety. These allow a small insight into the mechanisms at 
play within the immunological synapse, and further work, with novel compounds— 
for instance, halogenated CBZ derivatives—will lead to a better understanding of the 
requirements for TCR-MHC binding, and maybe even help to design drugs without the 
potentiality for these kinds of reactions.
The possibility that T-cells can interact with relatively small parts of a molecule is 
reminiscent of antibody binding, in which a similar phenomenon is well recognised. Al­
though the binding between TCR and antigen is significantly more stringent than that 
between antibody and antigen, there are a number of interesting parallels which will be 
explored here. The specificity of antibodies to small molecules has been investigated 
in some detail, including that to ethinyloestradiol (Monnet et al., 2002; Park & Whit­
taker, 1978), TMP (Pham et al., 1996), penicillins (Moreno et al., 1995) and SMX (Gill 
et al., 1997). The main finding of interest from these studies, at least for the purposes 
of this discussion, is that there is a considerable degree of degeneracy and promiscuity 
within the system, i.e. individual monoclonal antibodies are cross-reactive to differ­
ent structures, and different structures are recognised by multiple clones of antibodies 
(Parnes, 2004). Immunisation with a given antigen thus leads to a polyclonal response,
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involving multiple antibodies each with subtly differing fine specificities. Similarly, this 
has been observed amongst antigen-responding populations of T-cells (Wucherpfennig, 
2004), and is believed to be an intrinsic element in the immune system. However, 
several studies have looked for the degree of clonality amongst drug-responsive pop­
ulations of T-cells, and have found considerable heterogeneity (Pichler et al., 1997); 
some studies have found the expected polyclonality (Naisbitt et al., 2003a), however, 
many other studies have found suggestions of oligoclonality, with few V/? TCR chains 
involved (Mauri-Hellweg et al., 1995; Nassif et al., 2002). In these cases, however, the 
responses have been directed at the free drug in solution, and so may have missed T- 
cells directed at haptenic derivatives. In order to fully explore this possibility, and to 
define the limits of cross-reactivity between free drug and covalently-bound material, 
it may be necessary to design and synthesise modified peptides, which can be used di­
rectly in order to bypass the cellular mechanisms of antigen processing. This approach 
has been previously successful when applied to the study of certain haptens, such as 
dinitrohalobenzenes (Kohler et al., 1995; Martin et al., 1993) and penicillins (Padovan 
et al., 1996, 1997), but has never been applied to the study of pro-haptens such as the 
drugs used in this study.
In the general introduction to this thesis, the events which take place during the 
course of an immune reaction to a drug were sketched out (see 1.3.1). To conclude, I 
will describe how the findings reported in this thesis enhance our understanding, and 
try to answer some of the questions which were left unanswered originally.
The source of the danger signals involved in the activation of dendritic cells during 
the initiation of an immune response to a drug was considered, and three possibili­
ties suggested—viral or bacterial infection, or the cellular damage produced by reac­
tive metabolites. Of these, it was noted that dendritic cell activation by the reactive 
metabolites of drugs was plausible, but that there was no evidence to suggest it oc­
curred. The work presented in chapters 2 and 3 indicate that, at least for SMX, the 
process of localised metabolism can generate a toxic signal which leads to dendritic cell 
activation. This is likely to not be the only mechanism, as bacterial and viral infection 
may both occur concurrently.
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Signal i:TCR-MHCInteraction I Signal 2:Co-stimulation CD4Q:CD40L interaction
Figure 7.1: Routes by which the drugs studied herein have been found to activate the immune system in the induction of a hypersensitivity reaction
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The next important question arising from our discussion of the processes involved in 
hypersensitivity was regarding the nature of the antigen recognised by T-cells. Whether 
effector T-cells in drug hypersensitivity respond to free drug or haptens, or both, is one 
of the most important unanswered questions in the field of hypersensitivity. The data 
presented in chapters 5 and 6  provide evidence that, at least for T-cells isolated following 
the initial sensitisation event, they react in vitro to the parent drug in a processing- 
and metabolism-independent fashion.
In conclusion then, these studies offer some advances towards a greater understand­
ing of the role of metabolism in drug hypersensitivity, in that they show that metabolism 
may not be necessary for the source of signal 1, the T-cell specific antigenic signal, yet 
appears able to induce signal 2, or dendritic cell activation. Further work will better 
delineate these two important mechanisms, and allow insight into possible crosstalk 
between them.
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